Compounds, pharmaceutical compositions, and methods of use thereof
Compounds targeting AKR1C3 enzyme provide a selective inhibition approach to treat hormone-mediated disorders like PCOS and endometriosis, reducing androgen levels and minimizing adverse effects.
Patent Information
- Application Number
- PCT/US2026/027790
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Current hormonal treatments for conditions such as PCOS and endometriosis operate by broad, non-selective hormone suppression, failing to address the pathway-specific tissue-level regulation of steroid hormones, leading to adverse effects.
Development of compounds targeting the AKR1C3 enzyme to selectively inhibit its activity, providing targeted approaches for treating hormone-mediated disorders like PCOS and endometriosis.
The compounds effectively reduce androgen levels and ameliorate symptoms by selectively inhibiting AKR1C3, offering a more targeted and less adverse treatment option.
Smart Images

Figure IMGF000002_0001 
Figure IMGF000003_0001 
Figure IMGF000003_0002
Abstract
Description
Atorney Docket No. PSE-002WOCOMPOUNDS. PHARMACEUTICAL COMPOSITIONS. AND METHODS OF USE THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 804,432, filed May 12, 2025; the disclosure of which is hereby incorporated by reference in its entirety for all purposes.BACKGROUND
[0002] Hormone-mediated disorders (particularly those marked by hyperandrogenism) such as polycystic ovary syndrome (PCOS), endometriosis, and certain cancers (e.g., hepatocellular carcinoma, prostate, endometrial, and breast cancers) illustrate the crucial role of the enzyme AKR1C3 (Aldo-Keto Reductase 1C3) in regulating local hormone production (Liu, etal. J. Med. Chem. 2020, 63(20) 11305-11329; Liu, et al. Mol. Cancer Ther. 2017, 16(1), 35-44; Li, et al., Pharmacol. 2024, 15; Xing, et al. J. Med. Chem. 2025, 68(7), 7367-7389). This enzyme operates systematically and at a tissue-level and catalyzes redox reactions of steroid hormones. The conversion of androstenedione to testosterone and the conversion of estrone to estradiol are two examples. Endocrine disorders can exhibit steroid hormone imbalance, including androgens, estrogens, progesterones, and prostaglandins, signaling pathways AKR1C3 is a part of, resulting in increased local levels of androgens. This excess production of androgens has deleterious effects in various endocrine disorders and various cancers.
[0003] For example, polycystic ovary syndrome (PCOS), presents with symptoms such as hirsutism, acne, androgenic alopecia, irregular menstrual cycles, fertility issues, and metabolic disorders in women. Additionally, conditions such as obesity, insulin resistance, diabetes, and metabolic syndrome are common comorbidities (Paulukinas and Penning, Endocrin. 2023, 164(5), 1-14). Women with PCOS have heightened levels of androgens, specifically testosterone, due to the overexpression of the AKR1C3 enzyme (O’Reilly, et al. J. Clin.Endocrinol. Metab. 2017, 102(9), 3327-3339). AKR1C3 also plays a role in other endocrine and hormone-driven conditions such as endometriosis (Rizner and Penning, Pharm. Res. 2020, 152, 104446-104460). Endometriosis is characterized by excessive growth of endometrium which can implant in the ovaries and fallopian tubes. This excess tissue growth results in scarring, pelvic pain, infertility, and irregular or periods among other symptoms. A hallmark ofAttorney Docket No. PSE-002WOendometriosis is increased levels of estradiol. This excess estradiol mediates the growth of ectopic endometrial tissue that defines the disorder.
[0004] Additionally, AKR1C3 is implicated in various cancers. For example, elevated levels of AKR1C3 activate the androgen receptor signaling pathway, contributing to tumor recurrence and imparting resistance to cancer therapies. The overexpression of AKR1C3 is an oncogenic factor, promoting carcinoma cell proliferation, invasion, and metastasis, and is correlated with unfavorable prognosis and overall survival in carcinoma patients (Li, et al., Pharmacol. 2024, 15).
[0005] Due to its key role in the production and metabolism of steroid hormones, AKR1C3 is a potential therapeutic target for the treatment of endocrine disorders and certain cancers (Penning, Mol. Cell. Endocrinol. 2019, 489, 82-91). Current hormonal treatments for conditions such as PCOS and endometriosis operate by broad, and often non-selective hormone suppression. Consequently, any therapeutic effect can be accompanied by adverse effects. Current treatments fail to address the pathway specific tissue-level regulation of steroid hormones that defines these conditions. In contrast, selective AKR1C3 inhibitors could offer targeted approaches to ameliorating hyperandrogenism and related conditions. Compounds and compositions described herein are directed toward the targeted approaches.SUMMARY
[0006] Provided herein, in some embodiments, are compounds and compositions that are useful in treating a disease, disorder, or condition associated with suboptimal AKR1C3 activity.
[0007] In one aspect, provided herein is a compound of Formula (A):R1(R3)nNX5'R9Formula (A)Attorney Docket No. PSE-002WOor a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein the variables are defined as herein.
[0008] In another aspect, provided herein is a compound of Formula (I):Formula (I)or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein the variables are defined as herein.
[0009] In another aspect, provided herein is a compound of Formula (II):Formula (II)or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein the variables are defined as herein.
[0010] In another aspect, provided herein is a compound of Formula (III):Attorney Docket No. PSE-002WOFormula (III)or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein the variables are defined as herein.
[0011] Also disclosed herein is a compound selected from any of the compounds shown in Table 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
[0012] In certain embodiments, provided herein is a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, and one or more pharmaceutically acceptable carriers.
[0013] In another aspect, the present disclosure provides a method of treating a disease, disorder, or condition associated with suboptimal (e.g., upregulated or increased) AKR1C3 activity, comprising administering to the subject an effective amount (e g., a therapeutically effective amount) of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition disclosed herein. In some embodiments, the suboptimal AKR1C3 activity is associated with abnormal signaling of one or more pathways involving AKR1C3.DETAILED DESCRIPTION
[0014] The features and other details of the disclosure will now be more particularly described. Before further description of the present disclosure, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and as understood by a person of skill in the art.
[0015] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.Attorney Docket No. PSE-002WODefinitions
[0016] As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an agent” includes a plurality of such agents, and reference to “the cell” includes reference to one or more cells (or to a plurality of cells) and equivalents thereof known to those skilled in the art, and so forth. When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term “about” when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range, in some instances, will vary between 1% and 15% of the stated number or numerical range. The term “comprising” (and related terms such as “comprise” or “comprises” or “having” or “including”) is not intended to exclude that in other certain embodiments, for example, an embodiment of any composition of matter, composition, method, or process, or the like, described herein, “consist of’ or “consist essentially of’ the described features.
[0017] As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated below.
[0018] “Cyano” refers to -CN.
[0019] “Hydroxyl” or “hydroxy” refers to -OH.
[0020] Oxo” refers to =0.
[0021] “Alkyl” refers to an optionally substituted straight-chain, or optionally substituted branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, or from one to six carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-l-propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3-methyl-l-butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3 -methyl- 1 -pentyl, 4-methyl-l -pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tertamyl and hexyl, and longer alkyl groups, such as heptyl, octyl, and the like. Whenever it appears herein, a numerical range such as “Ci-Ce alkyl” means that the alkyl group consists of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms,Attorney Docket No. PSE-002WOalthough the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated. In some embodiments, the alkyl is a C1-C10 alkyl, a C1-C9 alkyl, a Ci-Cs alkyl, a C1-C7 alkyl, a Ci-Ce alkyl, a C1-C5 alkyl, a C1-C4 alkyl, a C1-C3 alkyl, a C1-C2 alkyl, or a Ci alkyl. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted, for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with halogen.
[0022] “Alkenyl” refers to an optionally substituted straight-chain, or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon doublebonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms. The group may be in either the cis or trans conformation about the double bond(s) and should be understood to include both isomers. Examples include, but are not limited to, ethenyl (-CH=CH2), 1-propenyl (-CH2CI-UCH2), isopropenyl [-CfCHiUCIU], butenyl, 1,3-butadienyl and the like. Whenever it appears herein, a numerical range such as “C2-C6 alkenyl” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated. In some embodiments, the alkenyl is a C2-C10 alkenyl, a C2-C9 alkenyl, a C2-C8alkenyl, a C2-C7 alkenyl, a C2-C6 alkenyl, a C2-C5 alkenyl, a C2-C4 alkenyl, a C2-C3 alkenyl, or a C2 alkenyl. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted, for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkenyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an alkenyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkenyl is optionally substituted with halogen.
[0023] “Alkynyl” refers to an optionally substituted straight-chain or optionally substituted branched-chain hydrocarbon mono-radical having one or more carbon-carbon triplebonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, 1,3-Attorney Docket No. PSE-002WObutadiynyl and the like. Whenever it appears herein, a numerical range such as “C2-C6 alkynyl” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated. In some embodiments, the alkynyl is a C2-C10 alkynyl, a C2-C9 alkynyl, a C2-C8 alkynyl, a C2-C7 alkynyl, a C2-C6 alkynyl, a C2-C5 alkynyl, a C2-C4 alkynyl, a C2-C3 alkynyl, or a C2 alkynyl. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted, for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkynyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an alkynyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkynyl is optionally substituted with halogen.
[0024] “Alkylene” refers to a straight or branched divalent hydrocarbon chain. Unless stated otherwise specifically in the specification, an alkylene group may be optionally substituted, for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an alkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen.
[0025] “Cycloalkylene” refers to a partially or fully saturated, monocyclic, or polycyclic carbocycle containing a divalent carbon atom. The cycloalkylene may be a bridged bycyclic cycloalkylene, as valency permits. Unless stated otherwise specifically in the specification, a cycloalkylene group may be optionally substituted, for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a cycloalkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a cycloalkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen.
[0026] “Haloalkylene” refers to an alklyene, as defined above, that is substituted by one or more halogen atoms. In some embodiments, the alkylene is substituted with one, two, or three halogen atoms. In some embodiments, the alkylene is substituted with one, two, three, four, five,Attorney Docket No. PSE-002WOor six halogen halogens. Haloalkylene includes, for example, trifluoromethylene, difluoromethylene, fluoromethylene, tri chloromethyl, 2,2,2-trifluoroethylene, 1,2-di fluoroethylene, 3-bromo-2-fluoropropylene, 1,2-dibromoethylene, and the like.
[0027] “Alkoxy” refers to a radical of the formula -Oalkyl wherein alkyl is as defined above. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted, for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkoxy is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an alkoxy is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkoxy is optionally substituted with halogen.
[0028] “Aryl” refers to a radical derived from a hydrocarbon ring system comprising hydrogen, 6 to 30 carbon atoms and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded through an aromatic ring atom) or bridged ring systems. In some embodiments, the aryl is a 6- to 10-membered aryl. In some embodiments, the aryl is a 6-membered aryl. Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. In some embodiments, the aryl is phenyl. Unless stated otherwise specifically in the specification, an aryl may be optionally substituted, for example, with halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl is optionally substituted with halogen.
[0029] “Cycloalkyl” or “carbocyclyl” (used interchangeably) refers to a partially or fully saturated, monocyclic, or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems. Representative cycloalkyls or carbocyclyls include, but are not limited to, cycloalkyls or carbocyclyls having from three to fifteen carbon atoms (C3-C15 cycloalkyl or C3-Attorney Docket No. PSE-002WOCis carbocyclyl), from three to ten carbon atoms (C3-C10 cycloalkyl or C3-C10 carbocyclyl), from three to eight carbon atoms (C3-C8 cycloalkyl or C3-C8 carbocyclyl), from three to six carbon atoms (C3-C6 cycloalkyl or C -C6 carbocyclyl), from three to five carbon atoms (C3-C5 cycloalkyl or C3-C5 carbocyclyl), or three to four carbon atoms (C3-C4 cycloalkyl or C3-C4 carbocyclyl). In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl or carbocyclyl. In some embodiments, the cycloalkyl or carbocyclyl is a 5- to 6-membered cycloalkyl or carbocyclyl. Monocyclic cycloalkyls or carbocyclyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls or carbocyclyls include, for example, adamantyl, norbomyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Partially saturated cycloalkyls or carbocyclyls include, for example cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless stated otherwise specifically in the specification, a cycloalkyl or carbocyclyl is optionally substituted, for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl or carbocyclyl, heterocycloalkyl or heterocyclyl, heteroaryl, and the like. In some embodiments, a cycloalkyl or carbocyclyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a cycloalkyl or carbocyclyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl or carbocyclyl is optionally substituted with halogen.
[0030] “Cycloalkoxy” refers to an alkoxy group wherein the alkyl group is a cycloalkyl or carbocyclyl, as defined above. Unless specifically stated otherwise, a cycloalkoxy is optionally substituted, for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl or carbocyclyl, heterocycloalkyl or heterocyclyl, heteroaryl, and the like. In some embodiments, a cycloalkoxy is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a cycloalkoxy is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkoxy is optionally substituted with halogen.[00031J “Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halogen atoms. In some embodiments, the alkyl is substituted with one, two, or threeAttorney Docket No. PSE-002WOhalogen atoms. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six halogen halogens. Haloalkyl includes, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. In some embodiments, the haloalkyl is trifluoromethyl.
[0032] “Halo” or “halogen” refers to bromo, chloro, fluoro or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro.
[0033] “Haloalkoxy” or “Haloalkoxyl” refers to an alkoxyl group that is substituted with at least one halogen. For example, -O-CH2F, -O-CHF2, -O-CF3, and the like.
[0034] ‘Heteroatom” refers to an atom other than carbon or hydrogen. For example, oxygen, nitrogen, sulfur, phosphorus, silicon, halogen, and the like.
[0035] “Heteroalkyl” refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or combinations thereof. A heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In one aspect, a heteroalkyl is a Ci-Ce heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or more atoms other than carbon, e.g., oxygen, nitrogen (e.g. -NH-, -N(alkyl)-), sulfur, or combinations thereof wherein the heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. Examples of such heteroalkyl are, for example, -CH2OCH2, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, or -CH(CH3)OCH3. Unless stated otherwise specifically in the specification, a heteroalkyl is optionally substituted for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroalkyl is optionally substituted with halogen.
[0036] “Heterocycloalkyl” or “heterocyclyl” (used interchangeably) refers to a 3 - to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur. In some embodiments, the heterocycloalkyl or heterocyclyl comprises 1 or 2 heteroatoms selected from nitrogen and oxygen. Unless stated otherwise specifically in the specification, the heterocycloalkyl or heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclicAttorney Docket No. PSE-002WOring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl or heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. Representative heterocycloalkyls or heterocyclyls include, but are not limited to, heterocycloalkyls or heterocyclyls having from two to fifteen carbon atoms (C2-C15 heterocycloalkyl or C2-C15 heterocyclyl), from two to ten carbon atoms (C2-C10 heterocycloalkyl or C2-C10 heterocyclyl), from two to eight carbon atoms (C2-C8 heterocycloalkyl or C2-C10 heterocyclyl), from two to six carbon atoms (C2-C6 heterocycloalkyl or C2-C6 heterocyclyl), from two to five carbon atoms (C2-C5 heterocycloalkyl or C2-C5 heterocyclyl), or two to four carbon atoms (C2-C4 heterocycloalkyl or C2-C4 heterocyclyl). In some embodiments, the heterocycloalkyl or heterocyclyl is a 3- to 6-membered heterocycloalkyl or heterocyclyl. In some embodiments, the heterocycloalkyl or heterocyclyl is a 5- to 6-membered heterocycloalkyl or heterocyclyl. Examples of such heterocycloalkyl or heterocyclyl radicals include, but are not limited to, aziridinyl, azetidinyl, dioxolanyl, thienyl [1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-l,3-dihydroisobenzofuran-l-yl, methyl-2-oxo-l,3-dioxol-4-yl, and 2-oxo-l,3-dioxol-4-yl. The term heterocycloalkyl or heterocyclyl also includes all ring forms of the carbohydrates, including but not limited to, the monosaccharides, the di saccharides, and the oligosaccharides. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl or heterocyclyl, the number of carbon atoms in the heterocycloalkyl or heterocyclyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl or heterocyclyl (i.e., skeletal atoms of the heterocycloalkyl or heterocyclyl ring). Unless stated otherwise specifically in the specification, a heterocycloalkyl or heterocyclyl is optionally substituted, for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heterocycloalkyl or heterocyclyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heterocycloalkylAttorney Docket No. PSE-002WOor heterocyclyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocycloalkyl or heterocyclyl is optionally substituted with halogen.
[0037] “Heterocycloalkoxy” refers to a formula of “-Oheterocyclyl”, or a cycloalkoxy group wherein the cycloakloxy group is a heterocycloalkyl or heterocyclyl, as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkoxy is optionally substituted, for example, with oxo, halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl or carbocyclyl, heterocycloalkyl or heterocyclyl, heteroaryl, and the like. In some embodiments, a heterocycloalkoxy is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heterocycloalkoxy is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocycloalkoxy is optionally substituted with halogen.
[0038] “Heteroaryl” refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur, and at least one aromatic ring. The heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotri azolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1 -phenyl -IH-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl,Attorney Docket No. PSE-002WOpyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, a heteroaryl is optionally substituted, for example, with halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroaryl is optionally substituted with halogen.
[0039] The terms “treat,” “prevent,” “ameliorate,” and “inhibit,” as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complete treatment, prevention, amelioration, or inhibition. Rather, there are varying degrees of treatment, prevention, amelioration, and inhibition of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the disclosed methods can provide any amount of any level of treatment, prevention, amelioration, or inhibition of the disorder in a mammal. For example, a disorder, including symptoms or conditions thereof, may be reduced by, for example, about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, or about 10%. Furthermore, the treatment, prevention, amelioration, or inhibition provided by the methods disclosed herein can include treatment, prevention, amelioration, or inhibition of one or more conditions or symptoms of the disorder, e.g., cancer or an inflammatory disease. Also, for purposes herein, “treatment,” “prevention,” “amelioration,” or “inhibition” encompass delaying the onset of the disorder, or a symptom or condition thereof.
[0040] The terms “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of a compound disclosed herein being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated, e.g., hyperandrogenism. In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound disclosed herein required to provide a clinically significantAttorney Docket No. PSE-002WOdecrease in disease symptoms. In some embodiments, an appropriate “effective” amount in any individual case is determined using techniques, such as a dose escalation study.
[0041] As used herein, the term “a disease, disorder, or condition associated with suboptimal AKR1C3 activity” means any disease, disorder, or other deleterious condition in which suboptimal (e.g., upregulated or increased) AKR1C3 activity is known to play a role, or a condition in which modulation (e.g., inhibition) of AKR1C3 achieves a therapeutic effect. In some embodiments, the disease, disorder, or condition is hyperandrogenism. In some embodiments, the disease, disorder, or condition is polycystic ovary syndrome (PCOS). In some embodiments, the disease, disorder, or condition is hirsutism. In certain embodiments, the disease, disorder, or condition is endometriosis. In certain embodiments, the disease, disorder, or condition is cancer. In certain embodiments, the disease, disorder, or condition is a metabolic disorder.Compounds
[0042] Described herein are compounds that are useful in treating a disease, disorder, or condition associated with suboptimal AKR1C3 activity.
[0043] In one aspect, provided herein is a compound of Formula (A):R1n / XR2\LR9I( A -j - (R5)tFormula (A)or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, whereinindicates single bond or double bond;Ring A is selected from the group consisting of a 5-6-membered heterocyclyl substituted with one or two oxo or =NR’ and comprising one, two, or three nitrogen ring atoms, a 5-membered heterocyclyl comprising at least one oxygen or sulfur ring atom, aN-bound 5-membered heteroaryl comprising one, two, or three nitrogen ring atoms, a C-bound 5-membered heteroarylAttorney Docket No. PSE-002WOcomprising at least one oxygen or sulfur ring atom, and a 6-membered heteroaryl comprising one or two nitrogen ring atoms;R' is H or C1-C4 alkyl;Z is CR7orN;L is selected from the group consisting of bond, C(O), S(0)o-2, O, CH2, and CF2;R1is selected from the group consisting of H, C1-C4 alkyl, and C1-C4 alkylene-Ci-C4 alkoxy-Si(Ci-C4alkyl)3;R2is selected from the group consisting of H, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C3-C4 cycloalkoxy, and 4-5 membered heterocycloalkoxy;X5is CR10or N, provided thati) when X5is CR10, R9and R10together with the carbon atoms to which the R9and R10are attached form a phenyl, 5-8 membered carbocyclyl, 5-6 membered heterocyclyl, or 6-membered heteroaryl, wherein the phenyl, 5-8 membered carbocyclyl, 5-6 membered heterocyclyl, or 6-membered heteroaryl is optionally substituted with one, two, three, or four R4; andii) when X5is N, R2and R9together with the carbon atoms to which the R2and R9are attached form a 5-8 membered carbocyclyl or 5-6 membered heterocyclyl, wherein the 5-8 membered carbocyclyl or 5-6 membered heterocyclyl is optionally substituted with one or two RD;R3is each independently selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, and C3-C6 cycloalkyl,or two R3S on the same carbon together with the carbon atom to which the two R3S are attached form a C3-C6 cycloalkylene, or two R3s on different carbons within the ring form a C1-C4 bridging alkylene;R4is each independently selected from the group consisting of H, halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkylene-C3-C6 cycloalkyl, Ci-Ce haloalkylene-C3-C6 cycloalkyl, Ci-Ce alkoxy-Cs-Ce cycloalkyl, Ci-Ce haloalkoxy-Cs-Ce cycloalkyl, Ci-Ce alkoxy-4-6 membered heterocyclyl, Ci-Ce alkoxy-5-6 membered heteroaryl, N(R8)2, and 4-6 membered heterocyclyl, wherein the Ci-Ce alkoxy, C3-C6 cycloalkyl, C -C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkoxy-Cs-Ce cycloalkyl, Ci-Ce haloalkoxy-Cs-Ce cycloalkyl,Attorney Docket No. PSE-002WOand 4-6 membered heterocyclyl are optionally substituted with one, two, three, or four RA;R5is each independently selected from the group consisting of H, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, and N(R8)2;or two adjacent R5s together with the atoms to which the R5s are attached form a phenyl, 5-6 membered carbocyclyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl, wherein the phenyl or 5-6 membered heteroaryl is optionally substituted with RB, and the 5-6 membered carbocyclyl or 5-6 membered heterocyclyl is optionally substituted with Rc;when - is double bond, R7is absent; when - is single bond, R7is selected from the group consisting of H, hydroxy, cyano, and C1-C4 alkyl;R8is each independently H or Ci-Ce alkyl;RAis each independently selected from the group consisting of halogen, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce alkyl-Ci-Ce alkoxy, and Ci-Ce haloalkoxy;RBis selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkyl;Rcis selected from the group consisting of oxo, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkyl;RDis each independently selected from the group consisting of halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, and Ci-Ce haloalkoxy;n is 0, 1, 2, 3, or 4;t is 0, 1, or 2;p is 0 or 1; andq is 0 or 1.
[0044] In some embodiments of Formula (A), when X5is CR10, R9and R10together with the carbon atoms to which the R9and R10are attached form a phenyl, 5-8 membered carbocyclyl, 5-6 membered heterocyclyl, or 6-membered heteroaryl, wherein the phenyl, 5-8 membered carbocyclyl, 5-6 membered heterocyclyl, or 6-membered heteroaryl is optionally substituted with one, two, three, or four R4.Attorney Docket No. PSE-002WO
[0045] In some embodiments of Formula (A), when X5is CR10, R9and R10together with the carbon atoms to which the R9and R10are attached form a phenyl, 5-8 membered carbocyclyl, 5-6 membered heterocyclyl, or 6-membered heteroaryl, wherein the phenyl, 5-8 membered carbocyclyl, 5-6 membered heterocyclyl, or 6-membered heteroaryl is optionally substituted with one or two R4.
[0046] In some embodiments of Formula (A), when X5is CR10, R9and R10together with the carbon atoms to which the R9and R10are attached form a phenyl, 5-8 membered carbocyclyl, 5-6 membered heterocyclyl, or 6-membered heteroaryl, wherein the phenyl, 5-8 membered carbocyclyl, 5-6 membered heterocyclyl, or 6-membered heteroaryl is optionally substituted with one R4.
[0047] In some embodiments of Formula (A), when X5is N, R2and R9together with the carbon atoms to which the R2and R9are attached form a 5-8 membered carbocyclyl or 5-6 membered heterocyclyl, wherein the 5-8 membered carbocyclyl or 5-6 membered heterocyclyl is optionally substituted with one or two RD.
[0048] In some embodiments of Formula (A), when X5is N, R2and R9together with the carbon atoms to which the R2and R9are attached form a 5-8 membered carbocyclyl or 5-6 membered heterocyclyl, wherein the 5-8 membered carbocyclyl or 5-6 membered heterocyclyl is optionally substituted with one RD.
[0049] In another aspect, provided herein is a compound of Formula (I):Formula (I)or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, whereinindicates single bond or double bond;X1, X2, X3, and X4are each independently CR4or N, provided that no more than two of X1, X2, X3, and X4are N;Attorney Docket No. PSE-002WORing A is selected from the group consisting of a 5-6-membered heterocyclyl substituted with one or two oxo or =NR’ and comprising one, two, or three nitrogen ring atoms, a 5-membered heterocyclyl comprising at least one oxygen or sulfur ring atom, a N-bound 5-membered heteroaryl comprising one, two, or three nitrogen ring atoms, a C-bound 5-membered heteroaryl comprising at least one oxygen or sulfur ring atom, and a 6-membered heteroaryl comprising one or two nitrogen ring atoms;Z is CR7orN;L is selected from the group consisting of bond, C(O), S(0)o-2, O, CH2, and CF2;R1is selected from the group consisting of H, C1-C4 alkyl, and C1-C4 alkylene-Ci-C4 alkoxy-Si(Ci-C4alkyl)3;R2is selected from the group consisting of H, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C3-C4 cycloalkoxy, and 4-5 membered heterocycloalkoxy;R3is each independently selected from the group consisting of halogen, hydroxy, cyano, C1-C6 alkyl, Ci-Ce haloalkyl, and C3-C6 cycloalkyl,or two R3S on the same carbon together with the carbon atom to which the two R3S are attached form a C3-C6 cycloalkylene, or two R3s on different carbons within the ring form a C1-C4 bridging alkylene;R4is each independently selected from the group consisting of H, halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkylene-C3-C6 cycloalkyl, Ci-Ce haloalkylene-C3-C6 cycloalkyl, Ci-Ce alkoxy-C3-Ce cycloalkyl, Ci-Ce haloalkoxy-Cs-Ce cycloalkyl, Ci-Ce alkoxy-4-6 membered heterocyclyl, Ci-Ce alkoxy-5-6 membered heteroaryl, N(R8)2, and 4-6 membered heterocyclyl, wherein the Ci-Ce alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkoxy-Cs-Ce cycloalkyl, Ci-Ce haloalkoxy-Cs-Ce cycloalkyl, and 4-6 membered heterocyclyl are optionally substituted with one, two, three, or four RA;R5is each independently selected from the group consisting of H, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, and N(R8)2;or two adjacent R5s together with the atoms to which the R5s are attached form a phenyl, 5-6 membered carbocyclyl, 5-6 membered heteroaryl, or 5-6 memberedAttorney Docket No. PSE-002WOheterocyclyl, wherein the phenyl or 5-6 membered heteroaryl is optionally substituted with RB, and the 5-6 membered carbocyclyl or 5-6 membered heterocyclyl is optionally substituted with Rc;when - is double bond, R7is absent; when - is single bond, R7is selected from the group consisting of H, hydroxy, cyano, and C1-C4 alkyl;R8is each independently H or Ci-Ce alkyl;RAis each independently selected from the group consisting of halogen, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce alkyl-Ci-Cs alkoxy, and Ci-Ce haloalkoxy;RBis selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkyl;Rcis selected from the group consisting of oxo, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkyl;n is 0, 1, 2, 3, or 4;t is 0, 1, or 2;p is 0 or 1; andq is 0 or 1.
[0050] In some embodiments of Formula (A) or (I), L is selected from the group consisting of bond, C(O), and CH2. In some embodiments of Formula (A) or (I), L is bond. In some embodiments of Formula (A) or (I), L is C(O). In some embodiments of Formula (A) or (I), L is CH2.
[0051] In some embodiments of Formula (I), X1is CR4. In other embodiments of Formula (I), X1is N.
[0052] In some embodiments of Formula (I), X2is CR4. In other embodiments of Formula (I), X2is N.
[0053] In some embodiments of Formula (I), X3is CR4. In other embodiments of Formula (I), X3is N.
[0054] In some embodiments of Formula (I), X4is CR4. In other embodiments of Formula (I), X4is N.
[0055] In some embodiments of Formula (A) or (I), p is 0. In other embodiments of Formula (A) or (I), p is 1.Attorney Docket No. PSE-002WO
[0056] In some embodiments of Formula (A) or (I), q is 0. In other embodiments of Formula (A) or (I), q is 1.
[0057] In some embodiments, the compound is a compound of Formula (I-A):Formula (I-A)or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
[0058] In some embodiments of Formula (I-A), X1is CR4. In other embodiments of Formula (I-A), X1is N.
[0059] In some embodiments of Formula (I-A), X2is CR4. In other embodiments of Formula (I-A), X2is N.
[0060] In some embodiments of Formula (I-A), X3is CR4. In other embodiments of Formula (I-A), X3is N.
[0061] In some embodiments of Formula (I-A), X4is CR4. In other embodiments of Formula (I-A), X4is N.
[0062] In another aspect, provided herein is a compound of Formula (II):or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, whereinRing A is selected from the group consisting of a 5-6-membered heterocyclyl substituted with one or two oxo or =NR’ and comprising one, two, or three nitrogen ring atoms, a 5-membered heterocyclyl comprising at least one oxygen or sulfur ring atom, aN-bound 5-membered heteroaryl comprising one, two, or three nitrogen ring atoms, a C-bound 5-membered heteroarylAttorney Docket No. PSE-002WOcomprising at least one oxygen or sulfur ring atom, and a 6-membered heteroaryl comprising one or two nitrogen ring atoms;R' is H or C1-C4 alkyl;Z is CR7orN;R1is H or C1-C4 alkyl;R2is selected from the group consisting of H, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C3-C4 cycloalkoxy, and 4-5 membered heterocycloalkoxy;R3is each independently selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, and C3-C6 cycloalkyl,or two R3S on the same carbon together with the carbon atom to which the two R3S are attached form a C -C6 cycloalkylene, or two R3s on different carbons within the ring form a C1-C4 bridging alkylene;R4is selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkylene-Cs-Ce cycloalkyl, Ci-Ce haloalkylene-C3-C6 cycloalkyl, Ci-Ce alkoxy-Cs-Ce cycloalkyl, Ci-Ce haloalkoxy-C3-C6 cycloalkyl, Ci-Ce alkoxy-4-6 membered heterocyclyl, Ci-Ce alkoxy-5-6 membered heteroaryl, N(R8)2, and 4-6 membered heterocyclyl,wherein the Ci-Ce alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkoxy-C3-C6 cycloalkyl, Ci-Ce haloalkoxy-Cs-Ce cycloalkyl, and 4-6 membered heterocyclyl are optionally substituted with one, two, three, or four RA;R5is each independently selected from the group consisting of H, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, and N(R8)2;when - is double bond, R7is absent; when - is single bond, R7is selected from the group consisting of H, hydroxy, cyano, and C1-C4 alkyl;R8is each independently H or Ci-Ce alkyl;RAis each independently selected from the group consisting of halogen, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce alkyl-Ci-Ce alkoxy, and Ci-Ce haloalkoxy;t is 0, 1, or 2; andn is 0, 1, 2, 3, or 4.Attorney Docket No. PSE-002WO
[0063] In some embodiments of Formula (A), (I), (I-A), or (II), Ring A is 5-6-membered heterocyclyl substituted with one or two oxo or =NH and comprising one, two, or three nitrogen ring atoms.
[0064] In some embodiments of Formula (A), (I), (I-A), or (II), Ring A is 6-membered heterocyclyl substituted with one or two oxo and comprising one or two nitrogen ring atoms.
[0065] In some embodiments of Formula (A), (I), (I-A), or (II), Ring A is 5-membered heterocyclyl substituted with oxo or =NH and comprising one, two, or three nitrogen atoms.
[0066] In some embodiments of Formula (A), (I), (I-A), or (II), Ring A is C-bound 5-membered heteroaryl comprising at least one oxygen or sulfur ring atom. In some embodiments of Formula (A), (I), (I-A), or (II), the heteroaryl comprises one oxygen or sulfur ring atom and one or two nitrogen ring atoms.
[0067] In some embodiments of Formula (A), (I), (I-A), or (II), Ring A is N-bound 5-membered heteroaryl comprising one, two, or three nitrogen ring atoms.
[0068] In some embodiments of Formula (A), (I), (I-A), or (II), Ring A is 6-membered heteroaryl comprising one or two nitrogen ring atoms.Attorney Docket No. PSE-002WO
[0069] In some embodiments of Formula (A), (I), (I-A), or (II), Ring A is selected from the group consisting of:Attorney Docket No. PSE-002WO
[0070] In some embodiments of Formula (A), (I), (I-A), or (II), Ring A is selected from the group consisting of:
[0071] In some embodiments of Formula (A), (I), (I-A), or (II), Ring A is selected from the group consisting of:R5[00072J In some embodiments of Formula (A), (1), (1-A), or (11), Ring A is selected from the group consisting of:Attorney Docket No. PSE-002WO
[0073] In some embodiments of Formula (A), (I), (I-A), or (II), Ring A is selected from the group consisting of:
[0074] In some embodiments of Formula (A), (I), (I-A), or (II), Z is CR7.
[0075] In some embodiments of Formula (A), (I), (I-A), or (II), R7is selected from the group consisting of H, hydroxy, and C1-C2 alkyl. In some embodiments of Formula (A), (I), (I-A), or (II), R7is H.
[0076] In some embodiments of Formula (A), (I), (I-A), or (II), Z is N.
[0077] In some embodiments of Formula (A), (I), (I-A), or (II), R1is H or C1-C2 alkyl. In some embodiments of Formula (A), (I), (I-A), or (II), R1is H.
[0078] In some embodiments of Formula (A), (I), (I-A), or (II), R2is selected from the group consisting of H, halogen, C1-C4 alkyl, and C3-C4 cycloalkoxy. In some embodiments of Formula (A), (I), (I-A), or (II), R2is selected from the group consisting of H, halogen, and C1-C2 alkyl. In some embodiments of Formula (A), (I), (I-A), or (II), R2is H.
[0079] In some embodiments of Formula (A), (I), (I-A), or (II), n is 0, 1, or 2. In some embodiments of Formula (A), (I), (I-A), or (II), n is 0 or 1. In other embodiments of FormulaAttorney Docket No. PSE-002WO(A), (I), (I-A), or (II), n is 0. In other embodiments of Formula (A), (I), (I-A), or (II), n is 1. In other embodiments of Formula (A), (I), (I-A), or (II), n is 2.
[0080] In some embodiments of Formula (A), (I), (I-A), or (II), R3is each independently selected from the group consisting of halogen, Ci-Ce alkyl, and C3-C6 cycloalkyl. In some embodiments of Formula (A), (I), (I-A), or (II), R3is each independently C1-C4 alkyl or C3-C4 cycloalkyl. In some embodiments of Formula (A), (I), (I-A), or (II), R3is each independently C1-C2 alkyl.
[0081] In some embodiments of Formula (A), (I), (I-A), or (II), two R3s on the same carbon together with the carbon atom to which the two R3s are attached form a C3-C4 cycloalkylene. In some embodiments of Formula (A), (I), (I-A), or (II), two R3s on different carbons within the ring form a C2-C3 bridging alkylene.
[0082] In some embodiments of Formula (A), (I), or (I-A), R4is each independently selected from the group consisting of H, halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkoxy-C3-Ce cycloalkyl, N(R8)2, 4-6 membered heterocyclyl, and C(O)C3-Cecycloalkyl, wherein the C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkoxy-Cs-Ce cycloalkyl, and 4-6 membered heterocyclyl are optionally substituted with one or two RA.
[0083] In some embodiments of Formula (A), (I), or (I-A), R4is each independently selected from the group consisting of H, halogen Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, and C3-C6 cycloalkoxy.
[0084] In some embodiments of Formula (A), (I), or (I-A), R4is each independently selected from the group consisting of H, Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkoxy.
[0085] In some embodiments of Formula (A), (I), (I-A), or (II), R4is each independently selected from the group consisting of Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkoxy.
[0086] In some embodiments of Formula (A), (I), (I-A), or (II), R4is C1-C4 alkoxy. In some embodiments of Formula (A), (I), (I-A), or (II), R4is C1-C4 haloalkoxy. In some embodiments of Formula (A), (I), (I-A), or (II), R4is C3-C4 cycloalkoxy.
[0087] In some embodiments of Formula (A), (1), (1-A), or (11), R5is each independently selected from the group consisting of H, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl,Attorney Docket No. PSE-002WOCi-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, andN(R8)2. In some embodiments of Formula (A), (I), (I-A), or (II), R5is each independently selected from the group consisting of H, halogen, hydroxy, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C3-C4 cycloalkyl, and NH2. In some embodiments of Formula (A), (I), (I-A), or (II), R4is each independently selected from the group consisting of C1-C4 alkoxy, C1-C4 haloalkoxy, and C3-C4 cycloalkoxy.
[0088] In some embodiments of Formula (A), (I), (I-A), or (II), R5is each independently selected from the group consisting of H, F, Cl, hydroxy, cyano, C1-C4 alkyl, C1-C4 haloalkyl, Ci-C4 alkoxy, and NH2.
[0089] In some embodiments of Formula (A), (I), (I-A), or (II), t is 0 or 1. In some embodiments of Formula (A), (I), (I-A), or (II), t is 0. In some embodiments of Formula (A), (I), (I-A), or (II), t is 1.
[0090] In another aspect, provided herein is a compound of Formula (III):Formula (III)or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein indicates single bond or double bond;Ring A is 6-membered heterocyclyl substituted with oxo and comprising one or two nitrogen ring atoms;X15is CH orN;L2is bond or C(O);R11is H or C1-C4 alkyl;R13is each independently selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, and Ci-Ce haloalkyl;R14is each independently selected from the group consisting of halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, and Ci-Ce haloalkoxy;Attorney Docket No. PSE-002WOs is 0, 1, 2, or 3; andt is 0, 1, or 2.
[0091] In some embodiments of Formula (III), X15is CH. In some embodiments of Formula (III), X15is N.
[0092] In some embodiments of Formula (III), L2is bond. In some embodiments of Formula (III), L2is C(O).
[0093] In some embodiments of Formula (III), R11is H.
[0094] In some embodiments of Formula (III), s is 0, 1, or 2. In some embodiments of Formula (III), s is 0 or 1. In some embodiments of Formula (III), s is 0. In some embodiments of Formula (III), s is 1. In some embodiments of Formula (III), s is 2.
[0095] In some embodiments of Formula (III), R13is each independently selected from the group consisting of halogen, hydroxy, cyano, C1-C4 alkyl, and C1-C4 haloalkyl. In some embodiments of Formula (III), R13is each independently selected from the group consisting of halogen and C1-C2 alkyl.
[0096] In some embodiments of Formula (III), R14is each independently C1-C4 alkyl or C1-C4 haloalkyl.
[0097] In some embodiments of Formula (III), t is 0 or 1. In some embodiments of Formula (III), t is 0. In some embodiments of Formula (III), t is 1. In some embodiments of Formula (III), t is 0.
[0098] In some embodiments, the compound is selected from Table 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.Table 1Number Structure Number Structure / \=O / \=O rfi-i NH P-1 P-2H \ / N— '1 IH X X zx0CM T ZAttorney Docket No. PSE-002WO X? \ Z 0 0 / NHP-3 P-4H \ / N— ' Cx1 X / M 'o b X X cM 'ozo NH2<TP-5 P-6N<C— / 1CM OT \\Z CM z X X zMT oo Zz \9 ^ JplH !TP-7 \^D oz JVj^ LDZ J P-8 oX X >XO TZy 7Xs IZ IZ^ XXo o oP-9z'o Vo iP-11 P-12(IX Attorney Docket No. PSE-002W I I I o o zOzl zzT^ |Z W^X''X^O o Z^zDJ P-13 P-14 TZ °TZXs"ZT ZTA x?^^^^N^NZ o Oz O O oHz \ N NHHN >' r^ o~P-15 o oI I P-16H \ / J T ZZ CIX H I N N z HH N ,^O N' VsN' Y V ZNzH VNH <Z °P-17 P-18H \ Z £ / O H \ / / <7^Nf T7 IZ> ^ Z O 1 X zMZIH.NH N' O ^^z o P-19 1 zP-20zI2- / / ^^N N^i / I ZA o 0P-21 P-22h _ NHN'^NHP-23 P-24H \ / Jf0Attorney Docket No. PSE-002WO H N NH o o VNHP-25 P-26H \ / Z 4ZT ZIs^X' oz^X^ crz 1 I N NH2ZX Nz / -' XX XX2oP-27 ' . Z oH \ / P-28oJ IxoOX* IZ hX zs^P-29 I 1 IX / O , P-30 / o C <)'Z / ^- TZXs"ZZIX-ZTs Xs ^OH o X zNV^X^ OZ 17EzP-31 P-32 XX zx^ ^xu z z X Xzxxo J y I I o OH IP-33 P-34X Xxx oAttorney Docket No. PSE-002WO0 0 o T NH ( / NH P-35 P-36H \ \ (ZTK H \ / 1 AH / L / T A^O^^-77oo o X^ doz <^ NH TP-37 JA P-38H \ / N^TNXN^V' »NC / lJ! o J!ToP-39 P-40zz / A“ (J\Z^O^ 1N X^^Z740.O OP-41 P-42 / °^N^N C3H TJG^b 0 N ^,0HN' Vs\=N - ( / NH P-43N ^ H \ / P-44- N W H \ / 11 A / T Aci^^^70 N^N1 JL / T AbAttorney Docket No. PSE-002WOO 0 N^^NH \ _ HP-45 P-46H \ / H \ / N^NJI / L 1 / Lb bo \0HN^ / V NH / NH P-47 P-48H \ / H \ / N-^N N^VNX / II / L ji JL / M<O O0 0 ( / NH / NH \=N"P-49 P-50 / - / \— F H \ / H ( )F FN^TNXN^NX11 1 1 / L / T Ab o0 0 / NH / NHP-51 P-52H \ / / ^^NH N^XIXZS)Attorney Docket No. PSE-002WO0 0 / NH F—P NH P-53 P-54H \ / H \ / N-NN-^TN\ / JU ±xo ir0 0 "QTH / NHP-55 P-56H \ / H\ / N"V\ / 11 1cTo 0 V NH / NH P-57 P-58H \ / N-^NN'NV_1I 1o tr0 0 JD— \lH / NHP-59 H \ / P-60 H \ / N^N N"\ / 1 ±O ILoFJUFFAttorney Docket No. PSE-002WO 0 O ( / NH / NH P-61 P-62H \ / H \ / N N^NA / \ JI / A \ I zM oL00 z^\ / OH NAN / T V NH KAP-63 P-64 H (j>N'-V'N WN'-'V'N JI / L / Hxo / =\ oN^X ° / / A _ Z' N— < / NH \= / NH P-65 P-66H \ / H \ / NN^TNX / ^T^N> < Jl JLA V o / OH N OH A AP-67 P-68 N^ VjOu / L AA ii J MAttorney Docket No. PSE-002WO O N OHoN\ J> / NHo\ Z=P-69 H \ / P-70ZZCN ii^ JBIIZT%.r \ °FoI J\ ^OH oZENKP-71 P-72H 0 N^N\ / II 1 } iF 0 N^V^F ( / NHH HP-73 P-74N^NII JL O U A / T AxotfFJ\ ^OHNVP-75 P-76- 0Attorney Docket No. PSE-002WOF FA ^°H A -OHN / T v kJ P-77 P-78 / RRR / i k^ ji 1 II J M p-N^^^70 0 F— AJF FA ^OH A ^OHN / TNV kJ kJ P-79 P-80H . H .X O nF AXR FN / TkJ VP-81 P-82 / ■"(sRH yW H F H NNJP-83 P-84C—1 ji J NA1 Xzxxo
[0099] In one aspect, provided herein is a pharmaceutical composition, comprising a compound described herein, for example, a compound of Formula A, Formula I, Formula T-A, Formula II, or Formula III, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.Attorney Docket No. PSE-002WOFurther Forms of Compounds Disclosed HereinIsomers / Stereoisomers[000100] In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the corresponding mixtures thereof. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R configuration or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers. In some embodiments, dissociable complexes are preferred. In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably, by separation / resolution techniques based upon differences in solubility. In some embodiments, the optically pure enantiomer is then recovered, along with the resolving agent.Labeled compounds[000101] In some embodiments, the compounds described herein exist in their isotopically labeled forms. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds described herein, or a solvate, orAttorney Docket No. PSE-002WOstereoisomer thereof, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, and chloride, such as2H,3H,13C,14C,15N,18O,170,31P,32P,35S,18F, and36C1, respectively. Compounds described herein, and the pharmaceutically acceptable salts, solvates, or stereoisomers thereof which contain the aforementioned isotopes and / or other isotopes of other atoms are within the scope of this disclosure. Certain isotopically labeled compounds, for example those into which radioactive isotopes such as3H and14C are incorporated, are useful in drug and / or substrate tissue distribution assays. Tritiated, i.e.,3H and carbon-14, i.e.,14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavy isotopes such as deuterium, i.e.,2H, produces certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. In some embodiments, the isotopically labeled compound or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is prepared by any suitable method.[000102] In some embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.Pharmaceutically acceptable salts[000103] In some embodiments, the compounds described herein exist as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.[000104] In some embodiments, the compounds described herein possess acidic or basic groups and therefor react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.[000105] Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid, or inorganic base, such salts including acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate,Attorney Docket No. PSE-002WObisulfate, bisulfite, bromide, butyrate, butyn-l,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, di nitrobenzoate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, y-hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-napthalenesulfonate, 2-napthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3 -phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylateundeconate, and xylenesulfonate.[000106] Further, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-l -carboxylic acid, glucoheptonic acid, 4,4’-methylenebis-(3-hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid.[000107] In some embodiments, those compounds described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, or sulfate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine. Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, andAttorney Docket No. PSE-002WOmagnesium, and aluminum salts and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N+(Cl-4 alkyl)4, and the like.[000108] Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quaternization.Solvates[000109] In some embodiments, the compounds described herein exist as solvates. The disclosure provides for methods of treating diseases by administering such solvates. The disclosure further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.[000110] Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.Tautomers[000111] In some situations, compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH.Attorney Docket No. PSE-002WOCompound SynthesisGeneral Synthetic Schemes[000112] Exemplary methods for preparing compounds described herein are illustrated in the following synthetic schemes. These schemes are given for the purpose of illustrating the scope of the disclosure, and should not be regarded in any manner as limiting the scope or the spirit of the claimed invention.[000113] The synthetic route illustrated in Schemes 1-2 depict exemplary procedures for preparing compounds of the disclosure.Scheme 1:[000114] As shown in Scheme 1, tetrahydropyridine 1 is prepared via cross coupling between boronate L-INT and halide R-INT (wherein X is halide) in the presence of a palladium catalyst. Compound FP-1 is prepared by a reduction process, for example, in palladium / carbon and hydrogen gas, wherein variables A, R1, R2, R3, X1, X2, X3, X4, t, p, q, and n are as defined herein (e.g., for compounds of Formula (A), (I), or (II)).Scheme 2:[000115] As shown in Scheme 2, compound FP-2 is prepared via amide coupling between carboxylic acid L-INT and intermediate R-INT, wherein variables A, R1, R2, R3, X1, X2, X3, X4, n, Z, L, t, p, and q are as defined herein (e.g., for compounds of Formula (A), (I), or (II)).Attorney Docket No. PSE-002WOPharmaceutical Compositions[000116] In certain embodiments, the compound described herein is administered as a pure chemical. In some embodiments, the compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21 st Ed. Mack Pub. Co., Easton, PA (2005)).[000117] Accordingly, provided herein is a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable excipient.[000118] In certain embodiments, the compound provided herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.[000119] Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and / or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and / or overall survival, or a lessening of symptom severity. Optimal doses are generally determined using experimental models and / or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient.[000120] In some embodiments, the pharmaceutical composition is formulated for oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, intrapulmonary, intradermal, intrathecal, and epidural and intranasal administration. Parenteral administration includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, the pharmaceutical composition is formulated for intravenous injection, oral administration, inhalation, nasal administration, topicalAttorney Docket No. PSE-002WOadministration, or ophthalmic administration. In some embodiments, the pharmaceutical composition is formulated for oral administration. In some embodiments, the pharmaceutical composition is formulated for intravenous injection. In some embodiments, the pharmaceutical composition is formulated as a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop, or an ear drop. In some embodiments, the pharmaceutical composition is formulated as a tablet.[000121] Suitable doses and dosage regimens are determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound disclosed herein.Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In some embodiments, the present method involves the administration of about 0.1 pg to about 50 mg of at least one compound described herein per kg body weight of the subject. For a 70 kg patient, dosages of from about 10 pg to about 2000 mg of the compound disclosed herein would be more commonly used, depending on a subject’s physiological response.[000122] By way of example only, the dose of the compound described herein for methods of treating a disease as described herein is about 0.001 to about 1 mg / kg body weight of the subject per day, for example, about 0.001 mg / kg, about 0.002 mg / kg, about 0.005 mg / kg, about 0.010 mg / kg, 0.015 mg / kg, about 0.020 mg / kg, about 0.025 mg / kg, about 0.050 mg / kg, about 0.075 mg / kg, about 0.1 mg / kg, about 0.15 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.5 mg / kg, about 0.75 mg / kg, or about 1 mg / kg body weight per day. In some embodiments, the dose of compound described herein for the described methods is about 1 to about 1000 mg / kg body weight of the subject being treated per day, for example, about 1 mg / kg, about 2 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 50 mg / kg, about 75 mg / kg, about 100 mg / kg, about 150 mg / kg, about 200 mg / kg, about 250 mg / kg, about 500 mg / kg, about 750 mg / kg, or about 1000 mg / kg body weight per day.Methods of Treatment[000123] The compounds disclosed herein, or pharmaceutically acceptable salts, solvates, tautomers or stereoisomers thereof, are useful in treating a disease, disorder, or condition associated with suboptimal (e.g., upregulated or increased) AKR1C3 activity.Attorney Docket No. PSE-002WO[000124] In some embodiments, the suboptimal AKR1C3 activity is associated with dysregulation or abnormal signaling of one or more pathways involving AKR1C3.[000125] In some embodiments, the compounds disclosed herein, or pharmaceutically acceptable salts, solvates, tautomers, or stereoisomers thereof are inhibitors of AKR1C3.[000126] Provided herein, in part, is a method of modulating (e.g., inhibiting) AKR1C3 in a subject in need thereof, comprising administering to the subject an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer, thereof or a pharmaceutical composition disclosed herein.[000127] In another aspect, the present disclosure provides a method of treating a disease, disorder, or condition associated with suboptimal (e.g., upregulated or increased) AKR1C3 activity, comprising administering to the subject an effective amount (e.g., a therapeutically effective amount) of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition disclosed herein.[000128] In some embodiments, the disease, disorder, or condition associated with suboptimal (e.g., upregulated or increased) AKR1C3 activity is selected from the group consisting of hyperandrogenism including but not limited to polycystic ovarian syndrome (PCOS), dysmenorrhea, precocious puberty, hirsutism, infertility, atopic dermatitis, seborrheic eczema, acne, obesity, alopecia such as androgenic alopecia, chronic obstructive pulmonary disease (COPD), endometriosis, uterine bleeding disorders, uterine fibroids, pain related to inflammation, benign prostatic hyperplasia (BPH), certain cancers (including but not limited to: lung cancer (including small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC)), prostate cancer (e.g., castration-resistant prostate cancer), breast cancer, invasive breast ductal carcinoma, triple negative breast cancer, endometrial carcinoma, renal cell carcinoma, bladder carcinoma, pancreatic adenocarcinoma, acute myeloid leukemia, T-Cell acute lymphoblastic leukemia, melanoma, non-Hodgkins lymphoma), certain metabolic disorders including but not limited to hyperinsulinemia, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD), increased cardiovascular risk such as hypertension, acne, rosacea, and femalepattern hair loss (such as androgenic alopecia).[000129] In some embodiments, the disease, disorder, or condition is hyperandrogenism. In some embodiments, the disease, disorder, or condition is polycystic ovary syndrome (PCOS). In some embodiments, the disease, disorder, or condition is hirsutism. In certain embodiments, theAttorney Docket No. PSE-002WOdisease, disorder, or condition is endometriosis. In certain embodiments, the disease, disorder, or condition is cancer. In some embodiments, the disease, disorder, or condition is a metabolic disorder.[000130] In some embodiments, the subject is a female human.[000131] In some embodiments, the subject is male human.Combination Therapy[000132] In certain instances, the compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered in combination with a second therapeutic agent.[000133] In some embodiments, the benefit experienced by a patient is increased by administering one of the compounds described herein with a second therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.[000134] In one specific embodiment, a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof, is co-administered with a second therapeutic agent, wherein the compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and the second therapeutic agent modulate different aspects of the disease, disorder or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.[000135] In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient is simply additive of the two therapeutic agents or the patient experiences a synergistic benefit.EXAMPLES[000136] The compounds described herein can be prepared in a number of ways based on the teachings contained herein and synthetic procedures known in the art. In the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be chosen to be the conditions standard for that reaction, unless otherwise indicated. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are thereforeAttorney Docket No. PSE-002WOindicated. The starting materials for the examples are either commercially available or are readily prepared by standard methods from known materials. At least some of the compounds identified as “Intermediates” herein are contemplated as compounds of the disclosure.AbbreviationsAcN: acetonitrileAcOH: acetic acidBINAP: (2,2'-bis(diphenylphosphino)-l,l'-binaphthyl)DABCO: (l,4-diazabicyclo[2.2.2]octane)DBU: l,8-Diazabicyclo[5.4.0]undec-7-eneDCM: dichloromethaneDIPEA: diisopropylethylamineDMAP: dimethylaminopyridineDMF: dimethylformamideDMSO: dimethyl sulfoxideEtOAc: ethyl acetateEDC1: l-Ethyl-3-(3-dimethylaminopropyl)carbodiimideEtOH: ethanolHATU: l-[Bis(dimethylamino)methylene]-l / -l,2,3-triazolo[4,5- / >]pyridinium-3-oxide hexafluorophosphateHPLC: high performance liquid chromatographyHOBt: 1 -Hydroxy benzotri azoleiPrMgBr: isopropyl magnesium bromideLAH: lithium aluminium hydrideLDA: lithium diisopropylamideMeOH: methanolMeCN: acetonitrilenBuLi: n-butyl lithiumOAc: acetatePE: petroleum etherPd(AcO)2: palladium(ll) acetatePd(dba)2: tris(dibenzylideneacetone)dipalladium(0)Attorney Docket No. PSE-002WOPd(dppf)Ch: 1,1 '-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)Pd(dtbupf)C12: dichloro[l,r-bis(di-tert-butylphosphino)ferrocene]palladium(II) Pd(PPh3)4: tetrakis(triphenylphosphine)palladium(0)SEM: 2-(trimethylsilyl)ethoxymethylSFC: supercritical fluid chromatographyt-BuO: tert-butoxideTEA: triethylamineTFA: trifluoroacetic acidTHF : tetrahydrofuranTMEDA: TetramethylethylenediamineXPhos: 2-dicyclohexylphosphino-2',4',6’-triisopropylbiphenylLCMS Methods:LCMS Method A - NanoChrom ChromCore 120 C18 3um,3.0*30mmLCMS Method B - Instrument: Agilent 1260-6125MSD, Column: Waters CORTESS C-18,4.6*30mm,2.7 um, Mobile phase: ACN(0.05%FA)-Water(0.05%FA), Gradient: 5% ACN to 95%ACN in 3.0min, hold l.Omin, total 5.0min, Flow rate:1.8mL / min, Column Temp: 40 degree CelsiusLCMS Method C - SHIMADZU ShimNex HE C18-AQ 3um,3.0*30mmLCMS Method D - Titank C18 5um 50*2.1mmLCMS Method E - Chromolith. Flash RP-18e 25-3 mmLCMS Method F - AB:ChromCore 120 C18, 3um, 3.0*30mm CD:Titank C18, 5um, 2.1*50mmRoutes to L-IntermediatesCommercially available L-IntermediatesNo Structure No StructureH H OH N"^r-N OHL-4 L-5 J!CAS: 4382-54-1 CAS: 17288-36-7H OH H0L-6 JI J L-70 OHCAS: 800401-68-7 CAS: 17288-33-4Attorney Docket No. PSE-002WORoute to L-lStep 1 - [000137] A solution of tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-l -carboxylate 1 (1 g, 3.23 mmol) in HC1 (4.0 M in 1,4-di oxane) (10 mL) was stirred at 25 °C for Ihr. TLC showed starting material was consumed completely and new one spot was detected. The solvent was removed to afford 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,2,3,6-tetrahydropyridine 2 (700 mg, crude) as a white solid.[000138]1H NMR (400 MHz, METHANOL-d4) 56.50 (br s, 1H), 3.77 (br d, J = 2.8 Hz, 2H), 3.35 (t, J = 1.6 Hz, 2H), 2.54 - 2.43 (m, 2H), 1.52 - 1.50 (m, 1H), 1.31 (s, 12H)Step 2 - [000139] A solution of 5-methoxy-lH-indole-2-carboxylic acid L-4 (548.61 mg, 2.87 mmol) in DMF (14.58 mL) was added HATU (1.20 g, 3.16 mmol) followed by DIEA (1.85 g, 14.35 mmol, 2.50 mL) and was stirred at 25 °C for 5 minutes. Then 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,2,3,6-tetrahydropyridine 2 (600 mg, 2.87 mmol) was added. The mixture was stirred at 25 °C for 3 hours. LCMS showed starting material was consumed completely and desired compound was detected. The residue was diluted with water (10 mL) and extracted withAttorney Docket No. PSE-002WOEtOAc (10 mL x 3). The combined organic layer was washed with saturated brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure before purification by flash silica gel chromatography to afford (5-methoxy-lH-indol-2-yl)-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridin-l-yl]methanone L-l (1 g, 2.22 mmol, 77.49% yield, 85% purity) as a yellow solid.[000140] LCMS (ESI): m / z = 383.0 [M+ H]+[000141]1H NMR (400 MHz, METHANOL-d4) 57.33 (d, J = 9.0 Hz, 1H), 7.10 (d, J = 2.4 Hz, 1H), 6.89 (dd, J = 2.4, 8.8 Hz, 1H), 6.79 (s, 1H), 6.51 (br s, 1H), 4.62 - 4.19 (m, 2H), 3.99 -3.83 (m, 2H), 3.82 (s, 3H), 2.37 (br s, 2H), 1.27 (s, 12H)Route to L-2HATU, DIEA1 Step 1 2 Step 2Step 1 - [000142] A solution of tert-butyl 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,5-dihydropyrrole-1 -carboxylate 1 (2 g, 6.78 mmol) in HCl / dioxane (15 mL) was stirred at 25 °C for Ihr. TLC showed starting material was consumed completely and new one spot was detected. The solvent was removed to afford 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,5-dihydro-IH-pyrrole 2 (1.3 g, crude) as a white solid.[000143]JH NMR (400 MHz, METHANOL-d4) 86.52 - 6.44 (m, 1H), 4.12 (s, 4H), 1.31 -1.26 (m, 12H)Step 2 - [000144] A solution of 5-methoxy-lH-indole-2-carboxylic acid L-4 (1.18 g, 6.15 mmol) in DMF (15 mL) was added HATU (2.57 g, 6.77 mmol) followed by DIEA (3.98 g, 30.76 mmol, 5.36 mL) and was stirred at 25 °C for 5 minutes. Then 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,5-dihydro-lH-pyrrole 2 (1.2 g, 6.15 mmol) was added. The mixture was stirred at 25 °C for 16 hours. LCMS showed starting material was consumed completely andAttorney Docket No. PSE-002WOdesired compound was detected. The residue was diluted with water (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic layer was fdtered and dried to afford (5-methoxy-lH-indol-2-yl)-[3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,5-dihydropyrrol-l-yl]methanone L-2 (2.2 g, 5.97 mmol, 97.12% yield) as a white solid.[000145] LCMS (ESI): m / z = 369.1 [M+ H]+[000146]1HNMR (400 MHz, DMSO-d6) 5 11.53 - 11.37 (m, 1H), 7.34 (d, J = 8.9 Hz, 1H), 7.19 - 7.05 (m, 1H), 6.94 - 6.89 (m, 1H), 6.89 - 6.84 (m, 1H), 6.57 (s, 1H), 4.74 - 4.62 (m, 2H), 4.48 - 4.35 (m, 2H), 3.81 - 3.73 (m, 3H), 1.29 - 1.21 (m, 12H)Route to L-31 Step 1 2 Step 2Step 1 - [000147] To a solution of tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-l -carboxylate 1 (3.3 g, 10.67 mmol), TFA (9.83 g, 86.25 mmol, 6.60 mL) in DCM (19.40 mL) was stirred at 20 °C for 30 minutes. LCMS showed starting material consumed and desired mass of product 2 appeared. The mixture was concentrated in vacuum to remove TFA, then basified with DIEA and concentrated in vacuum to get crude 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,2,3,6-tetrahydropyridine 2 (2.5 g, crude), which was directly used for next step.Step 2 - [000148] To a solution of 5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carboxylic acid L-5 (2.22 g, 11.57 mmol), HATU (6.00 g, 15.78 mmol) in DMF (25 mL) was stirred at 20 °C for 30 minutes, then 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,2,3,6-tetrahydropyridine 2 (2.2 g, 10.52 mmol) and DIEA (5.44 g, 42.09 mmol, 7.33 mL) were added and stirred at 20 °C for 12 hours. LCMS showed starting material was consumed and desired mass of product L-3 appeared. To the mixture was added water (50 mL), which precipitated a yellow solid that was collectedAttorney Docket No. PSE-002WOand dried. (5-methoxy-lH-pyrrolo[2,3-c]pyridin-2-yl)-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridin-l-yl]methanone L-3 (3.9 g, 9.16 mmol, 87.04% yield, 90% purity) was obtained as yellow solid.[000149] m / z= 384.2, [M+H]+[000150] 1HNMR (400 MHz, DMSO-d6) 5 = 11.76 (s, 1H), 8.39 (s, 1H), 6.90 (s, 1H), 6.68 (br s, 1H), 6.56 - 6.32 (m, 1H), 4.46 - 4.12 (m, 2H), 3.83 (s, 3H), 3.71 (br t, J = 5.4 Hz, 2H), 2.31 - 2.15 (m, 2H), 1.21 (s, 12H)Route to L-9o1 Step 1 3 Step 2 L-9Step 1 - [000151] To a mixture of aluminum chloride (2.13 g, 15.98 mmol, 859.41 pL) in DCM (16 mb) was added benzoyl chloride 2 (2.25 g, 15.98 mmol) under N2 atmosphere at 0 °C, before methyl lH-pyrrole-2-carboxylate 1 (1.0 g, 7.99 mmol) was added and the reaction mixture was stirred for lOh at 20 °C. LCMS indicated that desired product was observed. The reaction mixture was quenched with aq. HC1 (15mL,lM) and diluted with DCM (40mL) before the organic phase was washed with aq. NaHCCh (20mL), water (15mL), brine (15mL), dried over Na2SO4, filtered and concentrated. The crude material was purified by column chromatography to obtain methyl 4-benzoyl-lH-pyrrole-2-carboxylate 3 (1.51 g, 6.59 mmol, 82.42% yield).[000152] LCMS: m / z = 230.3 [M+H]+[000153] 'H NMR (400 MHz, METHANOL-d4) 57.85 - 7.78 (m, 2H), 7.65 - 7.59 (m, 1H), 7.57 - 7.49 (m, 3H), 7.29 (d, J = 1.5 Hz, 1H), 4.91 - 4.88 (m, 1H), 3.88 (s, 3H)Step 2 - [000154] To a mixture of methyl 4-benzoyl-lH-pyrrole-2-carboxylate 3 (1.51 g, 6.59 mmol) in methanol (10 mb) was added LiOH (631.01 mg, 26.35 mmol) in H2O (5 mL) at 20 °C, the reaction mixture was stirred for Ih at 40 °C. LCMS indicated that desired product wasAttorney Docket No. PSE-002WOobserved with some remaining starting material in the reaction mixture. NaOH (1.05 g, 26.35 mmol) was added, the reaction mixture was stirred for lOh at 40 °C. Followed by a second addition of NaOH (2.11 g, 52.70 mmol) and additional stirring for lOh at 60 °C. The reaction mixture was concentrated and diluted with water (20mL), the pH of the solution was adjusted to 4, the solution was extracted with EtOAc (20mL x 4), the organic phase was combined and concentrated to obtain 4-benzoyl-lH-pyrrole-2-carboxylic acid L-9 (1.4 g, 6.51 mmol, 98.76% yield).[000155] LCMS (ESI): m / z = 216.2 [M+H]1[000156]1H NMR (400 MHz, METHANOL-d4) 87.92 - 7.75 (m, 2H), 7.67 - 7.60 (m, 1H), 7.58 - 7.47 (m, 3H), 7.30 (d, J = 1.7 Hz, 1H), 4.96 - 4.91 (m, 1H)Route to L-10NaOH, MeOHStep 1Step 1 - [000157] To a solution of ethyl 5,5-dimethyl-4,6-dihydro-lH-cyclopenta[b]pyrrole-2-carboxylate 1 (1 g, 4.82 mmol) in MeOH (10 mL) was added H2O (2.5 mL) and NaOH (771.89 mg, 19.30 mmol). The mixture was stirred at 50 °C for 16 hours. TLC showed starting material was consumed completely and a new spot was detected. The mixture was concentrated to remove MeOH. The mixture was adjusted to pH 5-6 with HC1 (IM). The residue was diluted with H2O (10 mL) and extracted with EtOAc (15 mL x 3). The combined organic layer was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to afford 5,5-dimethyl-4,6-dihydro-lH-cyclopenta[b]pyrrole-2-carboxylic acid L-10 (800 mg, 3.48 mmol, 72.17% yield, 78% purity) as a brown solid.[000158] LCMS (ESI): m / z = 180.2 [M+ H]+[000159] ’HNMR (400 MHz, DMSO-d6) 8 = 11.84 (br s, 1H), 11.26 (br s, 1H), 6.44 (d, J = 1.7 Hz, 1H), 2.44 (s, 2H), 2.34 (s, 2H), 1.17 - 1.15 (m, 6H)Route to L-12Attorney Docket No. PSE-002WOStep 1 - A solution of DMF (24.92 g, 340.96 mmol, 26.4 mL) in 1,2-dichloroethone (40 mL) at 20 °C, was degassed and purged with N2 for 3 cycles, before POCI3 (41.78 g, 272.50 mmol, 25.4 mL) was added to the mixture dropwise at 0 °C. The mixture was allowed to stir at 20 °C for 30 minutes before a solution of norbornan-2-one 1 (15 g, 136.17 mmol) in 1,2-dichloroethone 10 mL) was added. The mixture was heated to 80 °C, the mixture was stirred under N2 at 80 °C for 12 hours. TLC showed starting material was consumed. The resulting mixture was concentrated under reduced pressure. Then the crude product was adjusted pH to 7 with sodium bicarbonate aqueous solution, extracted with DCM (100 mL), washed with water (100 mL x 2) and brine (100 mL), dried over Na2SC>4, fdtered and concentrated under vacuum before purification by automated flash column chromatography to afford 3-chlorobicyclo[2.2.1]hept-2-ene-2-carbaldehyde 2 (4.7 g, 30.01 mmol, 22.04% yield) as a colorless oil.[000160] 'H NMR (400 MHz, CHLOROFORM-d): 59.80 (s, 1 H), 3.42 (dd, >3.30, 1.59 Hz, 1 H), 3.07 (dd, >3.61, 1.77 Hz, 1 H), 1.87 - 1.94 (m, 1 H), 1.78 - 1.85 (m, 1 H), 1.64 - 1.69 (m, 1 H), 1.34 - 1.41 (m, 1 H), 1.30 (d, >8.93 Hz, 1 H), 1.17 - 1.25 (m, 1 H).Step 2 - [000161] A solution of 3-chlorobicyclo[2.2.1]hept-2-ene-2-carbaldehyde 2 (4.7 g, 30.01 mmol) in DCM (100 mL) was added ethyl 2-(triphenyl-phosphanylidene)acetate (10.46 g, 30.01 mmol) under N2 atmosphere, then the suspension was degassed and purged with N2 three times. The mixture was stirred under N2 at 20 °C for 16 hours at which point TLC showed most of the starting material was consumed. The resulting mixture was concentrated under reduced pressure before purification by flash column chromatography to afford (E)-3-(3-chloro-2-bicyclo[2.2.1]hept-2-enyl)prop-2-enoate 3 (4.75 g, 17.31 mmol, 57.67% yield, 82.6% purity) as a colorless oil.[000162] LCMS (ESI): m / z = 227.0 [M+H]+[000163] ‘HNMR (400 MHz, METHANOL-d4): 87.35 (d, >15.88 Hz, 1H), 5.97 (d, >15.76 Hz, 1H), 4.21 (q, J=7.05 Hz, 2H), 3.26 (br d, >1.50 Hz, 1H), 2.99 (br d, >1.63 Hz,Attorney Docket No. PSE-002WO1H), 1.80 - 1.94 (m, 2H), 1.61 - 1.67 (m, 1H), 1.34 (br d, J=8.38 Hz, 2H), 1.30 (t, J=7.13 Hz, 3H), 1.10 - 1.19 (m, 1H).Step 3 - [000164] To a solution of ethyl (E)-3-(3-chloro-2-bicyclo[2.2.1]hept-2-enyl)prop-2-enoate 3 (3 g, 13.23 mmol) in DMSO (25 mL) was added sodium azide (0.96 g, 14.77 mmol, 518.92 pL) at 25 °C under N2 atmosphere. The suspension was degassed and purged with N2 three times, before stirring under N2 at 100 °C for 16 hours. LCMS showed the starting material was consumed. The reaction mixture was quenched by addition of sodium carbonate aqueous solution, extracted with EtOAc (30 mL x 3), washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under vacuum obtain the crude product that was purified by flash column chromatography to afford ethyl (lS,7R)-3-azatricyclo[5.2.1.02,6]deca-2(6),4-diene-4-carboxylate 4 (2.1 g, 10.23 mmol, 77.31% yield) as a white solid.[000165] LCMS (ESI): m / z = 206.1 [M+H]+[000166] 'H NMR (400 MHz, METHANOL-d4): 86.62 (d, >0.66 Hz, 1 H), 4.30 (q, >7.12 Hz, 2H), 3.38 (br d, >1.54 Hz, 2H), 1.87 - 1.98 (m, 3H), 1.67 (dt, >8.47, 1.60 Hz, 1H), 1.39 (t, >7.15 Hz, 3H), 1.01 - 1.15 (m, 2H).Step 4 - [000167] To a solution of ethyl (lS,7R)-3-azatricyclo[5.2.1.02,6]deca-2(6),4-diene-4-carboxylate 4 (2.1 g, 10.23 mmol) in dioxane (15 mL) was added a solution of KOH (2.87 g, 51.16 mmol, 1.40 mL) in H2O (5 mL) at 25°C, before the mixture was stirred at 70 °C for 12 hours. LCMS showed starting material was consumed. The resulting mixture was concentrated under reduced pressure and adjusted to pH 6 with IM aqueous hydrochloric acid before being extracted with EtOAc (30 mL x 3), washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography to afford (lS,7R)-3-azatricyclo[5.2.1.02,6]deca-2(6),4-diene-4-carboxylic acid L-12 (1 g, 5.64 mmol, 55.16% yield) as a purple solid.[000168] LCMS (ESI): m / z = 178.1 [M+H]+[000169]1H NMR (400 MHz, DMSO-d6): 8 11.59 - 11.96 (m, 1H), 11.37 (br s, 1H), 6.40 (d, >0.88 Hz, 1H), 3.23 (br s, 1H), 3.20 (br s, 1H), 1.79 (br d, >6.82 Hz, 2H), 1.71 (br d, >8.36 Hz, 1H), 1.48 - 1.55 (m, 1H), 0.89 (br d, >5.94 Hz, 2H).Attorney Docket No. PSE-002WONaOHStep 1 L-14Step 1 - [000170] To a mixture of methyl l,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-carboxylate 1 (250 mg, 1.29 mmol) in MeOH (2 mL) was added NaOH (413.96 mg, 10.35 mmol) in water (5 mL), the reaction mixture was stirred for 10 hours at 50 °C. LCMS indicated that desired product was observed. The reaction mixture was concentrated and diluted with water (15 mL), the pH adjusted to 3, the water phase was extracted with EtOAc (15 mL x 4), the organic phase was combined and washed with brine (20 mL), dried over Na2SO4, filtered and concentrated to obtain l,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-carboxylic acid L-14 (231 mg, crude).[000171]1H NMR (400 MHz, METHANOL-d4) 86.60 (s, 1H), 2.77 - 2.67 (m, 2H), 2.59 - 2.51 (m, 2H), 1.89 - 1.80 (m, 2H), 1.66 (quint, J = 5.6, 10.9 Hz, 4H)Route to L-15Pc^dba^ XPhosStep 1 2 Step 2 3 Step 3 Step 4Step 1 - [000172] To a solution of 3-bromo-5-methoxy-pyridine 1 (1.5 g, 7.98 mmol) tert-butyl carbamate (934.57 mg, 7.98 mmol), XPhos (1.14 g, 2.39 mmol), CS2CO3 (6.50 g, 19.94 mmol) in Dioxane (18 mL) was stirred at 90 °C for 17 hours under N2. LCMS showed starting material was consumed and the desired product mass was detected. The reaction was quenched with water (15 mL) and extracted with EtOAc (20 mL x 3). The organic layer was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated before purification by columnAttorney Docket No. PSE-002WOchromatography to give tert-butyl N-(5-m ethoxy-3 -pyridyl)carbamate 2 (1.2 g, 4.97 mmol, 62.24% yield, 92.8% purity) as light-yellow solid.[000173] LCMS (ESI): m / z = 225.1 [M+H]+[000174]1H NMR (400 MHz, DMSO-d6) 59.58 (s, 1H), 8.33 - 8.10 (m, 1H), 7.92 (d, J = 2.6 Hz, 1H), 7.57 (br s, 1H), 3.79 (s, 3H), 1.49 (s, 9H)Step 2 - [000175] To a solution of tert-butyl N-(5-methoxy-3-pyridyl)carbamate 2 (600 mg, 2.68 mmol) in THF (5 m ) was added TMEDA (994.86 mg, 8.56 mmol, 1.28 mL). The solution was cooled to -78 °C then nBuLi (2.5 M, 3.42 mL) was added under N2 while maintaining the internal temperature below - 60 °C. The mixture was stirred at -78 °C for 30 minutes. I2 (1.09 g, 4.28 mmol) in THF (5 mL) was added dropwise while maintaining the internal temperature below - 60 °C. The mixture was allowed warm to 15 °C after addition and stirred for an additional 16 hours. LCMS show the mass of the desired product, and the reaction was quenched with NH4Cl.aq (15 mL) and extracted with EtOAc (15 mL x 3). The organic layer was washed with brine (lOmL), dried over Na2SC>4, filtered and concentrated before purification by flash silica gel chromatography to give tert-butyl N-(4-iodo-5-methoxy-3-pyridyl)carbamate 3 (470 mg, 1.31 mmol, 48.81% yield, 97.3% purity) as yellow solid.[000176] LCMS(ESI): m / z=351.0 [M+H]+[000177] 'H NMR (400 MHz, DMSO-d6) 58.72 (s, 1H), 8.08 (s, 1H), 8.01 (s, 1H), 3.96 (s, 3H), 1.46 (s, 9H)Step 3 - [000178] To a solution of tert-butyl N-(4-iodo-5-methoxy-3-pyridyl)carbamate 3 (470 mg, 1.34 mmol) in DCM (2 mL) was added HC1 (2.0 M in 1,4-dioxane) (5 mL) dropwise. The mixture was allowed to warm to 15 °C after addition and stirred for 7 hours. LCMS showed the mass of the desired product, and the reaction was concentrated to give 4-iodo-5-methoxy-pyri din-3 -amine 4 (340 mg, 1.33 mmol, 99.38% yield, 98.1% purity) as yellow solid.[000179] LCMS (ESI): m / z = 250.9 [M+H]+[000180]XH NMR (400 MHz, DMSO-d6) 57.72 (s, 1H), 7.70 - 7.65 (m, 1H), 6.77 - 6.11 (m, 1H), 3.97 (s, 3H)Step 4 -Attorney Docket No. PSE-002WO[000181] A mixture of 4-iodo-5-methoxy-pyridin-3-arnine 4 (340 mg, 1.36 mmol), 2-oxopropanoic acid 5 (179.62 mg, 2.04 mmol), DABCO (305.06 mg, 2.72 mmol, 299.08 pL) in DMF (6 mL) was degassed and purged with N2 three times. Then Pd(AcO)2 (61.06 mg, 271.96 pmol, 27.88 pL) was added. The mixture was stirred at 115 °C for 4 hours under N2 atmosphere.[000182] LCMS showed the starting material was consumed and one main peak with desired mass was detected. DMF was removed under reduced pressure. Toluene (4mL) was added to the mixture and sonicated in an ultrasound bath for 15 minutes. Then toluene was decanted while the brown solid remained. The solid was redissolved in water (5 mL) and the turbid liquid was sonicated while HC1 (IM, in water) was added dropwise to adjust pH to 5. The crude material was filtered, the filter cake was washed with MeCN (2 mL) and sonicated for 30 minutes. The aqueous phase was removed, and the remaining fraction was lyophilized for 48 hours to give the crude product that was diluted with MeOH(10 mL) and stirred for 15 minutes, filtered and concentrated in vacuum to give 4-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carboxylic acid L-15 (230 mg, 964.66 pmol, 70.94% yield, 80.6% purity) as yellow solid.[000183] LCMS (ESI): m / z = 193.1 [M+H]+[000184] 'H NMR (400 MHz, DMSO-d6) 5 13.67 (br s, 1H), 8.82 (s, 1H), 8.08 (s, 1H), 7.35 (s, 1H), 4.11 (s, 3H)Route to L-16Step 1 - [000185] A solution of methyl 3-fluoropyridine-4-carboxylate 1 (1 g, 6.45 mmol), tert-butyl 2-aminoacetate 2 (1.01 g, 7.74 mmol) and DIPEA (1.67 g, 12.89 mmol, 2.25 mL) in DMA (20 mL) was stirred at 80 °C for 12 hours in sealed tube. LCMS showed the reaction was incomplete, and the mixture was heated to 100 °C and stirred at this temperature for 21 h.[000186] The reaction mixture was poured into water (40 mL) and extracted with EtOAc (20 mLx3). the extract was concentrated in vacuo, the residue was purified by flash column chromatography to afford methyl 3-[(2-tert-butoxy-2-oxo-ethyl)amino]pyridine-4-carboxylate 3Attorney Docket No. PSE-002WO(850 mg, 2.55 mmol, 39.61% yield, 80% purity) as slight yellow oil and was used in the following reaction without further purification.Step 2 - [000187] To a solution of methyl 3-[(2-tert-butoxy-2-oxo-ethyl)amino]pyridine-4-carboxylate 3 (850 mg, 2.55 mmol) in toluene (20 mL) was added 30 wt.% NaOMe in methanol (919.69 mg, 5.11 mmol, 30% purity) at 20 °C. The solution was stirred at 80 °C for 1 hour. LCMS showed most of starting material was consumed and the mass of the desired product was seen. The mixture was cooled to rt and filtered and rinsed with toluene (20 mL). The solid was dissolved in water (10 mL), and solid NH4C1 (1.1 g) was added to the red solution, followed by EtOAc (10 mL). After agitation solid precipitated from the solution and was collected by filtration. The solid dried in vacuo to afford methyl 3-hydroxy-lH-pyrrolo[2,3-c]pyridine-2-carboxylate 4 (300 mg, 1.56 mmol, 61.13% yield).[000188]1HNMR(400MHz, DMSO-d6) 5 11.37 (br s, 1H), 8.70 - 8.67 (m, 1H), 8.06 (d, J = 5.6 Hz, 1H), 7.69 (dd, J = 1.0, 5.6 Hz, 1H), 3.86 (s, 3H)Step 3 - [000189] A mixture of methyl 3-hydroxy-lH-pyrrolo[2,3-c]pyridine-2-carboxylate 4 (200 mg, 1.04 mmol) and bromocyclobutane 5 (168.60 mg, 1.25 mmol) and K2CO3 (172.60 mg, 1.25 mmol) in DMF (5 mL) was heated at 80 °C for 16 hours. LCMS showed incomplete conversion to the desired product, and additional bromocyclobutane 4 (168.60 mg, 1.25 mmol) and K2CO3 (30 mg) were added. The mixture was stirred at 80 °C for 7.5 h. The reaction was cooled to rt and diluted with water (10 mL), extracted with EtOAc (10 mL x 3). The combined organics were washed with brine (10 mL), dried over Na2SO4 and concentrated in vacuo to afford methyl 3-(cyclobutoxy)-lH-pyrrolo[2,3-c]pyridine-2-carboxylate 6 (140 mg, 568.50 pmol, 54.62% yield) as yellow solid.[000190] LCMS (ESI): m / z = 2469 [M+H]+[000191]1HNMR(400MHz, DMSO-d6) 5 11.91 (s, 1H), 8.76 (s, 1H), 8.12 (d, J = 5.6 Hz, 1H), 7.63 (d, J = 5.6 Hz, 1H), 4.84 (t, J = 7.2 Hz, 1H), 3.89 (s, 3H), 2.27 - 2.09 (m, 4H), 1.72 (br d, J = 9.9 Hz, 1H), 1.57 - 1.45 (m, 1H)Step 4 - [000192] A stirred solution of methyl 3-(cyclobutoxy)-lH-pyrrolo[2,3-c]pyridine-2-carboxylate 6 (160 mg, 649.72 pmol) and NaOH (90.96 mg, 2.27 mmol) in EtOH (2 mL) andAttorney Docket No. PSE-002WOH2O (2 mL) was stirred at 90 °C for 1 hour. The reaction was cooled to 25 °C and stirred an additional 18 hours. LCMS showed the start material was consumed and the main peak with the desired mass of product was detected. The reaction was combined duplicate reaction for worked up. The combined solutions was concentrated in vacuum to remove EtOH, adjusted to pEI ~ 5 with IM HC1, affording some solid precipitate. The yellow suspension was filtered and washed with H2O (2 mL x 3). The filter cake was diluted with MeCN (20 mL) and concentrated in vacuum to give 3-(cyclobutoxy)-lH-pyrrolo[2,3-c]pyridine-2-carboxylic acid L-16 (195 mg, 837.81 pmol, 128.95% yield, 99.779% purity) as a light yellow solid.[000193] LCMS (ESI): m / z = 233.0 [M+H]+[000194] 'HNMR (400 MHz, DMSO-d6) 5 11.75 (br d, J=5.99 Hz, 1H), 8.74 (d, J=0.86 Hz, 1H), 8.10 (d, J=5.62 Hz, 1H), 7.61 (dd, J=5.62, 1.10 Hz, 1H), 4.85 (quin, J=7.09 Hz, 1H), 2.06 - 2.25 (m, 4H), 1.66 - 1.77 (m, 1H), 1.42 - 1.55 (m, 1H)Route to L-17Step 1 - [000195] To a mixture of cyclopropanol 2 (500 mg, 8.61 mmol) and 2-chloro-4-methyl-5-nitro-pyridine 1 (1 g, 5.79 mmol) in Toluene (15 mL) was added CS2CO3 (2.27 g, 6.95 mmol), BINAP (433 mg, 695.39 pmol) and Pd(dba)2 (166.6 mg, 289.74 pmol) under N2 atmosphere. The mixture was stirred at 100 °C for 16 hours under N2 atmosphere. LCMS showed the starting material was consumed. The resulting mixture was concentrated under reduced pressure before extraction with EtOAc (20 mL), washed with brine (20 mL), dried over Na2SC>4, filtered and concentrated in vacuo to obtain the crude product. The crude product was purified by flash column chromatography to yield 2-(cyclopropoxy)-4-methyl-5-nitro-pyridine 3 (970 mg, 4.00 mmol, 68.96% yield, 80% purity) which was obtained as a brown oil.[000196] LCMS (ESI): m / z = 1949 [M+H]+[000197]1H NMR (400 MHz, METHANOL-d4): 88.89 (s, 1H), 6.87 (s, 1H), 4.31 (tt, J=6.21, 3.05 Hz, 1H), 2.61 (s, 3H), 0.82 - 0.87 (m, 2H), 0.73 - 0.79 (m, 2H).Attorney Docket No. PSE-002WOStep 2 - [000198] A solution of 2-(cyclopropoxy)-4-methyl-5-nitro-pyridine 3 (970 mg, 4.00 mmol) and diethyl oxalate 4 (1.75 g, 11.99 mmol, 1.63 mL) in DBU (1.83 g, 11.99 mmol, 1.79 mL) was stirred at 50 °C for 3 hours. LCMS showed the starting material was consumed. The reaction mixture was quenched by addition of water (10 mL), extracted with DCM (10 mL x 3), washed with brine (20 mL) , dried over Na2SO4, filtered and concentrated in vacuo which was purified by flash column chromatography to yield ethyl 3-[2-(cyclopropoxy)-5-nitro-4-pyridyl]-2-oxo-propanoate 5 (420 mg, 1.43 mmol, 35.72% yield) which was obtained as a pink solid.[000199] LCMS (ESI): m / z = 295.0 [M+ H]+[000200] ’H NMR (400 MHz, METHANOL-d4): 88.83 (s, 1H), 7.77 (d, J=4.38 Hz, 1H), 7.10 - 7.46 (m, 1H), 6.91 (d, J=15.26 Hz, 1H), 4.35 - 4.39 (m, 2H), 4.29 - 4.33 (m, 1H), 1.35 -1.39 (m, 3H), 0.83 - 0.86 (m, 2H), 0.78 - 0.81 (m, 2H).Step 3 - [000201] To a solution of ethyl 3-[2-(cyclopropoxy)-5-nitro-4-pyridyl]-2-oxo-propanoate 5 (420 mg, 1.43 mmol) in acetic acid (5 mL), was added Iron (400 mg, 7.16 mmol, 50.89 pL) at 25°C. The mixture was stirred at 75 °C for 1 hour under N2 atmosphere. LCMS showed starting material was consumed. The reaction mixture was filtered, and the filter cake was washed with 15 mL (toluene) of solvent, dried in vacuum to obtain ethyl 5-(cyclopropoxy)-lH-pyrrolo[2,3-c]pyridine-2-carboxylate 6 (450 mg, 1.43 mmol, 99.86% yield, 78% purity) as a brown gum.[000202] LCMS (ESI): m / z = 247.0 [M+ H]+[000203]JH NMR (400 MHz, METHANOL-d4): 88.32 - 8.63 (m, 1H), 7.02 - 7.38 (m, 2H), 4.32 - 4.53 (m, 2H), 3.62 - 4.25 (m, 1H), 1.96 - 2.06 (m, 3H), 1.25 - 1.46 (m, 4H).Step 4 - [000204] To a solution of ethyl 5-(cyclopropoxy)-lH-pyrrolo[2,3-c]pyridine-2-carboxylate 6 (450 mg, 1.83 mmol) in MeOH (7 mL) and EtOH (7 mL) was added NaOH (3 M, 1.50 mL) at 20 °C, the mixture was allowed to stir at 70 °C for 1 hour. LCMS showed starting material was consumed and desired product mass was observed. The reaction was concentrated to removed MeOH / EtOH and adjusted to pH~4 with IN HC1. The mixture was filtered to give the 5-(cyclopropoxy)-lH-pyrrolo[2,3-c]pyridine-2-carboxylic acid L-17 (210 mg, 962.38 pmol, 52.67% yield) as a yellow solid.[000205] LCMS (ESI): m / z = 219.0 [M+ H]+Attorney Docket No. PSE-002WO[000206]1H NMR (400 MHz, METHANOL-d4): 88.72 (s, 1H), 7.94 (s, 1H), 7.37 (s, 1H), 4.28 (br d, J=1.10 Hz, 1H), 0.92 - 1.07 (m, 4H).Route to L-18Step 1 - [000207] A mixture of 4-methyl-5-nitro-pyridin-2-ol 1 (10 g, 64.88 mmol), 2-iodopropane 2 (33.09 g, 194.65 mmol, 19.45 mL) and Ag2COs (20.93 g, 75.91 mmol) in toluene (240 mb) was stirred at 60 °C for 16 hours. LCMS showed the starting material was consumed and desired product mass was detected. The mixture was fdtered and concentrated before purification by flash silica gel chromatography to afford 2-isopropoxy-4-methyl-5-nitro-pyridine 3 (12.2 g, 59.07 mmol, 91.04% yield, 95% purity) as yellow oil.[000208] 'H NMR (400 MHz, CHLOROFORM-d) 88.94 (s, 1H), 6.59 (s, 1H), 5.46 - 5.36 (m, 1H), 2.62 (s, 3H), 1.38 (d, J = 6.2 Hz, 6H)Step 2 - [000209] A mixture of 2-isopropoxy-4-methyl-5-nitro-pyridine 3 (12.2 g, 62.18 mmol), dimethyl oxalate 4 (7.34 g, 62.18 mmol, 6.40 mL) and t-BuOK (6.98 g, 62.18 mmol) in THF (220 mL) was stirred at 75 °C for 4 hours. LCMS showed the starting material was consumed and desired product mass was detected. The mixture was poured into water (200 mL) and extracted with EtOAc (150 mL x 3). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered and concentrated before purification by flash silica gel chromatography to afford methyl 3-(2-isopropoxy-5-nitro-4-pyridyl)-2-oxo-propanoate 5 (5.6 g, 17.26 mmol, 27.76% yield, 87% purity) as yellow solid.[000210] LCMS (ESI): m / z = 283.0 [M+H]+[000211] ‘HNMR (400 MHz, CHLOROFORM-d) 89.08 (s, 1H), 6.58 (s, 1H), 5.57 - 5.32 (m, 1H), 4.50 (s, 2H), 3.97 (s, 3H), 1.41 (s, 3H), 1.39 (s, 3H)Step 3 -Attorney Docket No. PSE-002WO[000212] In a flow chemical set up - A solution of methyl 3-(2-isopropoxy-5-nitro-4-pyridyl)-2-oxo-propanoate 5 (1.00 eq) in MeOH (101.2 mL) was stirred at 20 °C. The solution was pumped at 0.3 mL / min to a fixed bed (1 / 4” mm, 5 mL, 40 °C), which was packed with granular catalyst (l%Pt / C (1.00 eq)). The Hoback pressure regulator was adjusted to 1 MPa. The flow rate of H was 30 mL / min. The reaction mixture was collected after running 10 minutes. LCMS of a sample after 30 minutes showed the starting material was consumed and desired product mass was detected. The fixed bed was washed with additional MeOH. The rection solution was concentrated under vacuum to give the crude residue. The residue was purified by flash silica gel chromatography to provide methyl 5-isopropoxy-lH-pyrrolo[2,3-c]pyridine-2-carboxylate 6 (3 g, 11.53 mmol, 70.72% yield, 90% purity) as an orange solid.[000213]1H NMR (400 MHz, METHANOL-d4) 88.44 (s, 1H), 7.06 (d, J = 0.7 Hz, 1H), 6.98 (d, J = 1.1 Hz, 1H), 4.99 (td, J = 6.1, 12.3 Hz, 1H), 4.90 (s, 3H), 3.33 (td, J = 1.5, 3.1 Hz, 2H), 1.36 (s, 3H), 1.34 (s, 3H)Step 4 - [000214] A solution of methyl 5-isopropoxy-lH-pyrrolo[2,3-c]pyridine-2-carboxylate 6 (250 mg, 1.07 mmol), NaOH (2 M, 1.17 mL) in EtOH (2.33 mL) and MeOH (2.33 mL) was stirred at 90 °C for 1 hour. LCMS showed the starting material was consumed and the desired product mass was seen. The reaction mixture was concentrated under vacuum. 50 ml of water was added to the crude residue. The pH was adjusted to 4-5 with AcOH, precipitating 5-isopropoxy-lH-pyrrolo[2,3-c]pyridine-2-carboxylic acid L-35 (200 mg, 817.35 pmol, 76.59% yield, 90% purity) as a white solid.[000215] LCMS (ESI): m / z = 221.0 [M+H]+, RT = 0.675 min[000216] ‘HNMR (400 MHz, METHANOL-d4) 88.45 (s, 1H), 7.10 (s, 1H), 7.05 (s, 1H), 5.01 - 4.97 (m, 1H), 1.39 (s, 3H), 1.38 - 1.37 (m, 3H)Route to L-19Step 1Attorney Docket No. PSE-002WO[000217] A solution of 2-chloro-4-methyl-5-nitro-pyridine 1 (1.4 g, 8.11 mmol), 3,3-difluoroazetidine hydrochloride 2 (2.10 g, 16.23 mmol) and DIPEA (5.24 g, 40.56 mmol, 7.07 mL) in MeCN (20.00 mL) was stirred at 60 °C for 3 hours. LCMS showed the reaction was completed. The reaction solution was diluted with H2O (20 mL), many solid was precipitated out, filtered and the solid was concentrated in high vacuum to give 2-(3,3-difluoroazetidin-l-yl)- 4-methyl-5-nitro-pyridine 3 (1.95 g, crude) as a yellow solid.[000218] LCMS (ESI): m / z = 230.2 [M+H]+[000219]1H NMR (400 MHz, DMSO-d6) 58.88 (s, 1H), 6.54 (s, 1H), 4.56 (t, J = 12.4 Hz, 4H), 2.54 (s, 3H).Step 2 - [000220] To a mixture of diethyl oxalate 4 (4.85 g, 33.16 mmol, 4.5 mL) and 2-(3,3-difluoroazetidin-l-yl)-4-methyl-5-nitro-pyridine 3 (2 g, 8.73 mmol) DBU (4.58 g, 30.09 mmol, 4.5 mL) was added slowly, and the reaction was allowed to stir at 50 °C for 16 hours.[000221] LCMS showed some starting material was consumed and the major peak contained the mass of the desired product. To the reaction was added petroleum ether (30 mL) and H2O (30 mL), then AcOH (8 mL) was slowly added. The precipitate was collected and was identified as ethyl 3-[2-(3,3-difluoroazetidin-l-yl)-5-nitro-4-pyridyl]-2-oxo-propanoate 5 (2.87 g, crude) as a red solid which was used in the following reaction without further purification.Step 3 - [000222] To a mixture of ethyl 3-[2-(3,3-difluoroazetidin-l-yl)-5-nitro-4-pyridyl]-2-oxo-propanoate 5 (2.87 g, 8.72 mmol) in acetic acid (25 mL) was added Fe (1.22 g, 21.79 mmol). The reaction was stirred at 70 °C for 1 hour. LCMS showed starting material was consumed and the major peak contained the mass of the desired product. The reaction mixture was filtered, and the filtrate was concentrated in vacuo and purified by flash column chromatography to give ethyl 5-(3,3-difluoroazetidin-l-yl)-lH-pyrrolo[2,3-c]pyridine-2-carboxylate 6 (1.4 g, 4.98 mmol, 57.11% yield) as a light-yellow solid.[000223] LCMS (ESI): m / z = 282.0 [M+H]+[000224] 'HNMR (400 MHz, DMSO-d6) 5 12.05 (br s, 1H), 8.51 (s, 1H), 6.97 (d, J = 1.3 Hz, 1H), 6.71 (s, 1H), 4.39 - 4.25 (m, 6H), 1.34 (t, J = 7.2 Hz, 3H).Step 4 -Attorney Docket No. PSE-002WO[000225] A solution of ethyl 5-(3,3-difluoroazetidin-l-yl)-lH-pyrrolo[2,3-c]pyridine-2-carboxylate 6 (1.4 g, 4.98 mmol) and NaOH (497.73 mg, 12.44 mmol) in EtOH (20 mL) and H2O (5 mL) was stirred at 60 °C for 1 hour. LCMS showed the reaction was complete. The reaction solution was concentrated in vacuo to remove EtOH, H2O (10 mL) was added, then acidified to pH~6 with AcOH (1.5 mL). The precipitate was collected by filtration and toluene (30 mL) was added to the wet solid, concentrated in vacuo to give 5-(3,3-difluoroazetidin-l-yl)-lH-pyrrolo[2,3-c]pyridine-2-carboxylic acid L-19 (1.15 g, 4.54 mmol, 91.24% yield) as a yellow solid.[000226] LCMS (ESI): m / z= 254.0 [M+H]+[000227] 'HNMR (400 MHz, DMSO-d6) 5 14.25 - 12.47 (m, 1H), 11.91 (s, 1H), 8.48 (s, 1H), 6.91 (s, 1H), 6.70 (s, 1H), 4.29 (t, J = 12.5 Hz, 4H).Routes to R-IntermediatesAttorney Docket No. PSE-002WOCAS: 1781866-67-8 CAS: 794500-86-0H N NH HNZy HN' yR-23 R-24HN— / CAS: 1193387-59-5 CAS: 1325671-21-3H H N NH NZyyNHR-25 R-26HO CAS: 862280-59-9 CAS: 1250823-11-0H HN n N NHN' y NZyyNHR-27 R-29 yNHHN^ HOCAS: 933725-26-9 CAS: 118630-27-60\ / NH2 OHyryR-30 R-31NHO CAS: 1897758-41-6 CAS: 1521459-37-9h .NH N NH,N' szyy.hiHN^R-32 R-33NHO CAS: 1565512-96-0 CAS: 1384428-55-0H HN -0N^NHHN' yy_ NHR-34 yNR-35HO HN^CAS: 1601005-11-1 CAS: 147960-38-1Attorney Docket No. PSE-002WOGeneral Route R-INT-1General Procedureo oNaH, SEMCIIH - ■ - ISEM1 Step 1 R-INT-1Step 1 - SEM Protection[000228] To a solution of SM-1 in DMF was added NaH (60% dispersion in oil) and stirred at 0 °C. Then 2-(chloromethoxy)ethyl-trimethyl-silane was added and the reaction was stirred at ambient temperature. Upon completion, the reaction mixture was quenched by addition of water, extracted with ethyl acetate, washed with water and brine, dried over Na2SO4, filtered and concentrated under vacuum. The crude material was purified by automated column to afford R-INT-1Typified example - route to R-3Attorney Docket No. PSE-002WO1 Step 1 R-3Step 1 - [000229] To a mixture of 5-bromo-lH-pyridin-2-one 1 (10 g, 57.47 mmol) in DMF (60 mL) was added NaH (60% dispersion in oil) (1.79 g, 74.71 mmol) under N2 atmosphere at 0 °C and stirred for 1 hour before adding (2-(chloromethoxy)ethyl)trimethylsilane (12.46 g, 74.71 mmol, 13.22 mL). The reaction mixture was stirred for 16 hours at 20 °C. LCMS indicated that desired product was observed. The reaction mixture was diluted with ethyl acetate (40 mb) and washed with water (40 mL), brine (30 mL), dried over Na2SC>4, filtered and concentrated. The crude material was purified by flash silica gel chromatography to afford 5-bromo-l-(2-trimethylsilylethoxymethyl)pyridin-2-one R-3 (12.3 g, 39.21 mmol, 68.23% yield, 97% purity) as a yellow oil.[000230] LCMS (ESI): m / z = 305.9 [M+H]+[000231] 1H NMR (400 MHz, DMSO-d6) 5 = 7.98 (d, J = 2.8 Hz, 1H), 7.54 (dd, J = 2.8, 9.8 Hz, 1H), 6.40 (d, J = 9.8 Hz, 1H), 5.22 (s, 2H), 3.63 - 3.48 (m, 2H), 0.92 - 0.81 (m, 2H), - 0.04 (s, 9H)Typified example - route to R-4Step 1 - [000232] To a solution of 5-iodo-4-methyl-lH-pyridin-2-one 1 (250 mg, 1.06 mmol) in DMF (10 mL) was added NaH (60% dispersion in oil) (64 mg, 1.60 mmol, 60% purity) at 0 °C and stirred for 30 minutes. 2-(chloromethoxy)ethyl-trimethyl-silane (197.82 mg, 1.19 mmol, 210.00 uL) was added and the reaction was stirred at 20 °C for 1 hour. LCMS showed compound 1 was consumed. The reaction mixture was quenched by addition of water (10 mL), extractedAttorney Docket No. PSE-002WOwith ethyl acetate (15 mL x 2), washed with water (15 mL x 2) and brine (20 mb), dried over Na2SO4, filtered and concentrated in-vacuo to obtain the crude product. The crude product was purified by automated column to afford compound 5-iodo-4-methyl-l-(2-trimethylsilylethoxymethyl)pyridin-2-one R-4 (200 mg, 492.77 pmol, 46.32% yield, 90% purity) as a colorless oil.[000233] LCMS (ESI): m / z = 366.0 [M+H]+[000234] 'H NMR (400 MHz, METHANOL-d4): 88.36 (s, 1H), 6.85 (s, 1H), 5.48 (s, 2H), 3.79 (t, J=8.03 Hz, 2H), 2.38 (s, 3H), 0.93 (t, J=8.14 Hz, 2H), -0.01 (s, 9H)R-Inter mediates Prepared via General Route R-INT-1No SM-1 Structureo 0R-3 A NSEMB / B / 0 0R-4 — (( NSEM\ 0R-5 Z lMSEMA ho 0R-6 r / ^NH l / - ^NSEMBr^ / Br^wR-7 / NSEMBr= / oR-8 Z tJSEMyncr Cl0 0R-9 / NSEMB / bF3Br ” CF30 OR-10 F— F— / NSEMB / B / Attorney Docket No. PSE-002WORoute to R-14HCI1 Step 1 Step 2 R-14Step 1 - [000235] To a solution of tert-butyl piperazine- 1 -carboxylate 1 (200 mg, 1.07 mmol) in n-BuOH (10 mL) was added 6-chloro-lH-pyridin-2-one 2 (347.77 mg, 2.68 mmol) at 25 °C and stirred at 120 °C for 16 hours. LCMS showed the desired product mass 3 was observed. The solvent was removed by vacuum before purification by flash silica gel chromatography to yield tert-butyl 4-(6-oxo-lH-pyridin-2-yl)piperazine-l-carboxylate 3 (100 mg, 304.30 pmol, 28.34% yield, 85% purity) as a brown solid.[000236] LCMS (ESI): m / z = 280.2 [M+H]+Step 2 - [000237] A solution of tert-butyl 4-(6-oxo-lH-pyridin-2-yl)piperazine-l -carboxylate 3 (100 mg, 357.99 pmol) in HCl / dioxane (5 mL) was stirred at 25 °C for Ihour. TLC showed starting material was consumed completely. The solvent was removed to yield the crude product 6-piperazin-l-yl-lH-pyridin-2-one R-14 (60 mg, crude) as a white solid that was used without further purification. LCMS (ESI): m / z = 180.2 [M+H]+Route to R-15Attorney Docket No. PSE-002WO1 Step 1 3 Step 2 4 Step 2 R-15Step 1 - [000238] A solution of 5-benzyloxy-2-bromo-pyridine 1 (200 mg, 757.24 pmol) and tertbutyl piperazine- 1 -carboxylate 2 (150 mg, 805.37 pmol) in dioxane (3 mb) was added CS2CO3 (1.23 g, 3.79 mmol) followed by XPhos (73 mg, 153.13 pmol), then Pd2(dba)s (70 mg, 76.44 pmol) was added to the mixture at 25 °C under N2 atmosphere. The suspension was degassed and purged with N2 three times before the mixture was allowed to stir at 100 °C for 12 hours under N2 atmosphere. LCMS showed the starting material was consumed. The reaction mixture was quenched by addition of water (5 mL), extracted with ethyl acetate (10 mb), washed with water (10 mL x 2) and brine (10 mL), dried over Na2SC>4, filtered and concentrated in-vacuo. The crude material was purified by automated column chromatography to afford tert-butyl 4-(6-benzyloxy-3-pyridyl)piperazine-l-carboxylate 3 (250 mg, 652.58 pmol, 86.18% yield, 96.44% purity) as a yellow solid.[000239] LCMS (ESI): m / z = 370.2 [M+ H]+[000240] 'H NMR (400 MHz, METHANOL-d4): 87.79 (d, J=3.08 Hz, 1 H), 7.47 (dd, >9.02, 2.86 Hz, 1 H), 7.39 - 7.44 (m, 2 H), 7.34 (t, >7.37 Hz, 2 H), 7.26 - 7.30 (m, 1 H), 6.79 (d, >8.80 Hz, 1 H), 5.27 (s, 2 H), 3.57 (br s, 4 H), 2.99 - 3.07 (m, 4 H), 1.48 (s, 9 H).Step 2 - [000241] To a solution of tert-butyl 4-(6-benzyloxy-3-pyridyl)piperazine-l -carboxylate 3 (250 mg, 676.67 pmol) in MeOH (5 mL) was added Pd / C (10% on Carbon, wetted with ca. 55% water) (72 mg, 676.56 pmol) and degassed with argon, before stirring at 25 °C under H2 (30 Psi) for 16 hours. LCMS showed the starting material was consumed, at which time the mixture was washed with MeOH and filtered four times. The mixture was concentrated under vacuum to afford tert-butyl 4-(6-oxo-lH-pyridin-3-yl)piperazine-l-carboxylate 4 (155 mg, 499.40 pmol, 73.80% yield, 90% purity) as a black solid.Attorney Docket No. PSE-002WO[000242] LCMS (ESI): m / z = 280.1 [M+ H]+[000243]JH NMR (400 MHz, METHANOL-d4): 57.61 (dd, J=9.68, 2.86 Hz, 1 H), 6.93 (d, J=2.64 Hz, 1 H), 6.54 (d, J=9.68 Hz, 1 H), 3.55 (br s, 4 H), 2.82 - 2.93 (m, 4 H), 1.47 (s, 9 H). Step 3 - [000244] To a solution of tert-butyl 4-(6-oxo-lH-pyridin-3-yl)piperazine-l -carboxylate 4 (155 mg, 554.89 pmol) in DCM (5 m ) was added TFA (1.49 g, 13.07 mmol, 1 mL) at 25 °C, the mixture was allowed to stir at 25 °C for 1 hour. LCMS showed the starting material was consumed. The resulting mixture was concentrated under reduced pressure to afford 5-piperazin-l-yl-lH-pyridin-2-one R-15 (150 mg, crude) was obtained as a brown oil that was used without further purification.[000245] LCMS (ESI): m / z = 180.1 [M+H]+[000246] 'H NMR (400 MHz, METHANOL-d4): 87.73 (dd, J=9.68, 3.08 Hz, 1 H), 7.17 (d, J=2.86 Hz, 1 H), 6.69 (d, J=9.68 Hz, 1 H), 3.37 (br dd, J=6.27, 4.07 Hz, 4 H), 3.18 - 3.27 (m, 4 H).Route to R-22Step 1 - [000247] To a solution of tert-butyl 4-ethynylpiperidine-l -carboxylate 1 (1.6 g, 7.65 mmol) in K2CO3 (3 M, 12.74 mL) and ethyl acetate (25 mL) was added dropwise a solution of dibromomethanone oxime 2 (7.75 g, 38.23 mmol) in ethyl acetate (25 mL) over 1 hour at ambient temperature. The combined reaction mixture was then stirred at 25 °C for 16 hours under N2 atmosphere. LCMS showed the main peak was desired mass of product. The reaction was quenched by water (50 mL), extracted with ethyl acetate (20 mL x 3), separated, and the organic phase was dried over Na2SO4, before being concentrated under vacuum. The crudeAttorney Docket No. PSE-002WOmaterial was purified by automated chromatography to afford tert-butyl 4-(3-bromoisoxazol-5-yl)piperidine-l -carboxylate 3 (1.6 g, 4.83 mmol, 63.19% yield) as a yellow oil.[000248] LCMS (ESI): m / z = 331.2 [M+H]+[000249] 'H NMR (400 MHz, DMSO-d6) 8 = 6.69 (s, 1H), 3.95 (br d, J = 12.0 Hz, 2H), 3.12 - 3.00 (m, 1H), 2.87 (br s, 2H), 1.92 (br dd, J = 2.3, 12.9 Hz, 2H), 1.52 - 1.42 (m, 2H), 1.40 (s, 9H)Step 2 - [000250] A solution of tert-butyl 4-(3-bromoisoxazol-5-yl)piperidine-l-carboxylate 3 (200 mg, 603.86 pmol), KOH (338.82 mg, 6.04 mmol, 165.76 pL) in MeOH (6 m ) was stirred at 100 °C for 4 hours under N2atmophere. LCMS showed some starting material remained and main peak was desired mass of product. The reaction mixture was concentrated under vacuum, then redissolved with water (5 mL), before adding acetic acid (5 mb) and stirring at ambient temperature for 15 minutes. Afterward, the mixture was concentrated in vacuum to remove acetic acid and water, then DMF (5 mL) was added and mixture was filter to afford 5-(4-piperidyl)isoxazol-3-ol R-22 (150 mg, crude) in solution, which was used directly for next step.Route to R-281 Step 1 2 Step 2 R-28Step 1 - [000251] To a solution of tert-butyl 4-(hydrazinecarbonyl)piperidine-l -carboxylate 1 (500 mg, 2.06 mmol) in THF (20 mL) and DMF (2 mL) was added CDI (499.84 mg, 3.08 mmol) followed by TEA (415.90 mg, 4.11 mmol, 572.86 pL). The mixture was stirred at 50 °C for 12 hours. The reaction was observed to be complete by LCMS. Then the mixture was concentratedAttorney Docket No. PSE-002WOunder vacuum before purification by chromatography to give tert-butyl 4-(5 -hydroxy- 1,3, 4-oxadiazol-2-yl)piperidine-l -carboxylate 2 (370 mg, 1.37 mmol, 66.86% yield) as a white solid.[000252] LCMS (ESI): m / z = 213.9 [M-56+H]+[000253] 1HNMR (400 MHz, DMSO-d6) 5 = 12.12 (br s, 1H), 3.88 (br d, J = 13.0 Hz, 2H), 3.01 - 2.70 (m, 3H), 1.88 (br dd, J = 2.9, 13.1 Hz, 2H), 1.50 - 1.43 (m, 2H), 1.40 (s, 9H) Step 2 - [000254] To a solution of tert-butyl 4-(5-hydroxy-l,3,4-oxadiazol-2-yl)piperidine-l-carboxylate 2 (370 mg, 1.37 mmol) in DCM (2 mL) was added TFA (2.98 g, 26.14 mmol, 2 mL), before the reaction mixture was stirred at 20 °C for 1 hour. LCMS showed starting material was consumed and desired compound was detected. The mixture was concentrated under vacuum to give 5-(4-piperidyl)-l,3,4-oxadiazol-2-ol R-28 (560 mg, crude, TFA) as a white solid, which was used directly in the next step.[000255] LCMS (ESI): m / z = 170.2 [M+H]+[000256] 1HNMR (400 MHz, DMSO-d6) 8 = 12.21 (s, 1H), 3.30 (br d, J = 12.76 Hz, 2H), 2.92 - 3.08 (m, 3H), 2.05 (br d, J = 11.22 Hz, 2H), 1.67 - 1.84 (m, 2H)General Route R-INT-2General Procedure_ BPin HNN. J if -22► CMBPSM-1 Step 1 Step 2 4 Step 3 R-INT-2Step 1 - Misunobu Reaction[000257] A solution of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole 2, alcohol SM-1 and 2-(tributyl-phosphanylidene)acetonitrile in toluene was stirred at elevated temperature under inert atmosphere. Upon completion, the reaction mixture was concentrated under vacuum before purification by flash silica gel chromatography to afford alkylated product 3Step 2 - Boron oxidationAttorney Docket No. PSE-002WO[000258] Boronate 3 was dissolved in THF and cooled to 0 °C. NaOH and H2O2 solution were added and the reaction mixture was stirred at ambient temperature. Upon completion the reaction mixture was washed with aqueous solution of Na2S20s, extracted with DCM, washed with brine, dried over Na2SC>4 and concentrated under vacuum. The crude material was purified by flash silica gel chromatography to afford alcohol 4.Step 3 - Deprotection[000259] A solution of alcohol 4 in acid and DCM was stirred at ambient temperature. Upon completion, the solvent was removed under vacuum to afford amine R-INT-2, which was used directly in the next step.Typified example - route to R-401 Step 1 3 Step 2 4 Step 3 R-40Step 1 - [000260] A solution of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole 2 (500 mg, 2.58 mmol), tert-butyl 3-hydroxyazetidine-l-carboxylate 1 (490.96 mg, 2.83 mmol) and 2-(tributyl-phosphanylidene)acetonitrile (1.24 g, 5.15 mmol) in toluene (10 mL) was stirred at 115 °C for 16 hours under N2 atmosphere. LCMS indicated that mass of desired product was observed. The mixture was concentrated under vacuum before purification by flash silica gel chromatography to afford tert-butyl 3-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol-l-yl]azetidine-l -carboxylate 3 (800 mg, 1.81 mmol, 70.23% yield, 79% purity) as a yellow oil.[000261] LCMS (ESI): m / z = 350.2 [M+H]+[000262] 1HNMR (400 MHz, DMSO-d6) 6 = 8.08 (s, 1H), 7.71 (s, 1H), 5.32 - 5.16 (m, 1H), 4.26 (br t, J = 7.3 Hz, 2H), 4.11 (br s, 2H), 1.40 (s, 9H), 1.24 (s, 12H)Step 2 - [000263] tert-butyl 3-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol-l-yl]azetidine-l -carboxylate 3 (800 mg, 2.29 mmol) was dissolved in THF (10 mL) and cooled to 0 °C. NaOH (183.26 mg, 4.58 mmol) and H2O2 solution (519.39 mg, 4.58 mmol, 467.92 pL,Attorney Docket No. PSE-002WO30% purity) were added and the reaction mixture was stirred at room temperature for 45 minutes. LCMS showed the desired product mass was observed. The mixture was washed with aqueous solution of Na2S2O3(10 mL), extracted with DCM (10 mL x 2), washed with brine (10 mb x 2), dried over Na2SC>4 and concentrated under vacuum. The crude material was purified by flash silica gel chromatography to afford tert-butyl 3 -(4-hydroxypyrazol-l-yl)azetidine-l -carboxylate 4 (500 mg, 1.76 mmol, 76.63% yield, 84% purity) as a yellow oil.[000264] LCMS (ESI): m / z = 240.2 [M+H]+[000265] 1HNMR (400 MHz, DMSO-d6) 6 = 7.29 (s, 1H), 7.10 (s, 1H), 5.12 - 4.90 (m, 1H), 4.20 (br t, J = 7.5 Hz, 2H), 4.09 - 4.03 (m, 2H), 1.39 (s, 9H)Step 3 - [000266] A solution of tert-butyl 3-(4-hydroxypyrazol-l-yl)azetidine-l-carboxylate 4 (500 mg, 2.09 mmol) in TFA (2 mL) and DCM (2 mL) was stirred at 25 °C for 1 hour. TLC showed starting material was completely consumed. The solvent was removed under vacuum to afford 1-(azeti din-3 -yl)pyrazol-4-ol R-40 (250 mg, crude) as a yellow oil, which was used directly in the next step.[000267] LCMS (ESI): m / z =140.2 [M+H]+[000268] 1HNMR (400 MHz, DMSO-d6) 8 = 9.06 - 8.81 (m, 2H), 7.35 (s, 1H), 7.22 (s, 1H), 5.21 (t, J = 7.6 Hz, 1H), 4.39 - 4.17 (m, 4H)R-Intermediates Prepared via General Route R-INT-2No SM-1 StructureOH N^V0HR-39 ki— v. OHOH N^ lJWR-40Bocl\i— fOHz^OHR-41BocN— 1Attorney Docket No. PSE-002WOR-42BocRoute to R-431 Step 1 3 Step 2 4 Step 3 R-43Step 1 - [000269] To a solution of tert-butyl 3 -iodoazetidine- 1 -carboxylate 1 (2.73 g, 9.64 mmol) and 2-benzyloxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine 2 (1 g, 3.21 mmol) in DMF (20 mL) and H2O (2 mL) was added Pd(PPh3)4 (557.02 mg, 482.03 pmol) and K2CO3 (1.33 g, 9.64 mmol) under N2 atmosphere. Then the mixture was stirred at 120 °C for 12 hours. Determined by LCMS, the reaction was complete. Then the mixture was diluted with ethyl acetate (100 mL), washed with water (30 mL x3), brine, dried over Na2SC>4, filtered and concentrated under vacuum to give the residue, which was purified by chromatography to give tert-butyl 3 -(6-benzyloxy-3-pyridyl)azetidine-l -carboxylate 3 (800 mg, 2.35 mmol, 73.13% yield) as a white solid.[000270] LCMS (ESI): m / z = 341.1 [M+H]+[000271] 1H NMR (400 MHz, CHLOROFORM-d) 5 = 8.09 - 8.04 (m, 1H), 7.69 - 7.65 (m, 1H), 7.50 - 7.47 (m, 2H), 7.40 (t, J = 7.4 Hz, 3H), 6.88 - 6.83 (m, 1H), 5.41 - 5.38 (m, 2H), 4.35 (t, J = 8.7 Hz, 2H), 3.97 - 3.87 (m, 2H), 3.76 - 3.64 (m, 1H), 1.49 (s, 9H)Step 2 - [000272] To a solution of tert-butyl 3-(6-benzyloxy-3-pyridyl)azetidine-l-carboxylate 3 (600 mg, 1.76 mmol), Pd / C (10% on Carbon - wetted with ca. 55% water) (700 mg, 657.77 pmol, 10% purity) in MeOH (20 mL) was degassed with argon four times, and stirred at 35 °C for 12 hours under H2 at 35 psi. LCMS showed about half starting material remained and desiredAttorney Docket No. PSE-002WOmass of peak was observed. The reaction mixture was washed with MeOH (20 mb) and filtered four times. The organic phase was concentrated under vacuum before purification by automated chromatography to get tert-butyl 3-(6-hydroxy-3-pyridyl)azetidine-l -carboxylate 4 (280 mg, 1.12 mmol, 63.47% yield) as colorless gum.[000273] LCMS (ESI): m / z = 251.1 [M+H]+[000274] 1H NMR (400 MHz, DMSO-d6) 8 = 11.44 (br s, 1H), 7.51 (dd, J = 2.7, 9.4 Hz, 1H), 7.25 (d, J = 2.6 Hz, 1H), 6.35 (d, J = 9.4 Hz, 1H), 4.11 (br t, J = 8.4 Hz, 2H), 3.72 (br t, J = 7.1 Hz, 2H), 3.62 - 3.52 (m, 1H), 1.38 (s, 9H)Step 3 - [000275] To a solution of tert-butyl 3 -(6-hydroxy-3-pyridyl)azeti dine- 1 -carboxylate 4 (270 mg, 1.08 mmol) in DCM (8.25 mL) was added TFA (10.06 g, 88.21 mmol, 6.75 mL) before stirring at 20 °C for 30 minutes. LCMS showed starting material consumed and desired mass of product was obsereved. The reaction mixture was concentrated under vacuum to remove TFA, washed with DCM four times, to afford 5-(azetidin-3-yl)pyridin-2-ol R-43 (220 mg, crude) to which was added DIEA (0.2 mL) and used directly in next step.Route to R-46R-3Step 1 - [000276] To a mixture of tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-l -carboxylate 1 (6.10 g, 19.72 mmol) and 5-bromo-l-(2-trimethylsilylethoxymethyl)pyridin-2-one R-3 (6 g, 19.72 mmol) in dioxane (60 mL) and water (6 mL) was added Pd(dtBupf)C12 (2.57 g, 3.94 mmol) and K3PO4 (20.93 g, 98.60 mmol) under N2 atmosphere. The reaction mixture was stirred for 10 hours at 90 °C. LCMS indicated that desired product and des-SEM product was also observed. The reaction mixture was diluted with ethyl acetate (100 mL) and filtered. The filtrate was washed with water (40 mL), brine(40 mL),Attorney Docket No. PSE-002WOdried over Na2SO4, filtered it and concentrated under vacuum. The crude material was purified by column chromatography to obtain tert-butyl 4-[6-oxo-l-(2-trimethylsilylethoxymethyl)-3-pyridyl]-3,6-dihydro-2H-pyridine-l-carboxylate 2 (8.1 g, 19.92 mmol, 101.02% yield) as a mixture of product and des-SEM product.[000277] 1H NMR (400 MHz, METHANOL-d4) 5 = 8.18 (d, J = 2.4 Hz, 1H), 7.80 (dd, J = 2.6, 8.6 Hz, 1H), 6.84 (d, J = 8.7 Hz, 1H), 6.08 (br s, 1H), 5.75 (br s, 1H), 4.08 (br d, J = 5.0 Hz, 2H), 3.87 - 3.77 (m, 2H), 3.70 - 3.61 (m, 2H), 3.54 (br t, J = 5.5 Hz, 2H), 2.59 - 2.47 (m, 2H), 1.51 (s, 9H), 1.44 (br s, 9H), 0.96 - 0.89 (m, 2H), 0.05 - -0.04 (m, 9H)Step 2 - [000278] To a mixture of tert-butyl 4-[6-oxo-l-(2-trimethylsilylethoxymethyl)-3-pyridyl]-3, 6-dihydro-2H-pyridine-l -carboxylate 2 (250 mg, 614.87 pmol) in DCM (3 m ) was added TFA (7.45 g, 65.34 mmol, 5 mL) at 20 °C. The reaction mixture was stirred for 1 hour at 20 °C. LCMS indicated that the starting material was consumed completely and mass of the desired product was observed. The reaction mixture was concentrated under vacuum to obtained 5-(l,2,3,6-tetrahydropyridin-4-yl)-lH-pyridin-2-one R-46 (109 mg, crude), which was used directly in next step.[000279] LCMS (ESI): m / z = 177.1 [m+H]+General Route R-INT-3General ProcedureStep 1 - Cross coupling[000280] To a mixture of tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-l -carboxylate 1 and bromide SM-1 in dioxane and water was added Pd(dtBupf)C12 and K3PO4 under inert atmosphere. The reaction mixture was then stirred at elevated temperatures. Upon completion, the reaction mixture was then diluted with ethyl acetate and filtered. The organic filtrate was washed with water, brine, dried over Na2SC>4, filtered andAttorney Docket No. PSE-002WOconcentrated under vacuum. The crude material was purified by flash silica gel chromatography to afford tetrahydropyridine 2.Step 2 - ReductionTo a solution of tetrahydropyridine 2 in THF was added Pd / C (10% on Carbon - wetted with ca.55% water) at ambient temperature, which was degassed with argon. The reaction mixture was then stirred at ambient temperature under 20 Psi of H2. Upon completion, the reaction mixture was filtered and washed with additional THF, before concentrating under vacuum. The crude material was purified by flash silica gel chromatography to afford piperidine 3.Step 3 - Deprotection[000281] A mixture of tert-butyl 4-[6-oxo-l-(2-trimethylsilylethoxymethyl)-3-pyridyl]piperidine-l -carboxylate 3 (2 g, 4.89 mmol) in acid mixture was stirred at ambient temperature. Upon completion, the reaction mixture was filtered and concentrated to obtain R-INT-3, that was used directly in next step.Typified example - route to R-47Step 1 - [000282] To a mixture of tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-l -carboxylate 1 (6.10 g, 19.72 mmol) and 5-bromo-l-(2-trimethylsilylethoxymethyl)pyridin-2-one R-3 (6 g, 19.72 mmol) in dioxane (120 mb) and water (12 mL) was added Pd(dtBupf)Ch (1.54 g, 2.37 mmol) and K3PO4 (20.93 g, 98.60 mmol) under N2 atmosphere. The reaction mixture was then stirred for 16 hours at 100 °C. By LCMS, the desired product mass was observed. The reaction mixture was then diluted with ethyl acetate (100 mL) and filtered. The organic filtrate was washed with water (40 mL), brine (40 mL), dried over Na2SC>4, filtered and concentrated under vacuum. The crude material was purified by flash silica gel chromatography to afford tert-butyl 4-[6-oxo-l-(2-trimethylsilylethoxymethyl)-3-Attorney Docket No. PSE-002WOpyridyl]-3,6-dihydro-2H-pyridine-l-carboxylate 2 (7.7 g, 17.99 mmol, 91.23% yield, 95% purity) as a yellow oil.[000283] LCMS (ESI): m / z = 407.4 [M+H]+[000284] 1H NMR (400 MHz, DMSO-d6) 5 = 7.71 (dd, J = 2.6, 9.6 Hz, 1H), 7.64 (d, J = 2.4 Hz, 1H), 6.42 (d, J = 9.5 Hz, 1H), 6.04 (br s, 1H), 5.25 (s, 2H), 3.95 (br d, J = 7.8 Hz, 2H), 3.56 (t, J = 7.9 Hz, 2H), 3.50 (br t, J = 5.4 Hz, 2H), 2.32 (br s, 2H), 1.41 (s, 9H), 0.85 (t, J = 7.9 Hz, 2H), -0.05 (s, 9H)Step 2 - To a solution of tert-butyl 4-[6-oxo-l-(2-trimethylsilylethoxymethyl)-3-pyridyl]-3,6-dihydro-2H-pyridine-1 -carboxylate 2 (4 g, 9.84 mmol) in THF (40 m ) was added Pd / C (10% on Carbon -wetted with ca. 55% water) (2.09 g, 1.97 mmol, 10% purity) at 20 °C, which was degassed with argon four times, before the mixture was stirred at 25 °C for 3 hours under 20 Psi of H2. LCMS showed starting material was consumed completely and desired product mass was detected. The reaction mixture was fdtered and washed with additional THF, before concentrating under vacuum. The crude material was purified by flash silica gel chromatography to afford tert-butyl 4-[6-oxo-l-(2-trimethylsilylethoxymethyl)-3-pyridyl]piperidine-l-carboxylate 3 (2 g, 3.48 mmol, 35.32% yield, 71% purity) as a yellow oil.[000285] LCMS (ESI): m / z = 409.3 [M+H]1[000286] 1HNMR (400 MHz, DMSO-d6) 5 = 7.51 - 7.38 (m, 2H), 6.36 (d, J = 9.2 Hz, 1H), 5.21 (s, 2H), 3.55 (t, J = 7.9 Hz, 2H), 3.46 - 3.39 (m, 2H), 2.82 - 2.68 (m, 2H), 2.31 - 2.24 (m, 1H), 1.69 (brd, J = 12.3 Hz, 2H), 1.64 - 1.51 (m, 2H), 1.38 (s, 9H), 1.10 - 0.98 (m, 2H), -0.05 (s, 9H)Step 3 - [000287] A mixture of tert-butyl 4-[6-oxo-l -(2 -trimethyl silylethoxymethyl)-3 -pyridyl]piperidine-l -carboxylate 3 (2 g, 4.89 mmol) in HC1 (2.0 M in 1,4-dioxan) (10 mL) was stirred for 2 hours at 20 °C. LCMS detected the desired product mass. The reaction mixture was fdtered and concentrated to obtain 5-(4-piperidyl)-lH-pyridin-2-one R-47 (1 g, crude, HC1) that was used directly in next step.Attorney Docket No. PSE-002WO[000288] 1HNMR (400 MHz, DMSO-d6) 8 = 9.27 - 9.05 (m, 2H), 7.81 - 7.33 (m, 1H), 3.47 - 3.31 (m, 2H), 2.96 - 2.80 (m, 2H), 2.23 - 2.12 (m, 1H), 1.79 (br s, 2H), 1.42 (br d, J = 6.6 Hz, 2H)R-Intermediates Prepared via General Route R-INT-3No SM-1 StructureOO / NHR-47 NSEMy HN— / ==\ O / =\0A # \N— V NHR-48 N— / / NSEMB / KN— 'N^x ON^ O / / _ ft / / A _ \= / NHR-49 \= / NSEMB / KN^General Route R INT-4General ProcedureCMBPSM-1 Step 1 3 Step 2 4 Step 3 Step 4 R-INT-4 Step 1 - Mitsunobu Reaction[000289] To a solution of 4-bromo-3-fluoro-lH-pyrazole 2, secondary alcohol SM-1 (577.49 mg, 3.33 mmol) and 2-(tributyl-phosphanylidene)acetonitrile in toluene was stirred at elevated temperature under inter atmosphere. Upon completion, the reaction mixture was concentrated and purified by flash silica gel chromatography to afford alkylated product 3.Attorney Docket No. PSE-002WOStep 2 - Borylation[000290] A mixture bromide 3, 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane, KOAc and Pd(dppf)Ch in dioxane was stirred at elevated temperatures under inert atmosphere. Upon completion, the mixture was filtered and the filtrate was concentrated in vacuo before purification by automated chromatography to afford borylated product 4.Step 3 - Boron oxidation[000291] A solution of boronate 4 in THF was cooled to 0 °C. NaOH and H2O2 solution were added, then the combined reaction mixture was stirred at ambient temperature. Upon completion, the reaction was quenched with sat. Na2SCh until starch-KI paper did not change color, acidified to pH ~4 with TFA, diluted with H2O, extracted with DCM, washed with brine, dried over Na2SC>4 and concentrated under vacuum. The crude material was purified by flash silica gel chromatography to give alcohol product 5.Step 4 - Deprotection[000292] To a solution of alcohol 5 in DCM was added acid, before stirring at ambient temperature. Upon completion, the reaction solution was concentrated under vacuum to give amine product R-INT-4, which was used in the next step without further purification.Typified example - route to R-501 Step 1 3 Step 2 5 Step 4Step 1 - [000293] To a solution of 4-bromo-3-fluoro-lH-pyrazole 2 (500 mg, 3.03 mmol), tert-butyl 3-hydroxyazetidine-l-carboxylate 1 (577.49 mg, 3.33 mmol) and 2-(tributyl-phosphanylidene)acetonitrile (1.46 g, 6.06 mmol) in toluene (15 mL) was stirred at 115 °C for 16 hours under N2 atmosphere. TLC showed starting material was consumed. The reaction mixture was concentrated and purified by flash silica gel chromatography to afford tert-butyl 3-(4-bromo-Attorney Docket No. PSE-002WO3-fluoro-pyrazol-l-yl)azetidine-l-carboxylate 3 (500 mg, 1.41 mmol, 46.37% yield, 90% purity) as a yellow oil.[000294] 1H NMR (400 MHz, DMSO-d6) 8 = 8.14 (d, J = 2.0 Hz, 1H), 5.14 - 4.99 (m, 1H), 4.24 (br t, J = 8.3 Hz, 2H), 4.10 - 3.93 (m, 2H), 1.39 (s, 9H)Step 2 - [000295] A mixture of tert-butyl 3 -(4-bromo-3-fluoro-pyrazol-l-yl)azetidine-l -carboxylate 3 (250 mg, 780.87 pmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (237.95 mg, 937.04 pmol), KOAc (229.90 mg, 2.34 mmol, 146.43 pL) and Pd(dppf)Ch (57.14 mg, 78.09 pmol) in dioxane (10 mL) was purged with N2 three times, before stirring at 100 °C for 16 hours. LCMS showed the reaction was completed. The mixture was filtered and the filtrate was concentrated in vacuo before purification by automated chromatography to give tert-butyl 3-[3-fluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol-l-yl]azetidine-l -carboxylate 4 (200 mg, 381.24 pmol, 48.82% yield, 70% purity) as a yellow oil.[000296] LCMS (ESI): m / z = 312.1 [M+ H-56]~[000297] 1HNMR (400 MHz, DMSO-d6) 8 = 8.00 (d, J = 2.4 Hz, 1H), 5.16 - 5.00 (m, 1H), 4.29 - 4.15 (m, 2H), 3.92 (s, 2H), 1.24 (s, 9H), 1.07 (s, 12H)Step 3 - [000298] A solution of tert-butyl 3-[3-fluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol-l-yl]azetidine-l-carboxylate 4 (800 mg, 2.18 mmol) in THF (13 mL) was cooled to 0 °C. NaOH (174.28 mg, 4.36 mmol) and H2O2 solution (493.94 mg, 4.36 mmol, 444.99 pL, 30% purity) were added, then the combined reaction mixture was stirred at 20 °C for 1 hour. LCMS showed desired product mass was detected. The reaction was quenched with sat. Na2SOs (2 mL) until starch-KI paper did not change color, acidified to pH ~4 with TFA, diluted with H2O (5 mL), extracted with DCM (15 mL x 2), washed with brine (5 mL x 2), dried over Na2SO4 and concentrated under vacuum. The crude material was purified by flash silica gel chromatography to give tert-butyl 3-(3-fluoro-4-hydroxy-pyrazol-l-yl)azetidine-l-carboxylate 5 (400 mg, 1.26 mmol, 57.81% yield, 81% purity) as a yellow oil.[000299] LCMS (ESI): m / z = 202.0 [M+H-56]+Attorney Docket No. PSE-002WO[000300] 1H NMR (400 MHz, DMSO-d6) 8 = 8.93 - 8.30 (m, 1H), 7.38 (d, J = 2.2 Hz, 1H), 4.91 (dt, J = 2.5, 5.3 Hz, 1H), 4.18 (br t, J = 8.1 Hz, 2H), 4.02 - 3.97 (m, 2H), 1.39 (s, 9H) Step 4 - [000301] To a solution of tert-butyl 3-(3-fluoro-4-hydroxy-pyrazol-l-yl)azetidine-l-carboxylate 5 (200 mg, 777.42 pmol) in DCM (2 mL) was added TFA (1 mb), before stirring at 30 °C for 1 hour. LCMS showed starting material was consumed and desired product mass was detected.[000302] The reaction solution was concentrated in vacuo to give l-(azetidin-3-yl)-3-fluoro-pyrazol-4-ol R-50 (120 mg, crude) as the yellow oil, which was used in the next step without further purification.Typified example - route to R-53H2O2, NaOH BocN —1— ys; — ys) -ys)BocN — ' BocN — ' HN^Step 1 Step 2 Step 3 Step 4Step 1 - [000303] A solution of 4-bromo-3 -fluoro- IH-pyrazole 2 (500 mg, 3.03 mmol), tert-butyl (2S,4S)-4-hydroxy-2-methyl-piperidine-l -carboxylate 1 (880.92 mg, 4.09 mmol) and 2-(tributyl-phosphanylidene)acetonitrile (1.46 g, 6.06 mmol) in toluene (12 mL) was stirred at 115 °C for 16 hours. LCMS showed some start material remained and a peak with the desired pass of the product was detected. The reaction solution was cooled to 25 °C and concentrated under vacuum before purification by automated chromatography to afford tert-butyl (2S,4R)-4-(4-bromo-3-fluoro-pyrazol-l-yl)-2-methyl-piperidine-l -carboxylate 3 (390 mg, 925.03 pmol, 30.52% yield, 85.918% purity) as light-yellow gum.[000304] LCMS (ESI): m / z = 307.8 [M+H-56]+[000305] 1HNMR (400 MHz, DMSO-d6) 5 = 8.05 (d, J=1.88 Hz, 1H), 4.37 - 4.52 (m, 2H), 3.95 (br d, J=11.38 Hz, 1H), 2.99 (br s, 1H), 1.93 - 2.00 (m, 1H), 1.83 - 1.91 (m, 2H), 1.66 (qd, J=12.44, 4.69 Hz, 1H), 1.41 (s, 9H), 1.12 - 1.19 (m, 3H)Attorney Docket No. PSE-002WO[000306] 19F NMR (376 MHz, DMSO-d6) 5 = -135.30 (s, IF)Step 2 - [000307] A mixture of tert-butyl (2S,4R)-4-(4-bromo-3-fluoro-pyrazol-l-yl)-2 -methylpiperidine- 1 -carboxylate 3 (390 mg, 1.08 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (300.74 mg, 1.18 mmol), KOAc (316.99 mg, 3.23 mmol, 201.90 pL) and Pd(dppf)Ch (78.78 mg, 107.66 pmol) in dioxane (6 mb) was stirred at 100 °C for 16 hours. LCMS showed some start material was remained and the desired mas of the product was detected. The reaction was cooled to 25 °C, before an additional round of 4,4, 5, 5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (136.70 mg, 538.32 pmol), KOAc (211.33 mg, 2.15 mmol, 134.60 pL) and Pd(dppf)Ch (39.39 mg, 53.83 pmol) was added. The reaction was sealed and stirred at 80 °C for an additional 4 hours, at which point the reaction was deemed to be complete by LCMS. The reaction was cooled to 25 °C, filtered and washed with EtOAc (5 mL x 5). The filtrate was concentrated under vacuum before purification by automated chromatography to afford tert-butyl (2S,4R)-4-[3-fluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol-l-yl]-2-methyl-piperidine-l-carboxylate 4 (95 mg, 189.86 pmol, 17.63% yield, 81.8% purity) as yellow gum[000308] LCMS (ESI): m / z = 410.2 [M+H]+[000309] 1H NMR (400 MHz, DMSO-d6) 8 ppm 7.94 (s, 1H), 7.91 (d, J=2.13 Hz, 1H), 4.43 (br d, J=3.75 Hz, 2H), 3.94 (s, 3H), 2.87 - 3.10 (m, 1H), 1.93 - 2.01 (m, 1H), 1.82 - 1.91 (m, 2H), 1.61 - 1.75 (m, 1H), 1.41 (s, 9H), 1.25 (s, 12H), 1.13 - 1.19 (m, 16H), 1.07 (s, 11H)[000310] 19F NMR (376 MHz, DMSO-d6) 8 ppm -124.89 (s, IF)Step 3 - [000311] tert-butyl (2S,4R)-4-[3-fluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol-l-yl]-2-methyl-piperidine-l-carboxylate 4 (95 mg, 232.10 pmol) was dissolved in THF (4 mL) and cooled to 0 °C. A solution of NaOH (18.57 mg, 464.21 pmol) in H2O (0.5 mL) was added, followed by H2O2 solution (50 mg, 441.05 pmol, 45.05 pL, 30% purity). The combined reaction mixture was stirred at 25 °C for 1 hour. LCMS showed starting material was consumed and the main peak with the desired product mass was detected. The reaction was quenched with sat. Na2SOs (5 mL) until starch-KI paper did not change color, acidified to pH ~7 with IM HC1, diluted with H2O (10 mL) and extracted by EtOAc (20 mL x 2). The combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum.Attorney Docket No. PSE-002WO[000312] The crude material was purified by automated chromatography to give tert-butyl (2S,4R)-4-(3-fluoro-4-hydroxy-pyrazol-l-yl)-2-methyl-piperidine-l-carboxylate 5 (50 mg, 159.46 pmol, 68.70% yield, 95.464% purity) as colorless gum.[000313] LCMS (ESI): m / z =300.0 [M+H]+[000314] 1H NMR (400 MHz, DMSO-d6) 5 ppm 8.56 (s, 1H), 7.31 (d, J=2.42 Hz, 1H), 4.34 - 4.49 (m, 1H), 4.18 - 4.30 (m, 1H), 3.91 (br s, 1H), 2.85 - 3.10 (m, 1H), 1.86 - 1.93 (m, 1H), 1.75 - 1.86 (m, 2H), 1.54 - 1.67 (m, 1H), 1.41 (s, 9H), 1.13 - 1.18 (m, 3H)[000315] 19F NMR (376 MHz, DMSO-d6) 5 ppm -144.15 - -143.80 (m, IF)Step 4 - [000316] To a solution of tert-butyl (2S,4R)-4-(3-fluoro-4-hydroxy-pyrazol-l-yl)-2-methyl-piperidine-1 -carboxylate 5 (50 mg, 167.03 pmol) in DCM (3 m ) was added HC1 (2M in dioxane) (5 mb) at 0 °C, before stirring at 25 °C for 1 hour. LCMS showed some of the start material remained and the main peak with the desired mass of the product was detected. Then the reaction was stirred at 25 °C for an additional 1 hour. The reaction was concentrated under vacuum to afford 3-fluoro-l-[(2S,4R)-2-methyl-4-piperidyl]pyrazol-4-ol R-53 (39 mg, 148.93 pmol, 89.16% yield, 90% purity, HC1) as a yellow solid, which was used into next step without further purification.[000317] LCMS(ESI): m / z=200.1, [M+H]+;R-Intermec iates Prepared via General Route R-INT-4Number SM-1 StructureFL _OHOHR-50VBocl'j— (ndF OH ^OHN / TR-51BocN —£5Attorney Docket No. PSE-002WOF OH L <3HN / TR-53— ys; / BocN — '— y / s~;(R\ )HN^F OH zK -0HR-54 V.BOCN^F OH ^°HR-55 V.BocN^F OH J3HNVR-56 / ~(R\— ys; / BocN — <— y / s~;7s\ >HN^Step 1 - [000318] A solution of 4-iodo-lH-pyrazole 2 (1 g, 5.16 mmol), tert-butyl 3-hydroxyazetidine-1 -carboxylate 1 (1 g, 5.77 mmol) and 2-(tributyl-phosphanylidene)acetonitrile (2.49 g, 10.31 mmol) in toluene (20 mb) at 20 °C was stirred at 110 °C for 12 hours under N2 atmosphere. LCMS showed starting material 2 was consumed. The reaction mixture was concentrated under vacuum before purification by flash column chromatography to afford tertAttorney Docket No. PSE-002WObutyl 3 -(4-iodopyrazol-l-yl)azetidine-l -carboxylate 3 (1.8 g, 4.64 mmol, 90.00% yield, 90% purity) as a brown oil.[000319] 1HNMR (400 MHz, METHANOL-d4): 57.84 (s, 1H), 7.60 (s, 1H), 5.15 - 5.24 (m, 1H), 4.31 - 4.38 (m, 2H), 4.21 - 4.29 (m, 2H), 1.46 (s, 9H)Step 2 - [000320] To a solution of tert-butyl 3-(4-iodopyrazol-l-yl)azetidine-l-carboxylate 3 (1 g, 2.86 mmol) in THF (15.18 mb) at 20 °C, was added chloro(isopropyl)magnesium (2 M, 14.32 mb) dropwise at 0 °C under N2 atmosphere, before the reaction mixture was stirred at 20 °C for 30 minutes. Then, DMF (1.05 g, 14.32 mmol, 1.11 mL) was added to the mixture under N2 atmosphere, and the mixture was allowed to stir at 20 °C for an additional 3 hours. LCMS showed starting material 3 was consumed. The reaction mixture was quenched by addition of saturated aqueous NH4CI (20 mL), extracted with ethyl acetate (20 mL x 3), washed with brine (30 mL), dried over Na2SC>4, filtered and concentrated under vacuum. The crude material was purified by flash column chromatography to afford tert-butyl 3-(4-formylpyrazol-l-yl)azetidine-1-carboxylate 4 (140 mg, 557.15 pmol, 19.45% yield) as a yellow oil.[000321] 1HNMR (400 MHz, METHANOL-d4): 89.81 (s, 1H), 8.39 (s, 1H), 8.09 (s, 1H), 5.26 (tt, J = 7.95, 5.36 Hz, 1H), 4.35 - 4.39 (m, 2H), 4.27 - 4.32 (m, 2H), 1.47 (s, 9H)Step 3 - [000322] To a solution of tert-butyl 3 -(4-formylpyrazol- l-yl)azetidine- l -carboxylate 4 (140 mg, 557.15 pmol) in DCM (5 mL) was added DAST (268.40 mg, 1.67 mmol, 0.22 mL) portionwise at 0 °C under N2 atmosphere. The reaction was then stirred at 20 °C for 2 hours. LCMS showed starting material was consumed. The reaction mixture was quenched by addition of saturated sodium bicarbonate aqueous solution (10 mL), extracted with DCM (10 mL x 2), washed with brine (15 mL), dried over Na2SC>4, filtered and concentrated under vacuum. The crude material was purified by flash column chromatography to afford tert-butyl 3-[4-(difluoromethyl)pyrazol-l-yl]azetidine-l -carboxylate 5 (30 mg, 109.78 pmol, 19.70% yield) as a yellow oil.[000323] 1H NMR (400 MHz, METHANOL-d4): 88.00 (s, 1H), 7.76 (s, 1H), 6.55 - 7.07 (m, 1H), 5.19 - 5.26 (m, 1H), 4.34 - 4.41 (m, 2H), 4.22 - 4.31 (m, 2H), 1.47 (s, 9H)[000324] 19F NMR (376 MHz, METHANOL-d4) : 8 = - 108.16 (s, 2F)Attorney Docket No. PSE-002WOStep 4 - [000325] A solution of tert-butyl 3 -[4-(difluoromethyl)pyrazol-l-yl]azetidine-l -carboxylate 5 (30 mg, 109.78 pmol) in DCM (1 mb) was added TFA (745.00 mg, 6.53 mmol, 0.5 mL) at 20 °C, before the mixture was allowed to stir at 20 °C for 1 hour. LCMS showed starting material 5 was consumed. The resulting mixture was concentrated under vacuum to afford l-(azeti din-3 -yl)-4-(difluoromethyl)pyrazole R-52 (20 mg, crude), which was used for the next step directly.[000326] LCMS (ESI): m / z = 174.0 [M+H]+Routes to Final ProductsGeneral Route FP-1Step 1 - Cross coupling[000327] To a solution of halide R-INT in solvent was added based and boronate L-INT and the reaction mixture was degassed three times. Palladium catalyst was added and the reaction mixture was stirred at elevated temperature under N2 atmosphere. Upon completion, the mixture was concentrated and diluted by EtOAc, washed with H2O, brine and reconcentrated before purification by flash silica gel chromatography to afford cross couple product 1.Step 2 - Reduction[000328] To a solution of dihydropyridine 1 in MeOH was added Pd / C (10% on Carbon -wetted with ca. 55% water) at ambient temperature, and then degassed with argon four times. The mixture was stirred at ambient temperature under pressure of H2. Upon completion, the reaction mixture was filtered and washed with MeOH, and concentrated under vacuum. The crude material was purified by preparative HPLC and the pure fractions were concentrated under vacuum and lyophilized overnight to afford piperidine FP-1.Typified example - route to P-3Attorney Docket No. PSE-002WOStep 1 - [000329] To a solution of 5-iodo-lH-pyridin-2-one R-2 (693.75 mg, 3.14 mmol) in dioxane (10 mL) and H2O (1 mL) was added K2CO3 (433.86 mg, 3.14 mmol), (5-methoxy-lH-indol-2-yl)-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridin-l-yl]methanone (400 mg, 1.05 mmol) and the reaction mixture was degassed three times. Pd(dppf)Ch (76.57 mg, 104.64 pmol) was added and the reaction mixture was stirred at 100 °C for 16 hours under N2 atmosphere. LCMS showed the desired product mass was observed. The mixture was concentrated to remove dioxane and diluted by EtOAc (10 mL). The mixture was washed by water (10 mL x 3), brine (10 mL) and concentrated before purification by flash silica gel chromatography to afford 5-[l-(5-methoxy-lH-indole-2-carbonyl)-3,6-dihydro-2H-pyridin-4-yl]-lH-pyridin-2-one 1 (30 mg, 68.69 pmol, 6.56% yield, 80% purity).[000330] LCMS (ESI): m / z = 350.0 [M+H]+Step 2 - [000331] To a solution of 5-[l-(5-methoxy-lH-indole-2-carbonyl)-3,6-dihydro-2H-pyridin-4-yl]-lH-pyridin-2-one 1 (30.00 mg, 85.87 pmol) in MeOH (10 mL) was added Pd / C (10% on Carbon -wetted with ca. 55% water) (18.28 mg, 17.17 pmol, 10% purity) at 30 °C, and then degassed with argon four times. The mixture was stirred at 30 °C for 16 hours under 30 psi of H2. LCMS showed the desired product mass was observed. The reaction mixture was filtered and washed with MeOH, and concentrated under vacuum. The crude material was purified by preparative HPLC and the pure fractions were concentrated under reduced pressure and then lyophilized overnight to afford 5-[l-(5-methoxy-lH-indole-2-carbonyl)-4-piperidyl]-lH-pyridin-2-one P-3 (4.05 mg, 11.43 pmol, 13.31% yield, 99.15% purity) as awhite solid.[000332] LCMS (ESI): m / z =352.2 [M+H]+Attorney Docket No. PSE-002WO[000333] 1H NMR (400 MHz, METHANOL-d4) 8 = 7.64 (dd, J = 2.6, 9.4 Hz, 1H), 7.37 - 7.23 (m, 2H), 7.09 (d, J = 2.3 Hz, 1H), 6.88 (dd, J = 2.4, 8.9 Hz, 1H), 6.76 (d, J = 0.6 Hz, 1H),6.55 (d, J = 9.4 Hz, 1H), 4.71 (br d, J = 13.6 Hz, 2H), 3.81 (s, 3H), 3.29 - 2.96 (m, 2H), 2.86 -2.70 (m, 1H), 2.01 - 1.87 (m, 2H), 1.67 (dq, J = 3.7, 12.7 Hz, 2H)Step 1 - [000334] A solution of 5-iodo-4-methyl-l-(2-trimethylsilylethoxymethyl)pyridin-2-one R-4 (200 mg, 547.52 pmol) and(5-methoxy-lH-pyrrolo[2,3-c]pyridin-2-yl)-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridin-l-yl]methanone L-3 (210 mg, 547.95 pmol) in dioxane (5 mb) was added the solution of K3PO4 (350 mg, 1.65 mmol) in H2O (1 mb) followed by Pd(dtBupf)Ch (71.5 mg, 109.71 pmol), and the mixture was degassed with N2, before stirring at 100 °C for 16 hours in a sealed tube. LCMS showed that the starting material was and thedesired product mass was observed. The reaction mixture was quenched by addition of water (5 mL), extracted with EtOAc (10 mb x 3), washed with brine (20 mL), dried over Na SO4, filtered and concentrated under vacuum. The crude material was purified by flash columnchromatography to afford 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-3,6-dihydro-2H-pyridin-4-yl]-4-methyl-l-(2-trimethylsilylethoxymethyl)pyridin-2-one 1 (200 mg, 323.46 pmol, 59.08% yield, 80% purity) as a brown solid.[000335] LCMS (ESI): m / z = 495.3 [M+H]+[000336] 1H NMR (400 MHz, METHANOL-d4): 88.41 (s, 1H), 7.86 (br s, 1H), 7.00 (d, J=0.73 Hz, 1H), 6.81 (s, 1H), 6.73 (s, 1H), 5.65 - 5.88 (m, 1H), 5.47 (s, 2H), 4.31 - 4.58 (m, 2H), 4.02 (br t, J = 5.50 Hz, 2H), 3.91 (s, 3H), 3.74 - 3.85 (m, 2H), 2.52 (br s, 2H), 2.31 (s, 3H), 0.90 -0.97 (m, 2H), -0.06 - 0.07 (m, 9H).Step 2 -Attorney Docket No. PSE-002WO[000337] To a solution of 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-3,6-dihydro-2H-pyridin-4-yl]-4-methyl-l-(2-trimethylsilylethoxymethyl)pyridin-2-one 1 (200 mg, 404.32 pmol) in MeOH (10 mL) was added Pd / C (10% on Carbon - wetted with ca. 55% water) (88.40 mg, 83.07 pmol, 10% purity) at 25 °C, and then degassed with argon four times. Then the mixture was stirred at 25 °C for 16 hours under 25 psi of H2. LCMS showed the starting material was consumed and the desired mass of the product was detected. The mixture was washed with MeOH and fdtered four times, and the fdtrate was concentrated under vacuum to afford 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-4-piperidyl]-4-methyl-l-(2-trimethylsilylethoxymethyl)pyridin-2-one 2 (110 mg, 221.47 pmol, 54.78% yield) as a white solid.[000338] LCMS (ESI): m / z = 367.1 [M-SEM+H]+Step 3 - [000339] To a solution of 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-4-piperidyl]-4-methyl-l-(2-trimethylsilylethoxymethyl)pyridin-2-one (110 mg, 221.47pmol) in DCM (3 mL) was added TFA (1.49 g, 13.07 mmol, 1 mL), and the mixture was allowed to stir at 20 °C for 1 hour. LCMS showed that starting material was consumed. The resulting mixture was concentrated under vacuum before purification by preparative HPLC. The pure fractions were concentrated under reduced pressure and then lyophilized for overnight to afford 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-4-piperidyl]-4-methyl-lH-pyridin-2-one P-44 (60.6 mg, 165.06 pmol, 74.53% yield, 99.8% purity) as a white solid.[000340] LCMS (ESI): m / z = 367.2 [M+H]+[000341] 1H NMR (400 MHz, DMSO-d6) 5 = 11.75 (br s, 1 H), 11.34 (br d, J = 2.50 Hz, 1 H), 8.48 - 8.31 (m, 1 H), 7.08 (s, 1 H), 6.95 - 6.86 (m, 1 H), 6.66 (s, 1 H), 6.16 (s, 1 H), 4.69 -4.21 (m, 2 H), 3.83 (s, 3 H), 3.30 - 2.82 (m, 2 H), 2.76 (brt, J = 11.69 Hz, 1 H), 2.18 (s, 3 H), 1.78 (br s, 2 H), 1.68 - 1.29 (m, 2 H)Attorney Docket No. PSE-002WOFinal Products Prepared via General Route FP-1L- R- No Final Product Structure Characterization DataINT INT LCMS Method A - Retention time: 2.011 min, 98.56% purity at 220 nm, m / z = 352.2 [M+H]+1H NMR (400 MHz, METHANOL-d4) 5 = 7.54 (dd, J = / 7.0, 9.2 Hz, 1H), 7.33 (d, J = 8.8 Hz, 1H). 7.09 (d, J = 2.2 P-1 L-l R-l o Hz, 1H), 6.89 (dd, J = 2.4, 9.0 Hz, 1H), 6.77 (s, 1H), 6.40(d, J = 8.6 Hz, 1H), 6.29 (d, J = 7.0 Hz, 1H), 4.74 (br d, J = o 13.6 Hz, 2H), 3.81 (s, 3H), 3.13 (m, 2H), 2.93 - 2.81 (m,1H), 2.03 (brd, J = 12.3 Hz, 2H), 1.77 (brdd, J = 3.6, 12.4 Hz, 2H)o LCMS Method A - Retention time: 2.001 min, 99.15% purity at 220 nm. m / z = 352.2 [M+H]+1H NMR (400 MHz, METHANOL-d4) 5 = 7.64 (dd, J = 2.6, 9.4 Hz, 1H), 7.37 - 7.23 (m, 2H), 7.09 (d, J = 2.3 Hz, P-3 L-l R-2 o1H). 6.88 (dd, J = 2.4. 8.9 Hz. 1H). 6.76 (d. J = 0.6 Hz, N C— / 1H), 6.55 (d, J = 9.4 Hz. 1H), 4.71 (br d, J = 13.6 Hz, 2H),3.81 (s, 3H), 3.29 - 2.96 (in, 2H), 2.86 - 2.70 (m, 1H), 2.01 - 1.87 (m, 2H). 1.67 (dq, J = 3.7. 12.7 Hz. 2H) LCMS Method A - Retention time: 1.969 min. 98.09% purity at 220 nm, m / z = 338.1 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.42 (br s, 2H), 7.46 - 7.26 (m, 2H), 7.08 (d, J = 2.2 Hz, 1H). 6.93 - 6.82 (m, P-7 L-2 R-l 2H), 6.37 - 5.96 (m, 2H), 3.98 (br dd, J = 6.4, 11.4 Hz, XXH 1H). 3.87 - 3.82 (m, 1H), 3.75 (br d, J = 2.6 Hz, 3H), 3.57(brd, J = 8.1 Hz, 1H), 3.37 (brd, J = 3.5 Hz, 2H), 2.41 - 2.23 (in, 1H), 2.20 - 2.04 (m, 1H)Mixture of Enantiomers - ER: 50:50LCMS Method A - Retention time: 2.723 min. 99.786% purity at 220 nm, m / z = 367.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.75 (br s, 1 H). 11.34 (br d. J = 2.50 Hz, 1 H), 8.48 - 8.31 (m, 1 H). 7.08 P-44 L-3 R-4 (s, 1 H), 6.95 - 6.86 (in, 1 H), 6.66 (s, 1 H), 6.16 (s, 1 H),. AJ-JX 4.69 - 4.21 (m, 2 H), 3.83 (s, 3 H), 3.30 - 2.82 (m, 2 H), Deprotection as exemplified in 2.76 (br t, J = 11.69 Hz, 1 H), 2.18 (s, 3 H), 1.78 (br s, 2 P-44 step 3 H), 1.68 - 1.29 (m, 2 H)0HNA LCMS Method D - Retention time: 2.143 min, 98.799% 4 } purity at 220 nm, m / z = 367.1 [M+H]+1H NMR (400 MHz, METHANOL-d4) 5 = 8.57 (s, 1H), P-45 L-3 R-5 H \ / 7.59 (d, J = 9.4 Hz, 1H), 7.42 (s, 1H), 6.95 (s, 1H), 6.41 (d,J = 9.3 Hz, 1H). 4.83 (br s. 1H), 4.44 - 4.16 (m, 1H), 4.08 \ AXH o, (s, 3H), 3.54 - 3.34 (m, 1H), 3.12 - 2.86 (m, 2H), 2.38 (s, Deprotection as exemplified in 3H). 1.89 - 1.65 (m, 4H)P-44 step 3LCMS Method D - Retendon time: 1.449 min, 98.015% purity at 220 nm, m / z = 354.1 [M+H]+1H NMR (400 MHz, METHANOL-d4) 5 = 8.51 (s, 1H), 8.08 (d, J = 0.7 Hz, 1H), 7.36 - 7.19 (m, 2H), 6.86 (s, 1H), P-46 L-3 R-6 A4.81 - 4.64 (m, 1H), 4.46 - 4.19 (m, 1H), 4.03 (s, 3H), 3.51 AXX - 3.32 (m, 1H). 3.04 (brd. J = 4.5 Hz, 1H), 2.91 (tt, J = 3.6. Deprotection as exemplified in 11.8 Hz, 1H). 1.96 (br s, 2H), 1.79 (dq, J = 4.3, 12.6 Hz,P-44 step 3 2H)Attorney Docket No. PSE-002WOLCMS Method A - Retention time: 2.775 min. 99.134% purity at 220 mn, m / z = 367.2 [M+H]+1H NMR (400 MHz, CHLOROFORM-d) 5 = 8.51 (s, 1H).7.09 (d, J = 2.2 Hz, 1H), 6.92 (d, J = 0.9 Hz. 1H), 6.63 (s.P-47 L-3 R-7 1H), 4.86 - 4.75 (m, 2H), 3.97 (s, 3H), 3.56 - 2.78 (m, 2H),AA 2.72 - 2.55 (m, 1H), 2.18 (s, 3H), 1.96 (brd, J = 12.3 Hz. Deprotection as exemplified in 2H), 1.64 (dq. J = 4.1, 12.8 Hz. 2H) - three protons not P-44 step 3 obsereved0AAH LCMS Method A - Retention time: 1.804 min, 99.603% AH' purity at 220 mn, m / z = 354.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 12.83 - 12.94 (1 H, P-49 L-3 R-8 H \ / m), 11.75 - 11.82 (1 H, in), 8.40 (1 H, s), 7.49 (1 H, d, J =9.78 Hz). 6.90 - 6.92 (1 H. m), 6.87 (1 H, d, J = 9.78 Hz). AJA v 6.65 (1 H, s), 4.17 - 4.70 (2 H, m), 3.84 (3 H, s), 2.86 - Deprotection as exemplified in 2.96 (1 H, m), 1.87 - 1.98 (2 H, m), 1.51 - 1.67 (2 H. m) P-44 step 3oF HN^ LCMS Method A - Retention time: 1.456 min. 97.407%FH) purity at 220 mn, m / z = 421.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.79 (br s. 1H), 11.54 - 11.07 (in, 1H). 8.41 (s, 1H). 8.01 (d, J = 8.8 Hz, P-50 L-3 R-9 H \ / 1H). 6.95 - 6.88 (m, 2H), 6.69 (s, 1H), 4.76 - 4.51 (m, 1H),4.48 - 4.18 (m. 1H), 3.84 (s. 3H), 3.12 (br s. 2H), 3.03 - 2.78 (in, 1H). 1.95 - 1.60 (m. 4H)Deprotection as exemplified in 19F NMR (376 MHz, DMSO-d6) 6 = -60.91 (s, IF) P-44 step 3o LCMS Method A - Retention time: 2.06 min, 97.085% purity at 220 mn, m / z = 371.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 12.01 - 11.20 (m, 2H). 8.49 - 8.30 (m, 1H), 7.34 (d, J = 10.0 Hz, 1H), 6.96 - P-54 L-3 R-10 H \ / 6.87 (m, 1H). 6.77 - 6.62 (m. 1H), 6.12 (d, J = 13.5 Hz.N^r\ / 1H), 4.65 - 4.23 (m, 2H), 3.84 (s, 4H), 3.28 (br d, J = 5.4 A JLA v Hz, 1H). 2.91 - 2.80 (m. 1H), 1.92 - 1.74 (m, 2H), 1.74 - Deprotection as exemplified in 1.47 (m, 2H)P-44 step 3 19F NMR (376 MHz, DMSO-d6) 6 = -102.92 (br s, IF) oHN—LCMS Method A - Retention time: 2.195 min. 99.031% purity at 220 mn, m / z = 393.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.77 (br s, 1 H). P-55 L-3 R-ll , <A 10.69 (br s. 1 H), 8.58 (s, 1 H). 8.40 (s, 1 H), 7.80 (s. 1 H),6.90 (s, 1 H), 6.68 (s, 1 H), 6.42 (brd, J=2.13 Hz, 1 H), x. A^W V 4.71 - 4.22 (m, 2 H), 3.83 (s. 3 H), 3.21 - 2.87 (m, 3 H), Deprotection as exemplified in 2.13 - 1.99 (m, 2 H). 1.73 - 1.52 (m, 2 H)P-44 step 3oO— / NH LCMS Method D - Retention time: 1.616 min, 92.55% / A7purity at 220 mn, m / z = 383.1 [M+H]+1H NMR (400 MHz, DMSO-d6) S = 8.39 (s, 1H), 7.07 (s, P-59 L-3 R-12 H \ / 1H), 6.94 (d, J = 0.9 Hz, 1H), 6.67 (s, 1H), 5.77 (s, 1H),N-AA 4.68 - 4.40 (m, 1H), 4.37 - 4.12 (m, 1H), 3.81 - 3.79 (m, 1 1 / 1 3H), 3.77 - 3.74 (m, 3H). 3.37 - 3.09 (m, 1H), 2.92 - 2.77 Deprotection as exemplified in (m, 2H), 1.91 - 1.69 (m, 2H), 1.59 - 1.32 (m, 2H)P-44 step 3Attorney Docket No. PSE-002WOLCMS Method D - Retention time: 1.97 min, 98.459% purity at 220 nm, m / z = 352.1 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 12.20 - 11.90 (m, P-63 1H), 11.82 (br s, 1H), 8.42 (m, 3H), 6.93 (s, 1H), 6.74 (s,1H), 6.32 - 6.03 (brs, 1H), 4.52 - 4.17 (m, 2H), 3.85 (111, 5H), 2.58 - 2.52 (m, 2H)Deprotection as exemplified inP-44 step 3General Route FP-2General procedureL-INT Step 1 FP-2Step 1 - Amide coupling[000342] A solution of carboxylic acid L-INT and HATU in solvent was stirred at ambient temperature. Then amine R-INT and DIEA were added and the combined reaction mixture was stirred at ambient temperature under N2 atmosphere. Upon completion, the reaction underwent organic / aqueous workup before being concentrated under vacuum and purified by preparative HPLC. The pure fractions were concentrated under vacuum and lyophilized to afford amide FP-2.Typified example - route to P-9Attorney Docket No. PSE-002WOStep 1 - [000343] To a solution of 5-methoxy-lH-indole-2-carboxylic acid L-4 (70 mg, 366.14 pmol) in DCM (5 mL) was added HATU (206 mg, 541.78 pmol) followed by DIEA (237.44 mg, 1.84 mmol, 0.32 mL) at 25 °C under N2 atmosphere, then the suspension was degassed and purged with N2 three times, before stirring at 25 °C for 5 minutes. Then l-(4-piperidyl)pyrazol-4-amine R-18 (60 mg, 360.96 pmol) was added at 25 °C, and the combined reaction mixture was stirred under N2 atmosphere at 25 °C for 1 hour. LCMS showed that the starting material was consumed. The reaction mixture was quenched by addition of water (10 mL), extracted with DCM (10 mL), washed with citric acid aqueous solution (10 mL), water (10 mL x 2) and brine (10 mL), dried over NazSCM, filtered and concentrated under vacuum. The crude material was purified by preparative HPLC and the pure fractions were concentrated under reduced pressure and then lyophilized for overnight to afford [4-(4-aminopyrazol-l-yl)-l-piperidyl]-(5-methoxy- lH-indol-2-yl)methanone P-9 (8.1 mg, 23.45 pmol, 6.50% yield, 98.26% purity) as a yellow solid.[000344] LCMS (ESI): m / z = 340.2 [M+H]+[000345] 1HNMR (400 MHz, METHANOL-d4) 5 = 7.36 - 7.30 (m, 2 H), 7.18 (s, 1 H), 7.09 (d, J = 2.20 Hz, 1 H), 6.89 (dd, J = 9.02, 2.42 Hz, 1 H), 6.77 (s, 1 H), 4.69 (br d, J = 13.20 Hz, 2 H), 4.38 (tt, J = 11.28, 4.24 Hz, 1 H), 3.81 (s, 3 H), 3.40 - 3.32 (m, 1 H), 3.28 - 3.19 (m, 1 H), 2.18 - 2.11 (m, 2 H), 2.07 - 1.95 (m, 2 H)Typified example - route to P-36L-5 Step 1 P-36Step 1 - [000346] A solution of 5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carboxylic acid L-5 (205 mg, 1.07 mmol) and HATU (486.12 mg, 1.28 mmol) in DMF (8 mL) was stirred at 20 °C for 15Attorney Docket No. PSE-002WOminutes. Then 5-(azetidin-3-yl)pyridin-2-ol R-43 (160 mg, 1.07 mmol) and DIEA (550.77 mg, 4.26 mmol, 742.28 pL) were added and the combined reaction mixture was stirred at 20 °C for 1 hour under N2 atmosphere. LCMS showed starting material consumed and desired mass of the product of peak was detected. The reaction was concentrated under vacuum before purification by preparative HPLC. The pure fractions were concentrated under vacuum and lyophilized for 18 hours to afford [3-(6-hydroxy-3-pyridyl)azetidin-l-yl]-(5-methoxy-lH-pyrrolo[2,3-c]pyridin-2-yl)methanone P-36 (123 mg, 379.24 pmol, 35.60% yield) as a white solid.[000347] LCMS (ESI): m / z = 325.2 [M+H]1[000348] 1H NMR (400 MHz, DMSO-d6) 8 = 8.42 (s, 1H), 7.64 (dd, J = 2.8, 9.6 Hz, 1H), 7.38 (d, J = 2.4 Hz, 1H), 6.91 (d, J = 0.9 Hz, 1H), 6.75 (s, 1H), 6.38 (d, J = 9.5 Hz, 1H), 4.80 (br t, J = 8.7 Hz, 1H), 4.52 - 4.35 (m, 2H), 3.98 (br dd, J = 6.9, 9.6 Hz, 1H), 3.86 - 3.76 (m, 4H)Typified example - route to P-76L-18 Step 1 P-76Step 1 - [000349] A solution of 5-isopropoxy-lH-pyrrolo[2,3-c]pyridine-2-carboxylic acid L-18 (80 mg, 363.27 pmol) in DMF (3 mL) and HATU (138.12 mg, 363.27 pmol) was stirred at 20 °C for 30 minutes under N2 atmosphere. Then 3-fluoro-l-(4-piperidyl)pyrazol-4-ol R-51 (95 mg, 428.59 pmol, HC1) and DIEA (140.85 mg, 1.09 mmol, 189.82 pL) were added and the combined reaction mixture was stirred at 20 °C for 2 hours under N2 atmosphere. LCMS showed the starting material was consumed and the desired mass of the product was detected. The reaction was filtered and the filtrate was quenched with water (5 mL) and extracted with EtOAc (10 mL x 3). The organic layer was washed with aq Na CO3 (5 mL), dried over Na2SC>4, filtered and concentrated before purification by preparative HPLC. The pure fractions were concentratedAttorney Docket No. PSE-002WOunder vacuum and lyophilized for 18 hours to give [4-(3-fluoro-4-hydroxy-pyrazol-l-yl)-l-piperidyl]-(5-isopropoxy-lH-pyrrolo[2,3-c]pyridin-2-yl)methanone P-76 (84.1 mg, 216.17 pmol, 59.51% yield, 99.58% purity) as white solid.[000350] LCMS (ESI): m / z = 388.2 [M+H]+[000351] 1HNMR (400MHz, DMSO-d6) 5 = 11.76 (br s, 1H), 8.65 (br s, 1H), 8.39 (s,1H), 7.40 (s, 1H), 6.84 (s, 1H), 6.69 - 6.59 (m, 1H), 5.16 (quin, J = 6.1 Hz, 1H), 4.66 - 4.27 (m, 2H), 4.26 - 4.15 (m, 1H), 3.29 - 2.77 (m, 2H), 2.02 (br d, J = 10.5 Hz, 2H), 1.90 - 1.71 (m, 2H),1.30 - 1.22 (m, 6H)[000352] 19F NMR (376 MHz, DMSO-d6) 5 = -143.89 (s, IF)Final ’roducts Prepared via General Route FP-2L- R- No Final Product Structure Characterization DataINT INT / \=O LCMS Method A - Retention time: 1.977 min, 99.33% purity at 220 nm, m / z = 353.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.60 - 11.33 (m, 1H), 7.39 (t, J = 7.9 Hz, 1H). 7.32 (d, J = 8.8 Hz, 1H), P-2 L-4 R-14 7.08 (d, J = 2.3 Hz, 1H). 6.85 (dd, J = 2.4. 8.9 Hz,1H), 6.76 (s, 1H), 6.14 (d, J = 8.0 Hz, 1H), 5.90 (d. J = 7.9 Hz, 1H), 3.85 (m, J = 1.5 Hz, 4H), 3.76 (s, 3H), X X ZX 3.56 - 3.50 (m, 4H)0LCMS Method A - Retention time: 1.779 min. 92.63% purity at 220 nm, m / z = 353.1 [M+H]+1H NMR (400 MHz, METHANOL-d4) 5 = 7.66 (dd. J = 9.79, 3.26 Hz, 1 H), 7.33 (d, J = 9.03 Hz, 1 H), P-4 L-4 R-157.09 (d, J = 2.26 Hz, 1 H), 6.96 (d, J = 3.01 Hz, 1 H), 6.89 (dd, J = 9.03. 2.26 Hz, 1 H), 6.79 (s, 1 H), 6.56 N Cx (d. J = 9.79 Hz, 1 H), 4.00 (br s, 4 H), 3.81 (s, 3 H),3.06 - 2.99 (m, 4 H)'oz0\ / NH2 LCMS Method A - Retention time: 1.825 min, 100% purity at 220 mn, m / z = 341.3 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.40 (s. 1H), 7.30 (d. J = 9.0 Hz, 1H), 7.06 (d, J = 2.0 Hz, 1H). 6.83 P-6 L-4 R-16 (dd, J = 2.3, 8.9 Hz, 1H), 6.69 (d, J= 1.1 Hz, 1H), ^<5. N C— / 6.55 (s, 2H), 4.88 (s, 1H), 4.44 (br d, J = 13.4 Hz,2H), 3.75 (s, 3H), 3.27 - 2.99 (m, 2H), 2.84 (ddd, J = 3.7, 7.8, 11.2 Hz, 1H), 1.90 (brd, J= 11.2 Hz, 2H),1.58 (q, J = 11.2 Hz, 2H)Attorney Docket No. PSE-002WON NH2LCMS Method A - Retention time: 2.528 min, 99.87%N\ X purity at 220 nm, m / z = 358.1 [M+H]+1H NMR (400 MHz, DMSO-d6) 8 = 11.41 (s, 1H).P-8 L-4 R-17 7.31 (d, J = 8.8 Hz, 1H), 7.12 - 7.03 (m, 3H), 6.84 (dd,C— / J = 2.5, 8.9 Hz. 1H), 6.71 (d. J = 1.6 Hz, 1H), 4.45 (br d, J = 13.3 Hz, 2H), 3.76 (s, 3H), 3.32 - 3.04 (m, 3H).2.11 - 2.01 (m, 2H), 1.66 (brd, J= 10.0 Hz, 2H) ^NH2LCMS Method A - Retention time: 1.622 min,N98.256% purity at 220 nm. m / z = 340.2 [M+H]+ KJ V1H NMR (400 MHz, METHANOL-d4) 5 = 7.36 - 7.30 (m, 2 H), 7.18 (s, 1 H), 7.09 (d, J = 2.20 Hz, 1 TP-9 L-4 R-18 o H), 6.89 (dd, J = 9.02, 2.42 Hz, 1 H), 6.77 (s, 1 H).C— 4.69 (brd, J = 13.20 Hz. 2 H), 4.38 (tt, J = 11.28, 4.24 bl - Hz, 1 H), 3.81 (s, 3 H), 3.40 - 3.32 (m, 1 H), 3.28 - I X^X 3.19 (m, 1 H), 2.18 - 2.11 (m, 2 H), 2.07 - 1.95 (m. 2O H)N NH2NzLCMS Method B - Retention time: 1.464 min. 96% purity at 214 nm, m / z = 343.1 [M+H]+r 1H NMR (400 MHz, DMSO-d6) 5 = 11.47 (s, 1H), P-11 L-4 R-20 7.32 (d, J = 8.9 Hz, 1H), 7.07 (d, J = 2.4 Hz. 1H), 6.85NX (dd, J = 8.9. 2.4 Hz, 1H). 6.75 (d, J = 1.7 Hz. 1H),6.52 (s, 2H), 3.85 (br s, 4H), 3.75 (s, 3H) - four o 1 XZX protons not observed.o OH LCMS Method B - Retention time: 1.727 min. 100%Npurity at 214 nm, m / z = 343.1 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 12.28 (s, 1H).11.42 (s, 1H). 7.31 (d, J = 8.9 Hz, 1H), 7.07 (d, J = 2.3 P-12 L-4 R-21 Hz, 1H), 6.84 (dd, J = 8.9, 2.4 Hz, 1H), 6.70 (d, J = N ^N— / 1.7 Hz. 1H), 4.43 (d. J = 13.4 Hz. 2H), 3.75 (s. 3H),3.20 (d, J = 20.2 Hz, 2H), 3.01 (ddd, J = 15.0, 7.5, 3.8 1 X / H Hz, 1H), 1.98 (dd, J = 13.0, 2.6 Hz. 2H), 1.75 - 1.560 (m. 2H).LCMS Method B - Retention time: 1.796 min. 100% purity at 214 nm, m / z = 342.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 8 = 11.41 (s, 1H).11.13 (s, 1H). 7.30 (d, J = 8.9 Hz, 1H), 7.06 (d, J = 2.4 P-13 L-4 R-22 Hz, 1H). 6.83 (dd, J = 8.9. 2.4 Hz, 1H). 6.70 (d, J =1.7 Hz. 1H), 5.84 (s. 1H), 4.44 (d, J = 13.3 Hz. 2H), 3.75 (s, 3H), 3.17 (s, 2H), 3.05 (ddd, J = 11.3, 7.7, 3.8 Hz, 1H). 2.01 (dd, J = 12.8, 2.2 Hz. 2H), 1.59 (qd, J = 13.0, 3.5 Hz, 2H).LCMS Method B - Retention time: 1.574 min, HN' I787.47% purity at 214 nm, m / z = 355.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.40 (s, 1H), 10.70 (s. 1H), 7.30 (d. J = 8.9 Hz, 1H), 7.07 (d, J = 2.3 P-14 L-4 R-23 Hz, 1H), 6.83 (dd. J = 8.9, 2.4 Hz, 1H), 6.68 (d, J = H \ / 1.6 Hz, 1H), 5.21 (s, 1H), 4.44 (d, J = 12.7 Hz, 2H),3.75 (s, 3H), 3.43 (s, 2H), 3.17 (d, J = 5.0 Hz, 2H). 3.13 - 2.98 (m, 1H). 2.78 - 2.68 (m, 1H), 1.96 - 1.83 ^O7I^7X^7 / 7>A O (m, 2H), 1.54 (td, J = 14.8, 3.4 Hz, 2H).Attorney Docket No. PSE-002WOH N NH LCMS Method B - Retention time: 1.797 min, 100% HN' y purity at 214 mn, m / z = 340.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.41 (s, 1H), 11.14 (s, 1H), 7.30 (d, J = 8.9 Hz. 1H), 7.07 (d. J = 2.4 P-15 L-4 R-24 Hz, 1H), 6.83 (dd. J = 8.9, 2.4 Hz, 1H), 6.68 (d, J = H \ / 1.7 Hz, 1H), 5.22 (s, 1H), 4.46 (d, J = 13.1 Hz, 3H), I Xx. 3.75 (s, 3H), 3.12 (s, 1H), 2.80 (t, J = 11.4 Hz, 1H),1.98 - 1.86 (in, 2H). 1.54 (dd, J = 21.2, 11.7 Hz, 2H). H N OH LCMS Method B - Retention time: 1.568 min, 100% purity at 214 run, m / z = 357.1 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.42 (s, 1H), 10.78 (s, 1H), 7.30 (d. J = 8.9 Hz, 1H), 7.07 (d, J = 2.4 P-16 L-4 R-25 Hz, 1H), 6.84 (dd. J = 8.9, 2.4 Hz, 1H), 6.69 (d, J = ^x ,N C— / * 1.7 Hz, 1H), 4.52 (d, J = 13.1 Hz, 2H), 4.10 - 3.99 (m,1H). 3.94 (s, 2H). 3.75 (s, 3H). 3.08 (s, 2H). 1.77 (d, J = 10.0 Hz, 2H), 1.63 (dd. J = 21.1, 11.8 Hz, 2H). ^Q / fW 1^- / 7H 0HN^^NH LCMS Method B - Retention time: 1.26 min, 100% N' y purity at 214 mn, m / z = 341.2 [M+H]+VNH 1H NMR (400 MHz, DMSO-d6) 5 = 11.60 (s, 1H),11.41 (s, 1H). 7.30 (d, J = 8.9 Hz, 1H), 7.07 (d, J = 2.4 P-17 L-4 R-26Hz, 1H), 6.83 (dd, J = 8.9, 2.4 Hz, 1H), 6.67 (d. J = H \ / 1.6 Hz. 1H), 5.81 (s. 2H), 4.37 (d, J = 13.0 Hz. 2H), 1 XX 3.75 (s, 3H), 3.22 (s, 2H), 2.81 (s, 1H), 1.94 (d, J = O 10.7 Hz, 2H). 1.64 (td, J = 14.5, 3.7 Hz. 2H).H LCMS Method B - Retention time: 1.481 min, N nN' y 98.35% purity at 214 mn, m / z = 342.2 [M+H]+ VNH 1H NMR (400 MHz, DMSO-d6) 5 = 11.41 (s. 1H),11.29 (s, 1H), 11.17 (s, 1H), 7.30 (d, J = 8.9 Hz, 1H), P-18 L-4 R-27 7.07 (d, J = 2.4 Hz, 1H), 6.83 (dd, J = 8.9, 2.4 Hz, H \ / 1H). 6.69 (d, J = 1.7 Hz. 1H), 4.41 (d, J = 13.3 Hz.2H), 3.75 (s, 3H), 3.16 (s, 2H), 2.82 (tt, J = 11.2, 3.6 f Xx Hz, 1H), 1.99 - 1.87 (m, 2H), 1.62 (dd, J = 21.1, 11.3O Hz, 2H).N OHNzLCMS Method B - Retention time: 1.71 min, 96.82% purity at 214 run, m / z = 343.1 [M+H]+Vo1H NMR (400 MHz, DMSO-d6) 5 = 12.14 (s, 1H), 11.42 (s, 1H). 7.30 (d. J = 8.9 Hz, 1H), 7.06 (d, J = 2.4 P-19 L-4 R-28H \ / Hz, 1H), 6.83 (dd. J = 8.9, 2.4 Hz, 1H), 6.69 (d, J =1.6 Hz, 1H), 4.36 (d, J = 13.5 Hz, 2H), 3.75 (s, 3H), J XX 3.28 - 3.14 (m, 2H), 3.04 (tt. J = 10.7, 3.8 Hz. 1H), ^CV ^V^7o 2.00 (dd, J = 13.4. 3.1 Hz, 2H). 1.71 - 1.56 (m. 2H).Attorney Docket No. PSE-002WOH N NHNz¥ LCMS Method B - Retention time: 1.307 min. 100% purity at 214 nm, m / z = 342.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.44 (s, 1H), ZP-20 L-4 R-29NH11.03 (s, 1H). 7.31 (d, J = 8.9 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.84 (dd, J = 8.9, 2.4 Hz, 1H), 6.73 (d, J = N 1.6 Hz. 1H), 5.80 (s. 2H), 3.80 (br s, 4H), 3.75 (s, 3H),3.26 (br s, 4H). / 1 o Z / M.LCMS Method B - Retention time: 1.37 min, 88.88% purity at 214 nm, m / z = 341.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.40 (s, 1H), LZL- 7.30 (d, J = 8.9 Hz, 1H). 7.15 - 7.03 (m, 2H), 6.83 P-21 L-4 R-30 CMT Z CM (dd, J = 8.9, 2.4 Hz, 1H), 6.66 (d, J = 1.8 Hz, 1H), T11 T Z 6.45 (s, 2H), 4.41 (d, J = 13.3 Hz, 2H), 3.75 (s, 3H), z / Z^ 3.14 (s, 2H), 2.71 - 2.62 (m. 1H), 2.02 - 1.84 (m, 2H). ¥1 > ° 1.61 - 1.40 (m, 2H).O oH LCMS Method B - Retention time: 1.615 min, 100% ^ LDZ J purity at 214 nm, m / z = 359.1 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.49 (s, 1H), P-22 L-4 R-31 IZY " Y“NNZ 7.33 (d, J = 8.9 Hz, 1H). 7.08 (d. J = 2.4 Hz. 1H), 6.86(dd, J = 8.9, 2.5 Hz, 1H). 6.78 (d, J = 1.7 Hz, 1H), 4.04 (s, 2H), 3.94 (dd, J = 11.2, 8.7 Hz, 6H), 3.76 (s, - XXM 3H). 3.67 (dd, J = 6.0. 4.2 Hz, 2H).oO / h .NH LCMS Method B - Retention time: 1.345 min, 100% N' Y purity at 214 mn, m / z = 355.2 [M+H]+ YNH 1H NMR (400 MHz, DMSO-d6) 5 = 11.40 (s. 1H),7.29 (d, J = 8.9 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.83 P-23 L-4 R-32 (dd, J = 8.9, 2.5 Hz, 1H), 6.66 (d, J = 1.2 Hz, 1H), H \ / 6.03 (s, 2H), 4.36 (d, J = 13.2 Hz, 2H), 3.75 (s, 3H),3.44 (s. 3H), 3.28 - 3.06 (m, 2H). 2.84 - 2.71 (m, 1H), X TJM 1.92 (dd, J = 13.2, 2.8 Hz, 2H), 1.70 - 1.54 (m, 2H).LCMS Method B - Retention time: 1.685 min, 100% purity at 214 nm, m / z = 359.1 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.48 (s, 1H), P-24 L-4 R-33 7.32 (d, J = 8.9 Hz, 1H). 7.07 (d. J = 2.3 Hz. 1H), 6.85(dd, J = 8.9, 2.4 Hz, 1H), 6.77 (d, J = 1.7 Hz, 1H), 6.16 (s, 2H), 3.88 (s, 4H), 3.76 (s, 3H), 3.58 - 3.44 (m, 4H).LCMS Method B - Retention time: 1.459 min, 88.71% purity at 214 nm, m / z = 343.2 [M+H]+ 1H NMR (400 MHz, DMSO-d6) 5 = 11.44 (s, 1H), P-25 L-4 R-34 11.16 (s, 1H), 10.59 (s, 1H), 7.31 (d, J = 8.9 Hz, 1H),7.07 (d, J = 2.4 Hz, 1H), 6.85 (dd, J = 8.9, 2.4 Hz, 1H), 6.75 (d, J = 1.7 Hz, 1H), 3.81 (s, 4H), 3.75 (s, 3H), 3.24 - 3.17 (m, 4H).Attorney Docket No. PSE-002WOHN^NH1H NMR (400 MHz, DMSO-d6) 5 = 11.40 (s. 1H), V-NH 7.30 (d. J = 8.9 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.83(dd, J = 8.9, 2.5 Hz, 1H), 6.66 (s, 1H), 6.16 (s, 1H), P-26 L-4 R-35 4.97 (s, 1H), 4.43 (d, J = 13.4 Hz, 2H), 3.75 (s, 3H),H \ / 3.12 (s. 2H), 2.63 (d. J = 11.2 Hz. 1H), 1.92 (dd, J = 13.1, 2.5 Hz, 2H), 1.48 (qd, J= 12.3, 3.3 Hz, 2H). X X / K oN NH2LCMS Method B - Retention time: 1.538 min, 100% N'2purity at 214 nm, m / z = 342.1 [M+H]+\L-0 1H NMR (400 MHz. DMSO-d6) 5 = 11.42 (s, 1H).7.30 (d, J = 8.9 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.91 P-27 L-4 R-36 (s, 2H), 6.83 (dd, J = 8.9, 2.5 Hz, 1H), 6.70 (d. J = 1.4H \ ) Hz. 1H), 4.36 (d, J = 13.4 Hz. 2H), 3.75 (s. 3H), 3.31(d, J = 1.9 Hz, 2H), 3.14 (ddd, J = 10.5, 9.0, 4.5 Hz, J XZX 1H), 2.07 - 1.99 (m, 2H), 1.66 (td, J = 14.4, 3.7 Hz,2H).LCMS Method B - Retention time: 1.368 min, 100% h ,NH purity at 214 nm, m / z = 354.2 [M+H]+HN' Vs1H NMR (400 MHz, DMSO-d6) 5 = 11.39 (s. 1H),7.30 (d, J = 8.9 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.83 P-28 L-4 R-37 (dd, J = 8.9, 2.5 Hz, 1H), 6.67 (d. J = 1.6 Hz, 1H), H \ / / ^- ,N N— ' 5.13 (s, 1H), 5.04 (s, 2H), 4.42 (d, J = 13.1 Hz, 2H),3.75 (s. 3H), 3.43 (s. 3H), 3.11 (s. 2H), 2.69 (ddd, J = O 7.7, 5.6, 2.8 Hz, 1H), 1.88 (dd, J = 13.1, 2.4 Hz, 2H),1.61 - 1.41 (m. 2H).HN ^0HN' 7^LCMS Method B - Retention time: 1.523 min, 99% P-29 L-4 R-38H \ / purity at 214 mn, m / z = 341.1 [M+H]+ -0XXM LCMS Method A - Retention time: 2.323 min,x\ OH 99.898% purity at 220 nm, m / z = 341.2 [M+H]+ ex HNMR: 1H NMR (400 MHz. METHANOL-d4) 5 =7.35 (d, J = 8.8 Hz, 1H), 7.29 (d, J = 0.7 Hz. 1H), 7.12 P-31 L-4 R-39 (dd, J = 1.5, 7.1 Hz. 2H), 6.91 (dd, J = 2.4, 8.9 Hz.XXy- N <C— / > 1H), 6.79 (d, J = 0.6 Hz, 1H). 4.70 (br d, J = 13.4 Hz.2H), 4.37 (tt, J = 4.4, 11.4 Hz, 1H), 3.83 (s, 3H), 3.32 - 3.18 (m, 2H), 2.17 (brd, J = 9.7 Hz. 2H), 2.03 (dq, J = 4.3, 12.2 Hz, 2H)z\ „OH LCMS Method A - Retention time: 1.822 min,NK 99.727% purity at 220 nm. m / z = 313.2 [M+HJ+1H NMR (400 MHz, METHANOL-d4) 5 = 7.39 - P-32 L-4 R-40 7.31 (m, 2H), 7.23 (s, 1H), 7.10 (d, J = 2.3 Hz, 1H),6.91 (dd. J = 2.4, 8.9 Hz, 1H), 6.81 (s, 1H), 5.28 - 5.15 (m. 1H), 5.04 - 4.94 (m, 1H). 4.75 - 4.57 (m. 2H),4.46 (br d, J = 1.2 Hz, 1H), 3.81 (s, 3H)Attorney Docket No. PSE-002WOLCMS Method A - Retention time: 1.875 min, OH 99.788% purity at 220 nm, m / z = 327.2 [M+H]+ 1H NMR (400 MHz, DMSO-d6) 5 = 11.44 (s, 1 H), 8.40 (s. 1 H), 7.36 - 7.26 (m, 2 H), 7.08 (d. J = 2.38 P-33 L-4 R-41 Hz, 1 H), 7.02 (s, 1 H), 6.85 (dd, J = 8.94, 2.44 Hz, 1= H), 6.69 (d, J = 1.63 Hz, 1 H), 4.53 (brt, J = 8.44 Hz, o 1 H). 4.32 - 4.26 (m. 1 H), 4.23 (d, J = 7.25 Hz, 2 H).4.10 (br t, J = 9.07 Hz, 1 H), 3.86 (br dd, J = 9.38, 5.38 Hz, 1 H), 3.74 (s. 3 H), 3.18 - 3.04 (m, 1 H) LCMS Method C - Retention time: 2.187 min, 100% purity at 220 mn, m / z = 327 [M+H]+HNMR: 1H NMR (400 MHz, METHANOL-d4) 5 = 7.37 (d, J = 9.0 Hz, 1H), 7.29 (s, 1H), 7.20 - 7.06 (m, P-34 L-4 R-42 2H), 7.04 - 6.86 (m, 2H), 5.07 - 4.98 (m, 1H), 4.45 - 1 AZA 3.91 (m, 4H), 3.83 (s, 3H). 2.59 - 2.38 (m, 2H) 0Mixture of Enantiomers - ER: 41:590 LCMS Method A - Retention time: 1.778 min, 100% purity at 220 nm, m / z = 325.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 8.42 (s, 1H), 7.64 (dd, J = 2.8, 9.6 Hz, 1H), 7.38 (d, J = 2.4 Hz, P-36 L-5 R-43H CA 1H), 6.91 (d, J = 0.9 Hz, 1H), 6.75 (s, 1H), 6.38 (d, J =9.5 Hz. 1H), 4.80 (br t, J = 8.7 Hz, 1H), 4.52 - 4.35 AXA (m, 2H), 3.98 (br dd, J = 6.9. 9.6 Hz, 1H), 3.86 - 3.76(m, 4H)0A LCMS Method B - Retention time: 1.447 min, 100% P-37 L-6 R-44 purity at 214 tun, m / z = 374.1 [M+H]+- 'r!> PLCMS Method B - Retention time: 1.44 min, 99% P-38 L-6 R-15 purity at 214 nm, m / z = 358.1 [M+H]+H )N-^V\W,il / v0°HLCMS Method B - Retention time: 1.588 min, 100% P-39 L-4 R-44d ° purity’ at 214 mn, m / z = 369.2 [M+H]+oAttorney Docket No. PSE-002WOLCMS Method B - Retention time: 1.288 min, 99% P-40 L-7 R-15 purity at 214 mn, m / z = 354.1 [M+H]+o / \ o o OX LCMS Method B - Retention time: 1.278 min, 100% P-41 L-7 R-44 H purity at 214 nm, m / z = 370.1 [M+H]+AZ:E zix- \ Jl XXA 1 IT >=^XX^O Z o I ILCMS Method B - Retention time: 1.54 min, 99% P-42 L-8 R-15 purity at 214 nm, m / z = 354.1 [M+H]+LCMS Method B - Retention time: 1.339 min, 100% P-43 L-6 R-45 purity at 214 mn, m / z = 347.1 [M+H]+0XL LCMS Method D - Retention time: 1.724 min,97.03% purity at 220 mn, m / z = 374.1 [M+H]+ HNMR: 1H NMR (400 MHz. METHANOL-d4) 5 = 7.92 - 7.88 (m, 1H), 7.87 - 7.83 (m, 2H), 7.67 - 7.62 P-51 L-9 R-46H \ / (m, 1H), 7.58 - 7.52 (m, 3H), 7.47 (d, J = 2.3 Hz, 1H), N 7.16 (d. J = 1.5 Hz, 1H), 6.58 (d, J = 9.8 Hz, 1H), 6.12(br s, 1H), 4.67 - 4.36 (m, 2H), 4.17 - 3.94 (m, 2H), OJH 2.64 - 2.56 (m, 2H)0 LCMS Method A - Retention time: 2.35 min, 99.205% purity at 220 mn, m / z = 340.3 [M+H]+ rXH1H NMR (400 MHz. DMSO-d6) 5 = 11.51 - 11.01 (m,1H), 10.96 (s, 1H), 7.41 (dd, J = 2.6, 9.5 Hz, 1H), 7.14 P-52 L-10 R-47 (d. J = 2.4 Hz, 1H), 6.28 (d, J = 9.4 Hz, 1H), 6.21 (d, J = 1.7 Hz, 1H). 4.50 (brd. J = 13.4 Hz, 2H), 2.92 (brt. J = 12.1 Hz, 2H), 2.64 - 2.54 (in, 1H). 2.44 (s, 2H), 2.36 (s, 2H), 1.75 (br d, J = 11.0 Hz, 2H), 1.43 (dq, J =3.8, 12.6 Hz, 2H). 1.16 (s, 6H)Attorney Docket No. PSE-002WO0LCMS Method A - Retention time: 1.535 min, 100% purity at 220 nm, m / z = 327.2 [M+H]+1H NMR (400 MHz, METHANOL-d4) 5 = 7.64 (dd. J = 2.7, 9.4 Hz, 1H), 7.30 (d, J = 2.4 Hz, 1H), 6.56 (d, P-53 L-ll R-47 H \ / J = 9.4 Hz, 1H), 4.81 - 4.74 (m, 1H), 4.48 - 4.28 (m,1H), 3.28 - 3.17 (m, 1H). 2.99 - 2.83 (m, 1H), 2.80 - 2.65 (m, 3H), 2.62 - 2.54 (m, 2H), 1.90-1.75 (m, 6H), 1.70 - 1.57 (m, 2H)0 LCMS Method A - Retention time: 2.207 min,96.654% purity at 220 nm. m / z = 338.2 [M+H]+ 1H NMR (400 MHz, DMSO-d6) 5 = 11.13 - 11.68 (m, 1 H), 10.98 - 11.12 (m, 1 H), 7.42 (brd, J= 9.24 Hz, 1 H), 7.15 (brs, 1 H), 6.28 (brd. J = 9.24 Hz, 1 H), 6.20 P-56 L-12 R-47 x(s, 1 H), 4.48 (br d, J = 12.54 Hz, 2 H), 3.22 (br d, J = H \ / x / \ ,N 17.17 Hz, 2 H), 2.91 (br t, J = 12.65 Hz, 2 H), 2.63 - 2.55 (m, 1 H), 1.80 - 1.68 (m, 5 H). 1.53 - 1.39 (m. 3 K I JH 'o H). 0.87 (br d, J = 7.04 Hz. 2 H)Mixture of enantiomersIZ oLCMS Method A - Retention time: 2.368 min.97.784% purity at 220 nm, m / z = 315.2 [M+H]+ 1H NMR (400 MHz, DMSO-d6) 5 = 9.64 - 13.36 (m, M 1 H), 7.43 (dd, J = 9.44, 2.44 Hz. 1 H), 7.16 (d, J = P-57 L-13 R-47 o / H \ / 1.88 Hz, 1 H). 6.29 (d. J = 9.51 Hz, 1 H), 4.84 (br s, 2H), 4.76 (s, 2 H), 4.57 - 4.19 (m, 2 H), 3.03 - 3.70 (m, 2 H), 2.59 (br t. J = 12.01 Hz, 1 H). 1.78 (br d. J = 12.13 Hz. 2 H), 1.43 (qd. J = 12.55. 3.75 Hz. 2 H) eAoLCMS Method A - Retention time: 2.067 min, 98.643% purity at 220 nm, m / z = 340.3 [M+H]+ C5H1H NMR (400 MHz, METHANOL-d4) 5 = 7.64 (dd, P-62 L-14 R-47 J = 2.6, 9.4 Hz. 1H), 7.30 (d. J = 2.5 Hz, 1H), 6.56 (d,H \ / J = 9.4 Hz, 1H). 6.35 (s, 1H). 4.68 (m, 2H), 3.08 (m, N 2H), 2.78 - 2.69 (m, 3H), 2.59 - 2.54 (m, 2H), 1.94 - 1.82 (m, 4H). 1.71 - 1.57 (m. 6H) vJLHLCMS Method D - Retention time: 1.274 min, zx ^OH98.193% purity at 220 nm, m / z = 342.1 [M+H]+ A 1H NMR (400 MHz, DMSO-d6) 5 = 11.79 (br s, 1H),8.40 (s, 1H), 8.38 (s, 1H), 7.27 (d, J = 0.6 Hz, 1H). P-64 R-39 L-5 7.01 (d, J = 0.7 Hz, 1H), 6.91 (d, J = 1.0 Hz. 1H), 6.68(s, 1H), 4.53 - 4.40 (m, 1H), 4.38 - 4.24 (m, 2H). 3.84 A (s, 3H), 3.17 (br s, 2H), 2.09 - 2.01 (m, 2H), 1.94 - 1.83 (m, 2H)LCMS Method D - Retention time: 1.747 min.98.693% purity at 220 mu. m / z = 404.1 [M+H]+ 1H NMR (400 MHz, DMSO-d6) 6 = 11.79 (br s, 1H), 11.52 (br dd, J = 2.3, 3.3 Hz, 1H), 9.00 (dd, J = 1.9, 4.5 Hz, 1H), 8.54 (dd, J = 1.9, 8.0 Hz, 1H), 8.41 (s, P-65 R-48 L-5 1H). 7.54 (dd, J = 4.6. 7.9 Hz, 1H). 7.24 (s, 1H). 6.91(d, J = 0.9 Hz, 1H), 6.69 (s, 1H), 4.80 - 4.55 (m, 1H).4.49 - 4.26 (m, 1H), 3.84 (s, 3H), 3.66 - 3.57 (m. 1H), 3.50 - 3.41 (m, 1H). 3.13 - 2.86 (m. 1H), 2.13 - 1.87 (m. 2H), 1.86 - 1.52 (m, 2H)Attorney Docket No. PSE-002WON— , O LCMS Method D - Retention time: 3.603 min. 100% / / A _ purity at 220 mn, m / z = 404.1 [M+H]+\= / NH 1H NMR (400 MHz, DMSO-d6) 5 = 11.92 - 11.70 (m,1H), 11.69 - 11.39 (m, 1H). 9.36 (s, 1H). 8.78 (d. J = P-66 L-5 R-49 5.7 Hz, 1H), 8.41 (s, 1H), 7.84 (d, J = 5.7 Hz, 1H),7.23 (s, 1H), 6.91 (d, J = 0.9 Hz, 1H). 6.69 (s, 1H). 4.82 - 4.17 (m, 2H), 3.84 (s, 3H), 3.28 - 3.17 (m, 2H). AJAA 3.12 - 2.91 (m, 1H), 2.03 - 1.84 (m. 2H), 1.82 - 1.48 / (m, 2H)o ^OH\z=N / T LCMS Method D - Retention time: 1.566 min,A 96.749% purity at 220 nm, m / z = 370.1 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 12.01 - 12.16 4ZT^„ o (m, 1H), 8.41 (d, J = 9.46 Hz, 2H), 7.83 (s, 1H), 7.29 P-67 L-15 R-39 J (s, 1H). 7.01 (s, 1H). 6.76 (s, 1H). 4.77 - 4.88 (m. 1H),4.23 - 4.54 (m, 3H), 3.42 (br s, 2H), 2.03 (br d, J = 1.76 Hz, 2H). 1.78 - 1.94 (m, 2H), 1.36 (d, J = 5.94 Hz. 6H)oN O IHo' y LCMS Method A - Retention time: 2.056 min,98.613% purity at 220 nm. m / z = 343.2 [M+H]+ 1H NMR (400 MHz, DMSO-d6) 5 = 11.77 (br s, 1H), P-68 L-5 R-22 H \ / 8.39 (s, 1H), 6.90 (d, J = 0.8 Hz, 1H), 6.65 (s, 1H).N^\ A 5.81 (s, 1H), 4.55 - 4.13 (m, 2H). 3.83 (s, 3H). 3.21 - A J- / J 2.88 (m, 3H), 2.08 - 1.93 (m, 2H), 1.68 - 1.50 (m, 2H)LCMS Method A - Retention time: 1.877 min, 98.189% purity at 220 mn. m / z = 344.2 [M+H]+ 1H NMR (400 MHz. DMSO-d6) S = 11.78 (br s, 1 H), P-70 L-5 R-28 8.39 (s, 1 H), 6.90 (s, 1 H). 6.64 (s, 1 H), 4.4-4. l(m,2H), 3.83 (s, 3 H), 3.52 - 3.08 (m, 3 H). 2.00 (m. 2 H), 1.64 (m, 2 H)LCMS Method A - Retention time: 1.686 min.F 99.827% purity at 220 nm, m / z = 332.2 [M+H]+ J\ ^OH 1H NMR (400 MHz, DMSO-d6) 5 = 12.21 - 11.36 (in,1H). 9.36 - 8.58 (m. 1H), 8.44 (s. 1H), 7.49 (d, J = 2.2 A Hz. 1H), 6.92 (s, 1H), 6.77 (s, 1H), 5.19 - 5.07 (m, P-71 L-5 R-50 1H), 4.96 - 4.85 (m, 1H), 4.68 (br d, J = 2.6 Hz, 1H),NAA^ 4.55 - 4.44 (m, 1H). 4.25 (brdd, J = 4.6, 9.9 Hz, 1H), AJH 3.84 (s. 3H)19F NMR (376 MHz, DMSO-d6) 5 = -141.45 (br s, IF)F LCMS Method A - Retention time: 1.675 min, J\ ^OH 92.777% purity at 220 nm, m / z = 360.2 [M+H]+NKJ / T 1H NMR (400 MHz, DMSO-d6) 5 = 11.97 - 11.64 (m,1H), 8.72 - 8.54 (m, 1H), 8.41 (s, 1H), 7.34 (d, J = 2.4 P-72 L-5 R-51 Hz, 1H), 6.91 (d, J = 0.9 Hz, 1H), 6.68 (s, 1H), 4.42„ oA (br s, 2H), 4.27 - 4.17 (m, 1H), 3.84 (s, 3H), 3.31 - A AM. 2.90 (m, 2H). 2.08 - 1.97 (m. 2H), 1.89 - 1.75 (m, 2H)19F NMR (376 MHz, DMSO-d6) 6 = -143.90 (s. IF)Attorney Docket No. PSE-002WOF LCMS Method A - Retention time: 1.732 min,96.756% purity at 220 nm, m / z = 348.2 [M+H]+ t / A'F 1H NMR (400 MHz, METHANOL-d4) 5 = 8.45 (s, 1 A H). 8.08 (s, 1 H), 7.80 (s. 1 H), 7.01 (d, J = 1.00 Hz, 1 P-73 L-5 R-52 H), 6.98 - 6.67 (m, 2 H), 5.44 (tt, J = 8.08, 5.24 Hz, 1hd H), 5.12 - 5.02 (m, 1 H). 4.97 - 4.92 (m, 1 H), 4.75 - A AAA 4.66 (m, 1 H). 4.56 (brdd, J = 10.51, 4.13 Hz, 1 H),3.91 (s, 3 H)19F NMR (376 MHz, MeOD) 8 = -108.204 (s) LCMS Method A - Retention time: 3.056 min, 99.356% purity at 220 nm, m / z = 393.2 [M+H]+ 1H NMR (400 MHz, DMSO-d6) 6 = 11.72 (br s, 1 H), 11.43 (br s, 1 H), 8.71 (s, 1 H), 8.11 (d, J = 5.63 Hz, 1 H), 7.58 (d. J = 5.50 Hz, 1 H), 7.42 (dd, J = 9.44, 2.56 P-74 L-16 R-47 A o Hz, 1 H). 7.15 (d, J = 1.75 Hz, 1 H), 6.33 (d, J = 9.38Hz, 1 H). 4.75 - 4.66 (m, 1 H), 4.65 - 4.54 (m, 1 H), A-AA 4.02 - 3.87 (m, 1 H), 3.23 - 3.12 (m, 1 H), 2.95 - 2.75(m, 1 H), 2.70 - 2.60 (m, 1 H), 2.28 - 2.17 (m, 2 H), ^ LOz , 2.13 - 2.00 (m, 2 H), 1.93 - 1.66 (m, 3 H), 1.64 - 1.40 J(m, 3 H)rzA^ LCMS Method E - Retention time: 0.755 min, F 99.804% purity at 220 nm, m / z = 386.1 [M+H]+ z / = ^OH 1H NMR (400 MHz, DMSO-d6) 8 = 11.84 (br s, 1 H),N / T 8.66 (br s, 1 H), 8.41 (s, 1 H), 7.33 (d, J = 2.20 Hz. 1 R-51 H), 7.05 (d, J = 0.66 Hz, 1 H), 6.71 (s, 1 H), 4.68 - P-75 L-17 4.28 (m, 2 H). 4.21 (brt, J= 10.89 Hz, 1 H). 4.05 (tt, J = 6.05, 3.08 Hz, 1 H), 3.59 - 3.48 (m, 1 H), 3.27-2.85A„ c5N'Y" / (m, 1 H). 2.01 (brd. J = 10.34 Hz, 2 H), 1.81 (brd, J = A A AAA 9.68 Hz, 2 H). 0.79-0.69 (m. 2 H), 0.68 - 0.59 (m, 2H)19F NMR (376 MHz, DMSO-d6) 6 = -143.876 (s, IF) LCMS Method A - Retention time: 1.961 min, FA 99.584% purity at 220 nm, m / z = 388.2 [M+H]+NA A 1H NMR (400 MHz, DMSO-d6) 6 = 11.76 (br s, 1H),8.65 (br s, 1H), 8.39 (s, 1H), 7.40 (s, 1H), 6.84 (s, 1H), 6.69 - 6.59 (m, 1H), 5.16 (quin, J = 6.1 Hz, 1H), P-76 R-51 L-184.66 - 4.27 (m, 2H). 4.26 - 4.15 (m. 1H), 3.29 - 2.77 „ A(m, 2H), 2.02 (br d, J = 10.5 Hz, 2H), 1.90 - 1.71 (m, i A2H), 1.30 - 1.22 (m, 6H) 1 A AAA19F NMR (376 MHz, DMSO-d6) 8 = -143.89 (s, IF) LCMS Method A - Retention time: 1.398 min, 99.304% purity at 220 nm, m / z = 421.2 [M+H]+ 1H NMR (400 MHz, DMSO-d6) 6 = 11.75 (br s, 1H), 8.63 (br s, 1H), 8.44 (s, 1H), 7.33 (d, J = 2.3 Hz, 1H), 6.66 (s. 1H), 6.62 (s, 1H), 4.60 - 4.37 (m, 1H), 4.29 (t, P-77 R-51 L-19J = 12.4 Hz, 5H), 4.24 - 4.16 (m, 1H), 3.25 - 2.85 (m, 2H), 2.01 (br d, J = 11.0 Hz. 2H), 1.88 - 1.73 (m, 2H) 19F NMR (376 MHz, DMSO-d6) 8 = -97.93 (s, 2F), - 143.90 (s, IF)Attorney Docket No. PSE-002WOLCMS Method A - Retention time: 3.462 min, 99.859% purity at 220 nm, m / z = 402.2 [M+H]+ F 1H NMR (400 MHz, DMSO-d6) 5 = 11.76 (br s, 1 H), A ^OHNK 8.65 (br s, 1 H), 8.39 (s, 1 H), 7.33 (d. J = 1.75 Hz, 1 kJ H), 6.84 (s, 1 H), 6.61 (s, 1 H), 5.20 - 5.09 (m, 1 H), P-78 L-18 R-53 / ~(R)\ 4.66 (br s, 1 H), 4.43 (br s. 2 H), 3.24 - 3.00 (m, 1 H), / 1.96 (m, 4 H). 1.34 (br s. 3 H), 1.26 (d, J = 6.13 Hz, 6H)1 A 19F NMR (376 MHz, DMSO-d6) 5 ppm -143.80 (1 F, br s)Single Enantiomer - ER: >99:1LCMS Method F - Retention time: 1.753 min, 99.222% purity at 220 nm, m / z = 402.2 [M+H]+ F 1H NMR (400 MHz, DMSO-d6) 5 = 11.74 (br s, 1H), A. ^OHN8.66 (br s, 1H), 8.38 (s, 1H), 7.40 (d, J = 2.3 Hz, 1H), / TkJ 6.83 (d, J = 0.8 Hz, 1H), 6.62 (s, 1H), 5.20 - 5.11 (m.P-79 L-18 R-54 1H), 4.43 (qd, J = 6.5, 13.0 Hz, 1H), 4.27 - 4.19 (m,„ . A 1H), 4.13 - 4.04 (m, 1H), 3.51 - 3.45 (m, 1H), 2.22 - 1 N^N W2.10 (m, 3H), 2.08 - 2.01 (m. 1H), 1.27 (s, 3H), 1.25 AxXM (s, 3H). 1.08 (d, J = 6.8 Hz, 3H)19F NMR (376 MHz, DMSO-d6) 6 = -143.58 (s, IF) Single Enantiomer - ER: >99:1LCMS Method A - Retention time: 2.063 min, 96.13% F purity at 220 nm, m / z = 402.3 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.76 (s, 1H), J\ ^OHV 8.62 (s. 1H), 8.39 (s. 1H), 7.33 (d, J = 2.0 Hz, 1H),6.84 (s, 1H), 6.61 (d, J = 1.3 Hz, 1H), 5.16 (quin, J = P-80 L-18 R-55 6.2 Hz, 1H), 5.06 - 4.56 (m, 1H), 4.55 - 3.99 (m, 2H),H . 3.30 - 2.89 (m, 1H), 2.06 - 1.72 (m, 4H). 1.41 - 1.29 i (m, 3H), 1.28 - 1.23 (in, 6H)1 A AZA 19F NMR (376 MHz, DMSO-d6) 6 = -143.82 (br s,IF)Single Enantiomer - ER: >99:1LCMS Method A - Retention time: 2.109 min, 100% purity at 220 nm, m / z = 402.3 [M+H]+F 1H NMR (400 MHz, DMSO-d6) 5 = 11.74 (br s. 1H), A _OHN8.75 - 8.61 (m, 1H), 8.39 (s, 1H), 7.40 (d, J = 2.1 Hz. tfkJ 1H), 6.84 (s, 1H), 6.63 (s, 1H), 5.15 (td, J = 6.1, 12.3 P-81 L-18 R-56 Hz, 1H), 4.50 - 4.38 (m, 1H), 4.29 - 4.18 (m, 1H), H A3 / 4.14 - 4.03 (m, 1H), 3.54 - 3.46 (m. 1H), 2.23 - 1.95 1 N^N A1 AAH (m, 4H), 1.26 (d, J = 6.1 Hz, 6H), 1.08 (d, J = 6.8 Hz,3H)19F NMR (376 MHz, DMSO-d6) 6 = -143.57 (s, IF) Single Enantiomer - ER: >99:1LCMS Method A - Retention time: 1.538 min, F 98.301% purity at 220 nm. m / z = 358.2 [M+H]+ ^OH 1H NMR (400 MHz, DMSO-d6) 6 = 11.91 (br s, 1H), V 8.96 - 8.78 (m, 1H), 8.44 (s, 1H), 7.49 (s, 1H), 7.06 (s, P-82 L-17 R-50 1H), 6.80 (s, 1H), 5.21 - 5.05 (m, 1H), 4.89 (br t, J =H rf 8.9 Hz, 1H), 4.74 - 4.61 (m, 1H), 4.50 (brt, J = 8.8 A N-^A / A, 1 AH Hz, 1H), 4.29 - 4.17 (m, 1H). 4.09 - 4.02 (m. 1H), 0.75 (br d, J = 6.2 Hz, 2H), 0.65 (br s, 2H)19F NMR (376 MHz, DMSO-d6) 6 = -141.46 (s, IF)Attorney Docket No. PSE-002WOLCMS Method A - Retention time: 1.591 min, F 98.721% purity at 220 nm, m / z = 360.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.81 (br d, J = V 1.1 Hz. 1H), 8.97 - 8.78 (m, 1H), 8.42 (s, 1H), 7.49 (d, P-83 L-18 R-50 J = 2.4 Hz, 1H), 6.84 (d, J= 1.1 Hz, 1H), 6.73 (s, 1H),5.25 - 5.02 (m, 2H).4.97 - 4.83 (m. 1H), 4.72 - 4.59 1 (m. 1H), 4.49 (br t, J = 9.4 Hz, 1H). 4.23 (br dd, J =4.8, 10.6 Hz, 1H), 1.26 (d, J = 6.2 Hz, 6H)19F NMR (376 MHz, DMSO-d6) 5 = -141.48 (s, IF) H LCMS Method E: Retention time: 0.805min. 96.7% N purity at 220 mn, m / z = 343.1 [M+H]+H NMR (400 MHz, DMSO-d6) 5 = 11.40 (br s, 1H), 7.30 (d, J = 8.8 Hz, 1H), 7.07 (s, 1H), 6.88 - 6.77 (m, P-84 L-4 R-57 1H), 6.69 (s, 1H), 6.29 (s, 1H), 4.52 (brd, J = 13.0 C— Hz, 2H), 3.81 (td, J = 5.5, 10.6 Hz, 1H), 3.75 (s, 3H),3.28 (br d, J = 7.9 Hz, 2H), 3.25 - 2.90 (m, 4H), 1.71 -1.55 (m, 4H)Route to P-5Step 1 - [000353] A solution of (5-methoxy-lH-indol-2-yl)-[3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,5-dihydropyrrol-l-yl]methanone L-2 (400 mg, 1.09 mmol), 2-benzyloxy-5-bromo-pyridine 1 (401.66 mg, 1.52 mmol), K3PO4 (691.75 mg, 3.26 mmol), Pd(PPh3)4 (251.05 mg, 217.25 pmol) in dioxane (12 mL) and H2O (2 mb) was degassed with N2, and then stirred at110 °C for 1 hour in a sealed tube. LCMS showed the starting material was consumed anddesired mass of the product appeared. The mixture was added water (30 ml), extracted withDCM (40 mL x 3), separated, and organic phase was concentrated in vacuum, then added EtOAc(10 mL), and petroleum ether (10 mL), and stirred at room temperature for 30 minutes. Themixture was filtered and the filtrate was condensed under vacuum to afford [3-(6-benzyloxy-3-pyridyl)-2,5-dihydropyrrol-l-yl]-(5-methoxy-lH-indol-2-yl)methanone 2 (400 mg, 940.12 pmol, 86.55% yield) as white solid.[000354] LCMS (ESI): m / z = 426.3 [M+H]+Attorney Docket No. PSE-002WO[000355] 1H NMR (400 MHz, DMSO-d6) 5 = 11.45 (br d, J = 12.3 Hz, 1H), 8.46 - 8.27 O(m, 1H), 8.05 (ddd, J = 2.4, 8.5, 12.6 Hz, 1H), 7.50 - 7.42 (m, 2H), 7.42 - 7.31 (m, 4H), 7.11 (dd, J = 2.1, 6.5 Hz, 1H), 6.94 (dd, J = 3.4, 8.5 Hz, 1H), 6.88 (br d, J = 8.8 Hz, 1H), 6.51 (br s, 1H), 5.39 (d, J = 3.4 Hz, 2H), 5.02 (br s, 1H), 4.88 - 4.72 (m, 2H), 4.53 (brd, J = 1.6 Hz, 1H), 3.79 -3.75 (m, 3H)Step 2 - co[000356] To a solution of [3-(6-benzyloxy-3-pyridyl)-2,5-dihydropyrrol-l-yl]-(5-methoxy- lH-indol-2-yl)methanone 2 (400 mg O, 94 / 0 z—.12 pmol) in MeOH (50 mL) was added Pd / C (10% on ZE yCarbon -wetted with ca. 55% water) (400 m 0g, 375.87 pmol, 10% purity), which was then degassed with argon. The reaction mixture was stirred for 12 hours at 50 °C under 50 psi of H2. LCMS showed starting material was consumed and desired the desired mass of the product was observed. Upon completion, the mixture was washed with MeOH (20 mL) and filtered four times). Then the organic phase was concentrated under vacuum before purification by preparative HPLC. The pure fractions were concentrated under vacuum and lyophilized to afford 5-[l-(5-methoxy-lH-indole-2-carbonyl)pyrrolidin-3-yl]-lH-pyridin-2-one P-5 (52 mg, 154.13 pmol, 16.40% yield).[000357] LCMS (ESI): m / z = 338.1 [M+H]+[000358] 1H NMR (400 MHz, DMSO-d6) 5 = 11.38 (br d, J = 5.9 Hz, 2H), 7.53 (br t, J = 8.6 Hz, 1H), 7.40 - 7.23 (m, 2H), 7.07 (br d, J = 5.0 Hz, 1H), 6.94 - 6.80 (m, 2H), 6.34 (d, J = 9.5 Hz, 1H), 4.23 - 3.83 (m, 2H), 3.75 (br d, J = 6.2 Hz, 5H), 3.29 - 3.17 (m, 1H), 2.35 - 2.10 (m, 1H), 2.09 - 1.85 (m, 1H)No Final Product Structure Characterization DataLCMS Method A - Retention time: 2.622 min, 99.69% purity at 220 nm, m / z = 338.1 [M+H]+1H NMR (400 MHz, DMSO-d6) 6 = 11.38 (br d, J = 5.9 Hz, 2H), 7.53 (br t, J = 8.6 Hz. 1H), 7.40 - 7.23 (m, 2H). 7.07 (br d, J = 5.0 Hz, 1H), 6.94 - 6.80 (m, P-5 2H), 6.34 (d, J = 9.5 Hz, 1H), 4.23 - 3.83 (m, 2H),3.75 (br d, J = 6.2 Hz, 5H), 3.29 - 3.17 (m, 1H), 2.35 - 2.10 (m, 1H), 2.09 - 1.85 (m, 1H)Mixture of Enantiomers - ER: 51 : 49Attorney Docket No. PSE-002WORoute to P-30OBn o1 Step 1 2 step 2 3 Step 3 P-30Step 1 -[000359J A solution of tert-butyl 4-(6-benzyloxy-3-pyridyl)-3,6-dihydro-2H-pyridine-l-carboxylate 1 (1 g, 2.73 mmol), TFA (8.94 g, 78.41 mmol, 6 mb) in DCM (15 mL) was stirred at 25 °C for 30 minutes. LCMS showed starting material was consumed and desired the desired mass of the product was observed. The reaction mixture was concentrated under vacuum to afford 2-benzyloxy-5-(l,2,3,6-tetrahydropyridin-4-yl)pyridine 2 (900 mg, crude), that was used directly in next step.[000360] LCMS (ESI): m / z = 267.2 [M+H]+Step 2 - [000361] A solution of 5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carboxylic acid L-5 (130 mg, 676.48 pmol) and HATU (308.66 mg, 811.78 pmol), in DCM (10 mL) and DMF (2 mL) was stirred at 25 °C for 30 minutes. Then 2-benzyloxy-5-(l,2,3,6-tetrahydropyridin-4-yl)pyridine 2 (200 mg, 750.93 pmol) and DIEA (349.71 mg, 2.71 mmol, 471.31 pL) were added and the combined reaction was stirred at 25 °C for 3 hours. LCMS showed starting material was consumed and desired the desired mass of the product was observed. The mixture was added water (20 mL), and extracted with EtOAc (15 mL x 3), separated, and organic phase was dried over Na2SC>4, and concentrated under vacuum. The crude material was purified by automated chromatography to afford [4-(6-benzyloxy-3-pyridyl)-3,6-dihydro-2H-pyridin-l-yl]-(5-methoxy-lH-pyrrolo[2,3-c]pyridin-2-yl)methanone 3 (260 mg, 590.25 pmol, 87.25% yield) as yellow solid.[000362] LCMS (ESI): m / z = 441.2 [M+H]+[000363] 1HNMR (400 MHz, DMSO-d6) 3 = 11.79 (s, 1H), 8.41 (s, 1H), 8.26 (d, J = 2.2 Hz, 1H), 7.95 (s, 1H), 7.89 - 7.82 (m, 1H), 7.47 - 7.41 (m, 2H), 7.37 (t, J = 7.3 Hz, 2H), 7.34 -Attorney Docket No. PSE-002WO7.29 (m, 1H), 6.92 (s, 1H), 6.88 (d, J = 8.7 Hz, 1H), 6.75 (s, 1H), 5.36 (s, 2H), 4.64 - 4.16 (m, 2H), 3.94 - 3.87 (m, 2H), 3.84 (s, 3H), 2.66 - 2.58 (m, 2H)Step 3 - [000364] To a solution of [4-(6-benzyloxy-3-pyridyl)-3,6-dihydro-2H-pyridin-l-yl]-(5-methoxy-lH-pyrrolo[2,3-c]pyridin-2-yl)methanone 3 (750 mg, 1.70 mmol), 1,1,2-tri chloroethane (1.14 g, 8.51 mmol), Pd / C (10% on Carbon - wetted with ca. 55% Water) (850 mg, 798.72 gmol, 10% purity) in MeOH (30 mL) was stirred at 40 °C for 12 hours under 35 psi of H2. LCMS showed starting material was consumed and desired the desired mass of the product was observed. Upon completion, the reaction mixture was washed with MeOH (40 mL) and filtered four times. The organic phase was concentrated under vacuum before purification by preparative HPLC. Pure fractions were condensed under vacuum and lyophilized to obtain [4-(6-hydroxy-3-pyridyl)-l-piperidyl]-(5-methoxy-lH-pyrrolo[2,3-c]pyridin-2-yl)methanone P-30 (140 mg, 397.29 pmol, 23.33% yield) as white solid.[000365] LCMS (ESI): m / z = 353 2 [M+H]+[000366] 1H NMR (400 MHz, DMSO-d6) 5 = 8.39 (s, 1H), 7.52 (dd, J = 2.5, 9.4 Hz, 1H), 7.21 (s, 1H), 6.94 (s, 1H), 6.67 (s, 1H), 6.39 (d, J = 9.4 Hz, 1H), 4.73 - 4.18 (m, 2H), 3.80 (s, 3H), 3.41 - 2.76 (m, 2H), 2.73 - 2.61 (m, 1H), 1.94 - 1.70 (m, 2H), 1.62 - 1.34 (m, 2H)No Final Product Structure Characterization DataO / NH LCMS Method A - Retention time: 1.908 min, 100%purity at 220 ran, m / z = 353.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 8.39 (s, 1H), 7.52 P-30 (dd, J = 2.5. 9.4 Hz, 1H). 7.21 (s, 1H). 6.94 (s, 1H).H \ / 6.67 (s, 1H). 6.39 (d. J = 9.4 Hz. 1H), 4.73 - 4.18 (m,2H), 3.80 (s, 3H), 3.41 - 2.76 (m, 2H), 2.73 - 2.61 (m, N^NX1H), 1.94 - 1.70 (m, 2H). 1.62 - 1.34 (m, 2H) 11 J MAttorney Docket No. PSE-002WORoute to P-35L-3 Step 1 1 Step 2 P-35 Step 1 - [000367] To a mixture of (5-methoxy-lH-pyrrolo[2,3-c]pyridin-2-yl)-[4-(4, 4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridin-l-yl]methanone L-3 (200 mg, 521.86 pmol) and 5-bromo-l-(2-trimethylsilylethoxymethyl)pyridin-2-one R-3 (158.78 mg, 521.86 pmol) in dioxane (5 mL) and H2O (0.5 mL) was added Pd(dppf)C12 (76.37 mg, 104.37 pmol) and K2CO3 (216.37 mg, 1.57 mmol) under N2 atmosphere, and the reaction mixture was stirred for 10 hours at 80 °C. LCMS showed the desired the desired mass of the product was observed. The reaction mixture was diluted with EtOAc (30 mL) and filtered, before the filtrate was washed with water (10 mL), brine (10 mL), dried over Na2SC>4, filtered and concentrated. The crude material was purified by column chromatography to give 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-3,6-dihydro-2H-pyridin-4-yl]-l-(2-trimethylsilylethoxymethyl)pyridin-2-one 1 (68 mg, 141.48 pmol, 27.11% yield).[000368] 1H NMR (400 MHz, METHANOL-d4) 8 = 8.42 (s, 1H), 8.22 (br s, 1H), 7.84 (br s, 1H), 7.02 (s, 1H), 6.90 - 6.78 (m, 2H), 6.31 - 6.00 (m, 1H), 5.62 - 5.45 (m, 2H), 4.66 - 4.28 (m, 2H), 4.03 (br s, 2H), 3.92 (s, 3H), 3.81 (t, J = 8.1 Hz, 2H), 2.69 (br s, 2H), 0.95 (t, J = 8.1 Hz, 2H), 0.10 - -0.07 (m, 9H)Step 2 - [000369] To a mixture of 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-3,6-dihydro-2H-pyridin-4-yl]-l-(2-trimethylsilylethoxymethyl)pyridin-2-one 1 (68 mg, 141.48 pmol) in dioxane (3 mL) was added HC1 (2.0 M in dioxane) (7 mL) at 20 °C, before the reaction mixture was stirred for 1 hour at 20 °C. LCMS showed the desired the desired mass of the product was observed. Then, the reaction mixture was concentrated before purification by preparative HPLC to give 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-3,6-dihydro-2H-pyridin-4-yl]-lH-pyridin-2-one P-35 (9.23 mg, 26.34 pmol, 18.62% yield).Atorney Docket No. PSE-002WO[000370] LCMS (ESI): m / z = 351.3 [M+H]+[000371] 1HNMR (400 MHz, DMSO-d6) 5 = 11.91 - 11.77 (br,s, 1H), 8.41 (s, 1H), 8.20 (s, 1H), 7.79 - 7.64 (m, 1H), 7.34 (br s, 1H), 6.93 (s, 1H), 6.74 (s, 1H), 6.35 (br d, J = 9.6 Hz, 1H), 6.14 - 5.89 (m, 1H), 4.50 - 4.36 (m, 1H), 4.32 - 4.19 (m, 1H), 3.89 - 3.85 (m, 2H), 3.85 (s, 3H), 2.55 (m, 2H)No Final Product Structure Characterization DataO LCMS Method A - Retention time: 1.968 min, 100% / NH purity at 220 nm. m / z = 351.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 3 = 11.91 - 11.77 (br.s, 1H), 8.41 (s, 1H), 8.20 (s, 1H), 7.79 - 7.64 (m,P-35 1H), 7.34 (br s, 1H), 6.93 (s, 1H), 6.74 (s, 1H), 6.35 (br H \ / d, J = 9.6 Hz, 1H), 6.14 - 5.89 (m, 1H), 4.50 - 4.36 (m,1H), 4.32 - 4.19 (m, 1H). 3.89 - 3.85 (m, 2H), 3.85 (s, 3H), 2.55 (m, 2H)Route to P-48Step 1 - [000372] A solution of (5-methoxy-lH-pyrrolo[2,3-c]pyridin-2-yl)-[4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridin-l-yl]methanone L-3 (200 mg, 313.11 pmol), 5-bromo-l-(2-trimethylsilylethoxymethyl)pyrimidin-2-one R-13 (216.72 mg, 497.00 pmol), Pd(dtBupf)C12 (64.78 mg, 99.40 pmol), K3PO4 (316.50 mg, 1.49 mmol) in dioxane (5 mL) and H2O (1 mL) was degassed with N2 four times, and stirred at 100 °C for 1 hour in a sealed tube before stirring an additional 16 hours at 20 °C. LCMS showed the starting material was consumed. The reaction was concentrated and quenched with water (10 mL) and extracted with EtOAc (10 mL x 3). The organic layer was washed with brine (10 mL x 2), dried over Na2SC>4, filtered and concentrated under vacuum. The crude material was purified by flash silica gel chromatography to give 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-3,6-dihydro-Attorney Docket No. PSE-002WO2H-pyridin-4-yl]-lH-pyrimidin-2-one 1 (60 mg, 107.58 pmol, 21.65% yield, 63% purity) as black gum.[000373] LCMS (ESI): m / z = 352.2 [M+H]+[000374] 1HNMR (400 MHz, DMSO-d6) 5 = 11.84 (s, 1H), 8.74 (s, 2H), 8.42 (s, 1H), 6.93 (s, 1H), 6.77 (s, 1H), 5.55 (s, 2H), 3.94 (s, 4H), 3.85 (s, 3H), 3.74 -3.78 (m, 2H)Step 2 - [000375] To a solution of 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-3,6-dihydro-2H-pyridin-4-yl]-lH-pyrimidin-2-one 1 (42.62 mg, 121.30 pmol) in MeOH (5 m ) was added Pd / C (10% on Carbon - wetted with ca. 55% Water) (51.63 mg, 48.52 pmol, 10% purity) at 10 °C, and then degassed with argon four times. The reaction mixture was stirred at 30 °C for 16 hours under 20 psi of H2. LCMS showed the starting material was consumed and mass of the product was observed. Upon completion, the mixture was filtered and washed with MeOH, concentrated under vacuum, redissolved in MeOH before NH3-H2O (0.2mL) was added. The mixture was stirred for 10 minutes before concentrating and purified by preparative HPLC. The pure fractions were concentrated under vacuum and lyophilized for 24 hours to give 5-[l-(5-methoxy-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-4-piperidyl]hexahydropyrimidin-2-one P-48 (8.5 mg, 23.73 pmol, 19.57% yield, 99.8% purity) as a white solid.[000376] LCMS (ESI): m / z = 358.2 [M+H]+[000377] 1HNMR (400MHz, DMSO-d6) 6 = 11.75 (br s, 1 H), 8.39 (s, 1 H), 6.90 (d, J = 0.98 Hz, 1 H), 6.61 (s, 1 H), 6.09 (br s, 2 H), 4.57 - 4.16 (m, 2 H), 3.84 (s, 3 H), 3.24 - 3.11 (m, 3 H), 2.96 - 2.82 (m, 3 H), 1.83 - 1.67 (m, 2 H), 1.61 - 1.47 (m, 2 H), 1.31 - 1.16 (m, 2 H)No Final Product Structure Characterization DataO HN^ / / NH LCMS Method A - Retention time: 0.977 min, 99.209% purity at 220 nm, m / z = 358.3 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 11.75 (br s. 1 H), P-48 8.39 (s, 1 H), 6.90 (d, J = 0.98 Hz. 1 H), 6.61 (s, 1 H).H \ / 6.09 (br s, 2 H), 4.57 - 4.16 (m, 2 H), 3.84 (s, 3 H), 3.24 - 3.11 (m. 3 H), 2.96 - 2.82 (m, 3 H), 1.83 - 1.67 (m, 2 H), 1.61 - 1.47 (m. 2 H), 1.31 - 1.16 (m, 2 H)11 JRoute to P-58Attorney Docket No. PSE-002WOStep 1 - [000378] To a solution of ethyl 3-bromo-5-methoxy-l-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-c]pyridine-2-carboxylate 1 (200 mg, 465.79 pmol), methylboronic acid 2 (36.25 mg, 605.52 pmol), K2CO3 (193.13 mg, 1.40 mmol) in dioxane (2 mb) was added Pd(dppf)Ch (68.16 mg, 93.16 pmol). The mixture was stirred at 80 °C for 1 hour under N2. LCMS showed the starting material was consumed and the mass of the desired product was observed. The mixture was concentrated, quenched with water (10 mb) and extracted with EtOAc (10 mL x 3). The organic layer was washed with brine (10 mb x 2), dried over Na2SO4, fdtered and concentrated to give crude material that was purified by flash silica gel chromatography to afford ethyl 5-methoxy-3-methyl-l-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-c]pyridine-2-carboxylate 3 (140 mg, 337.99 pmol, 72.56% yield, 88% purity) as colorless oil.[000379] LCMS (ESI): m / z = 365.2 [M+H]+[000380]1H NMR (400 MHz, DMSO-d6) 58.67 - 8.73 (m, 1H), 6.99 - 7.07 (m, 1H), 5.87 (br s, 2H), 4.28 - 4.48 (m, 2H), 3.80 - 3.94 (m, 3H), 2.39 - 2.47 (m, 3H), 1.29 - 1.45 (m, 3H), 1.18 (br d, J=7.09 Hz, 1H), 0.64 - 0.79 (m, 2H), -0.07 - 0.16 (m, 1H), -0.18 - -0.09 (m, 9H) Step 2 - [000381] A solution of ethyl 5 -m ethoxy-3 -methyl- 1 -(2-trimethylsilylethoxymethyl)pyrrolo[2,3-c]pyridine-2-carboxylate 3 (140 mg, 384.08 pmol), NaOH (3 M, 281.66 pL) in MeOH (2 mL) and EtOH (2 mL) was stirred at 60 °C for 1 hour. LCMS showed the starting material was consumed and desired product mass was observed. The reaction mixture was adjusted to pH 5-6 with 2N HC1 before concentration, quench with water (10 mL), and extraction with EtOAc (10 mL x 3). The organic layer was washed with brine (lOmL x 2), dried over Na2SO4, fdtered and concentrated to give 5-methoxy-3-methyl-l-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-c]pyridine-2-carboxylic acid 4 (105 mg, 280.87 pmol, 73.13% yield, 90% purity) as yellow gum.[000382] LCMS (ESI): m / z = 337.2 [M+H]+Attorney Docket No. PSE-002WO[000383] ‘HNMR(400MHz, DMSO-d6) 5 13.71 (br s, 1H), 8.79 (s, 1H), 7.13 (s, 1H), 6.02 (s, 2H), 3.98 - 4.01 (m, 3H), 3.51 (t, J=7.82 Hz, 2H), 2.57 (s, 3H), 0.88 (t, J=7.88 Hz, 2H), 0.00 (s, 9H)Step 3 - [000384] To a solution of 5-methoxy-3-methyl-l-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-c]pyridine-2-carboxylic acid 4 (105 mg, 312.08 pmol) in DMF (2 mL) was added HATU (130.53 mg, 343.28 pmol), and the mixture was stirred at 15 °C for 30 minutes under N2 atmosphere. 5-(4-piperidyl)-lH-pyridin-2-one (134.00 mg, 624.15 pmol, HC1) and DIEA (282.33 mg, 2.18 mmol, 380.50 pL) were added and the combined reaction mixture was stirred at 15 °C for 2 hours under N2 atmosphere. LCMS showed the starting material was consumed and the desired mass of the product was detected. The reaction was quenched with water (10 mL) and extracted with EtOAc (10 mL x 3). The organic layer was washed with brine (10 mL), dried over Na2SC>4, filtered and concentrated to give 5-[l-[5-methoxy-3-methyl-l-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-c]pyridine-2-carbonyl]-4-piperidyl]-lH-pyridin-2-one 5 (100 mg, 140.94 pmol, 45.16% yield, 70% purity) as yellow liquid.[000385] LCMS (ESI): m / z = 497.3 [M+H]+[000386]1HNMR(400MHz, DMSO-d6) 8 = 11.43 (br s, 1H), 8.57 (dd, J = 8.31, 0.86 Hz, 1H), 7.31 - 7.48 (m, 1H), 7.05 - 7.20 (m, 1H), 6.90 (d, J = 1.10 Hz, 1H), 6.26 - 6.33 (m, 1H), 5.40 - 5.61 (m, 2H), 4.66 (br s, 1H), 3.52 - 3.70 (m, 1H), 3.36 - 3.53 (m, 2H), 2.99 - 3.11 (m, 1H), 2.90 (br d, J = 2.45 Hz, 1H), 2.58 - 2.69 (m, 1H), 2.22 (s, 1H), 2.11 - 2.19 (m, 2H), 1.82 -1.92 (m, 1H), 1.63 - 1.79 (m, 1H), 1.47 (br s, 1H), 1.22 - 1.36 (m, 1H), 0.67 - 0.92 (m, 2H), -0.16 - 0.05 (m, 9H)Step 4 - [000387] To a solution of 5-[l-[5-methoxy-3-methyl-l-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-c]pyridine-2-carbonyl]-4-piperidyl]-lH-pyridin-2-one 5 (100 mg, 161.07 pmol) in dry DCM (3 mL) was added TFA (5.65 g, 49.53 mmol, 3.79 mL) at rt 0 °C, and then the mixture was stirred at 20 °C for 2 hours. LCMS showed the starting material was consumed and the desired mass of the product was observed. The mixture was concentrated, dissolved in MeOH, before NH -H2O (0.2mL) was added. The mixture was stirred for 10 minutes and then concentrated under vacuum before purification by preparative HPLC. The pureAttorney Docket No. PSE-002WOfractions were concentrated under vacuum and lyophilized for 24 hours to give 5-[l-(5-methoxy-3-methyl-lH-pyrrolo[2,3-c]pyridine-2-carbonyl)-4-piperidyl]-lH-pyridin-2-one P-58 (36.6 mg, 99.49 pmol, 61.77% yield, 99.6% purity) as a white solid.[000388] LCMS (ESI): m / z = 367.1 [M+H]+[000389] 1H NMR (400 MHz, DMSO-d6) 5 = 8.32 (s, 1 H), 7.43 (dd, J = 9.44, 2.56 Hz, 1 H), 7.15 (d, J = 2.25 Hz, 1 H), 6.86 (s, 1 H), 6.31 (d, J = 9.38 Hz, 1 H), 6.20 - 5.85 (m, 1 H), 4.73 - 4.35 (m, 1 H), 3.84 (s, 3 H), 3.67 (m, 1 H), 3.14 - 2.78 (m, 2 H), 2.68 - 2.56 (m, 1 H), 2.20 (s, 3 H), 1.77 (m, 2 H), 1.48 (m, 2 H)No Final Product Structure Characterization DataO LCMS Method D - Retention time: 2.154 min, 99.684% V NH purity at 220 ran, m / z = 367.1[M+H]+1H NMR (400 MHz. DMSO-d6) S = 8.32 (s, 1 H), 7.43 (dd, J = 9.44, 2.56 Hz, 1 H), 7.15 (d, J = 2.25 Hz. 1 H), P-58 6.86 (s. 1 H), 6.31 (d, J = 9.38 Hz, 1 H). 6.20 - 5.85 (m.H \ / 1 H), 4.73 - 4.35 (m, 1 H), 3.84 (s. 3 H), 3.67 (m, 1 H),3.14 - 2.78 (m, 2 H), 2.68 - 2.56 (m, 1 H), 2.20 (s, 3 H), JI / L 1.77 (m, 2 H). 1.48 (m, 2 H)0General Route FP-3Typified example - route to P-60Step 1 - [000390] A solution of [4-(trifluoromethyl)phenyl]boronic acid 1 (248.32 mg, 1.31 mmol), 5-bromo-2-(2-trimethylsilylethoxymethyl)pyrazole-3-carboxylic acid 2 (350 mg, 1.09 mmol), Pd(dppf)C12 (159.44 mg, 217.90 pmol), K2CO3 (451.75 mg, 3.27 mmol) in dioxane (6 mL) and H2O (1.2 mL) was degassed with N2 four times, and stirred at 80 °C for 1 hour in a sealed tube. LCMS showed the starting material was consumed and the desired mass of the product was detected. The reaction was quenched with water (2 mL) and extracted with EtOAc (5 mL x 3).Attorney Docket No. PSE-002WOThe organic layer was washed with brine (5mL), dried over Na2SC>4, filtered and concentrated before purification by preparative HPLC. The pure fractions were concentrated under vacuum and lyophilized for 18 hours to give 5-[4-(trifluoromethyl)phenyl]-2-(2-trimethylsilylethoxymethyl)pyrazole-3-carboxylic acid 3 (110 mg, 278.96 pmol, 25.60% yield, 98% purity) as white solid.[000391] 1HNMR (400 MHz, DMSO-d6) 8 = 8.01 (d, J = 8.1 Hz, 2H), 7.74 (d, J = 8.1 Hz, 2H), 6.91 (s, 1H), 5.97 (s, 2H), 3.63 - 3.58 (m, 4H), 0.81 (t, J = 8.0 Hz, 2H), -0.04 - -0.09 (m, 9H)[000392] 19F NMR (376 MHz, DMSO-d6) 8 = -60.83 (br s, IF)Step 2 - [000393] To a stirred solution of 5-[4-(trifluoromethyl)phenyl]-2-(2-trimethylsilylethoxymethyl)pyrazole-3-carboxylic acid 3 (60 mg, 155.26 pmol) in DMF (3 mb) was added 5-(4-piperidyl)-lH-pyridin-2-one R-47 (27.67 mg, 155.26 pmol), HOBT (35.67 mg, 232.90 pmol), DIEA (60.20 mg, 465.79 pmol, 81.13 pL) and the mixture was stirred at 20 °C for 1 minute. Then EDCI (14.88 mg, 77.63 pmol) was added and the combined reaction mixture was stirred at 20 °C for 2 hours under N2 atmosphere. LCMS showed some starting material remained and the desired mass of the product was detected. The mixture was stirred at 20 °C for an additional 16 hours under N2 atmosphere. At which time the reaction was quenched with water (5 mL) and extracted with EtOAc (10 mL x 3). The organic layer was washed with brine (5 mL), dried over Na2SC>4, fdtered and concentrated. The crude material was purified by flash silica gel chromatography to give the 5-[l-[5-[4-(trifluoromethyl)phenyl]-2-(2-trimethylsilylethoxymethyl)pyrazole-3-carbonyl]-4-piperidyl]-lH-pyridin-2-one 4 (50 mg, 56.07 pmol, 36.11% yield, 61.3% purity) as yellow gum.[000394] LCMS (ESI): m / z = 547.3 [M+H]+Step 3 - [000395] To a solution of 5-[l-[5-[4-(trifluoromethyl)phenyl]-2-(2-trimethylsilylethoxymethyl)pyrazole-3-carbonyl]-4-piperidyl]-lH-pyridin-2-one 4 (70 mg, 128.05 pmol) in MeCN (1 mL) was added TFA (2 mL) at 0 °C, and then the mixture was stirred at 20 °C for 2 hours. LCMS showed some starting material remained and the desired mass of the product was detected. The mixture was concentrated, diluted with MeCN (2 mL) and the mixture was adjusted to pH 8 with NH3-H2O and concentrated before purification by preparative HPLC.Attorney Docket No. PSE-002WOThe pure fractions were concentrated under vacuum and lyophilized for 18 hours to give 5-[ 1 -[3 -[4-(trifluoromethyl)phenyl]-lH-pyrazole-5-carbonyl]-4-piperidyl]-lH-pyridin-2-one P-60 (16.3 mg, 36.48 pmol, 28.49% yield, 93.2% purity) as white solid.[000396] LCMS (ESI): m / z = 417.2 [M+H]+[000397] 1H NMR (400 MHz, DMSO-d6) 5 = 12.21 - 10.86 (m, 1H), 8.07 (d, J = 8.1 Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H), 7.45 (dd, J = 2.6, 9.5 Hz, 1H), 7.23 - 7.14 (m, 2H), 6.30 (d, J = 9.5 Hz, 1H), 4.71 - 4.44 (m, 2H), 3.24 - 3.13 (m, 1H), 2.89 - 2.73 (m, 1H), 2.71 - 2.58 (m, 1H), 1.89 - 1.71 (m, 2H), 1.65 - 1.39 (m, 2H)[000398] 19F NMR (376 MHz, DMSO-d6) 5 = -60.93 (br s, IF)Final Products Prepared via ( General Route FP-3No SM-1 Final Product Structure Characterization Data0 LCMS Method A - Retention time: 2.319 min, 93.219% purity at 220 nin, m / z = 417.2 [M+H]+1H NMR (400 MHz, DMSO-d6) 5 = 12.21 - 10.86 (m, 1H), 8.07 (d, J = 8.1 Hz, 2H), 7.82 (d. J = 8.4 Hz, 2H). 7.45 (dd, J = 2.6, 9.5 Hz, P-60Frj H \ / 1H), 7.23 - 7.14 (m, 2H), 6.30 (d. J = 9.5 Hz, FA 11 1H), 4.71 - 4.44 (m, 2H), 3.24 - 3.13 (m, 1H),02.89 - 2.73 (m, 1H). 2.71 - 2.58 (m, 1H), 1.89 - FJU 1.71 (m, 2H), 1.65 - 1.39 (m. 2H)19F NMR (376 MHz, DMSO-d6) 5 = -60.93 (br s, IF)0 LCMS Method A - Retention time: 2.123 min, 98.376% purity at 220 nm, m / z = 377.3 / / NH [M+H]+ / L ,B(OH)21H NMR (400 MHz, DMSO-d6) 8 = 13.22 - 12.95 (m, 1H), 11.59 - 11.13 (in, 1H), 7.45 (dd, ex J = 2.6, 9.5 Hz, 1H), 7.24 (br d, J = 7.9 Hz, P-61 -Use of (2,6- H \ / 1H), 7.19 - 7.13 (m, 3H), 6.53 (s, 1H), 6.29 (d.dimethylphenyl)boronic J = 9.4 Hz, 1H), 5.01 - 4.76 (m, 1H), 4.65 (br acid as SM-1 in step 1 NA / \ Ji dd, J = 2.3, 12.5 Hz, 1H), 3.22 - 3.06 (m, 1H),2.82 - 2.72 (m, 1H), 2.68 - 2.60 (m, 1H). 2.08 (s, 6H), 1.84 - 1.73 (m, 2H), 1.62 - 1.42 (in, °2H)Attorney Docket No. PSE-002WORoute to P-69Step 1- [000399J To a solution of 5-tert-butoxycarbonyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-3-carboxylic acid L-20 (200 mg, 748.28 pmol) in DMF (3.49 mb) was added HOBT (171.89 mg, 1.12 mmol) EDCI (172.13 mg, 897.93 pmol) at 20 °C under N2 atmosphere. The resulting suspension was degassed and purged with N2 three times, before the mixture was stirred at 20 °C for 10 minutes. Then 5-(4-piperidyl)-lH-pyridin-2-one R-47 (333.41 mg, 1.87 mmol) was added followed by DIEA (290.12 mg, 2.24 mmol, 391.00 pL) and the combined reaction mixture was stirred under N2 atmosphere at 20 °C for 16 hours. LCMS showed the desired product mass was observed. The reaction mixture was quenched by addition of water (5 mL), extracted with EtOAc (5 mL x 2), washed with brine (5 mL x 2), dried over Na2SO4, filtered and concentrated under vacuum. The crude material was purified by flash column chromatography to afford tert-butyl 3-[4-(6-oxo-lH-pyri din-3 -yl)piperidine-l-carbonyl]-2, 4,6, 7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate 1 (130 mg, 231.11 pmol, 30.89% yield, 76% purity) as a colorless solid.[000400] LCMS (ESI): m / z = 248.4 [M+H]+Step 2 -[000401] A solution of tert-butyl 3-[4-(6-oxo-lH-pyridin-3-yl)piperidine-l-carbonyl]-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate 1 (100 mg, 233.92 pmol) in TFA (3 mL) and DCM (3 mL) was stirred at 25°C for 1 hour. TLC showed starting material was consumed completely. The solvent was removed under vacuum to afford 5-[l-(4, 5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-carbonyl)-4-piperidyl]-lH-pyridin-2-one 2 (80 mg, crude) as the yellow oil, that was used directly in next step.[000402] LCMS (ESI): m / z = 328.2 [M+H]+Step 3 -Attorney Docket No. PSE-002WO[000403] A solution of 5-[l-(4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-carbonyl)-4-piperidyl]-lH-pyridin-2-one 2 (80 mg, 244.36 pmol), formaldehyde (18.34 mg, 244.36 pmol, 16.94 pL) in AcOH (0.1 mL) and MeOH (4 mL) was stirred at 25 °C for 1 hour. Then NaBH(OAc)3 (155.37 mg, 733.09 pmol) was added and the combined reaction mixture was stirred at 25 °C for 4 hours. LCMS showed desired product mass was detected. The reaction mixture was quenched by addition of water (2 mL), and solvent was removed under reduced pressure before purification by preparative HPLC. The pure fractions were concentrated under reduced pressure and then lyophilized for overnight to afford 5-[ l-(5-methyl-2, 4,6,7-tetrahydropyrazolo[4,3-c]pyridine-3-carbonyl)-4-piperidyl]-lH-pyridin-2-one P-69 (2.51 mg, 7.26 pmol, 2.97% yield, 98.69% purity) as a white solid.[000404] LCMS (ESI): m / z =342.1 [M+H]+[000405] 1HNMR (400 MHz, DMSO-d6) 8 = 13.07 - 12.33 (m, 1H), 11.86 - 10.98 (m, 1H), 7.42 (dd, J = 2.4, 9.5 Hz, 1H), 7.14 (d, J = 2.2 Hz, 1H), 6.28 (d, J = 9.5 Hz, 1H), 5.18 - 4.70 (m, 1H), 4.65 - 4.49 (m, 1H), 3.10 - 3.00 (m, 1H), 2.66 (br d, J = 5.1 Hz, 4H), 2.63 - 2.53 (m, 4H), 2.33 (s, 3H), 1.74 (br s, 2H), 1.49 - 1.36 (m, 2H)No Final Product Structure Characterization DataLCMS Method D - Retention time: 1.689 min, 98.691% purilv at 220 nm, m / z = 342.1 [M+H]+1H NMR (400 MHz. DMSO-d6) 5 = 13.07 - 12.33 (m, 1H), 11.86 - 10.98 (m, 1H). 7.42 (dd, J = 2.4. 9.5 Hz, P-69 1H), 7.14 (d, J = 2.2 Hz, 1H). 6.28 (d, J = 9.5 Hz, 1H),5.18 - 4.70 (m, 1H). 4.65 - 4.49 (m. 1H), 3.10 - 3.00 (m, 1H), 2.66 (br d, J = 5.1 Hz, 4H), 2.63 - 2.53 (m, 4H), 2.33 (s, 3H), 1.74 (br s, 2H), 1.49 - 1.36 (m, 2H)Biological Assay ProceduresPurification of 17bHSD Type 5 (AKR1C3) enzyme[000406] The enzyme used was recombinant human AKR1C3 (aldo-keto reductase family 1 member 3) or 17bHSD Type 5 protein based on protein sequence from Accession number P42330. It was cloned into pET21b vector with N-terminal hexa-histidine tag. The plasmid was expressed in E. coli and purified by high affinity Ni-NTA column followed by size-exclusion chromatography with Resin Superdex75 column. Purity of the human AKR1C3 enzyme wasAttorney Docket No. PSE-002WOverified by SDS-polyacrylamide gel electrophoresis and intact mass analysis. Protein concentration was determined by the absorbance measurement at 280 nm using NanoDrop UV-Vis spectrophotometer. The homogeneous enzyme was stored in aliquots at -80 °C.Measurement of enzymatic activities of human 17bHSD Type 5 (AKR1C3) enzyme [000407] The AKR1C3 enzyme activity is measured by quantification of the coumberol from Coumberone (Halim M et al., JACS 130, 2008, 14123-141128; Yee D. et al., PNAS 103, 2006, 13304-13309). In this test, the increase of highly fluorescent coumberol product in NADPH-dependent manner by recombinant AKR1C3 protein indicates enzymatic reduction of the non-fluorescent synthetic coumberone substrate and the interference with the reduction by the compounds described herein can be quantified.[000408] For the assay, 50 nL of a 100-fold concentrated solution of the test substance in DMSO were pipetted into a black low-volume 384-well microtiter plate (PerkinElmer-6008289). After, 2.5 pL of a 2x solution of recombinant hAKRlC3 protein in assay buffer [50 rnM potassium phosphate buffer pH 7, 1 mM DTT, 0.0022% (w / v) Pluronic F-l 27, 0.01% BSA (w / v) and protease inhibitor cocktail (Complete, EDTA-free Protease Inhibitor Cocktail from Roche) were added to the 384-well microtiter plate and the mixture was centrifuged at lOOOrpm for 1 minute. The enzyme reaction was then started by addition of 2.5 pl of a 2x solution of NADPH (Roche-10107824001) and coumberone (MCE-HY-D1341) in assay buffer, whereby final assay reaction volume is 5 pl with 1.0 nM final recombinant hAKRlC3 protein concentration, 1.5 pM final NADPH concentration, and 0.6 pM final coumberone concentration. The resulting mixture was incubated at 25 °C for the reaction time of 60 minutes.[000409] The fluorescence of the formed coumberol was then measured using a suitable measuring instrument (Envision microplate reader). The intensity of the fluorescence was used as a measure of the amount of coumberol formed and thus of the enzyme activity of AKR1C3. The data were normalized (enzyme reaction without inhibitor = 0% inhibition; enzyme reaction with a known control inhibitor ASP9521 = 100% inhibition). The test substances were tested on the same microtiter plate at 11 different concentrations in the range from 10 pM top concentration with 4-fold dilutions down to 9.5 pM (10 pM, 2.5 pM, 0.625 pM, 0.156 pM, 39 nM, 9.8 nM, 2.4 nM, 0.6 nM, 0.15 nM, 38 pM, and 9.5pM). The dilution series were prepared prior to the assay on the level of the 100-fold concentrated solution by serial 1 :4 dilutions withAttorney Docket No. PSE-002WO100% DMSO in triplicates for each concentration, and the ICso values were calculated using a 4-parameter fit.ELISA SKOV3 cell-based assay[000410] AKR1C3 enzyme activity can also be measured by using a cell line which expresses human AKR1C3 (170HSD type 5) protein. SKOV3 cell line expressing high levels of human AKR1C3 (17PHSD type 5) protein from a human ovarian cancer-derived cell line was supplied 4-androstenedione (Sigma, SML2364) substrate and inhibitory activity of the compound of the present invention was evaluated on the ability to convert 4-androstenedione to testosterone.[000411] SKOV3 cells were seeded in a 96-well plate and cultured overnight at a density of 18,000 cells / well. Next, compound of interest was added at a top concentration of 10 pM with 1:4 dilution and pre-incubated with the cells for 1 hour. Then, androstenedione, was added thereto at a final concentration of 0.75 pM, followed by cell culturing for 24 hours. After the treatment, the level of testosterone was measured using Testosterone ELISA Immunoassay Kit (Arbor, K032-H1) following the manufacturer’s instructions. The kit quantitatively measured level of testosterone present in tissue culture media samples. A testosterone standard was provided to generate a standard curve for the assay and all samples were read off the standard curve. Standards and diluted samples were pipetted into a clear microtiter plate coated with an antibody to capture rabbit antibodies. A testosterone peroxidase conjugate was added to the standards and samples in the wells. The binding reaction was initiated by the addition of a polyclonal antibody to testosterone to each well. After a 2-hour incubation the plate was washed and substrate was added. The substrate reacted with the bound testosterone-peroxidase conjugate. After a short incubation, the reaction was stopped and the intensity of the generated color was detected in a microtiter plate reader capable of measuring 450 nm wavelength. The concentration of the testosterone in the sample was calculated, after making suitable correction for the dilution of the sample.[000412] The amount of testosterone in the presence of a test compound was calculated as a relative value with respect to the amount of testosterone in the absence of the test compound which was considered as 0% inhibition, while the amount of testosterone detected in the presence of 10 pM known control inhibitor ASP9521 was set at 100% inhibition. The dilution series were prepared prior to the assay on the level of the 100-fold concentrated solution by serialAttorney Docket No. PSE-002WO1 :4 dilutions with 100% DMSO in duplicates for each concentration, and the ICso values were calculated using a 4-parameter fit.Biological ResultshAKRlC3 hAKRlC3Coumberone hAKRlC3-SKOV3 Coumberone hAKRlC3-SKOV3 AC50 (nM) Testosterone-ELISA AC50 (nM) Testosterone-ELISA AC50 (nM) AC50 (nM) No (A<1 nM < B < 10 (A<1 nM < B < 10(F <5 nM < G < 50 No (F <5 nM < G < 50 nM < C < 100 nM nM < C < 100 nMnM < H < 500 nM nM < H < 500 nM < D < 1000 nM < <D < 1000 nM <<I) < I) E) E)P-1 D P-2 EP-3 B P-4 CP-5 E P-6 DP-7 E P-8 DP-9 E P-12 EP-11 E P-14 EP-13 C P-16 EP-15 D P-18 DP-17 E P-20 EP-19 C P-22 EP-21 D P-24 EP-23 E P-26 EP-25 E P-28 EP-27 D P-30 B IP-29 B P-32 CP-31 B I P-34 DP-33 D P-36 A HP-35 B P-38 DP-37 E P-40 DP-39 E P-42 CP-41 E P-44 CP-43 D P-46 BP-45 E P-48 DP-47 C P-50 DP-49 C P-52 DP-51 B P-54 BP-53 E P-56 C IP-55 C P-58 CP-57 C P-60 CP-59 B P-62 DP-61 D P-64 B HP-63 B IP-66 DAttorney Docket No. PSE-002WOP-65 D P-68 BP-67 B P-70 B H P-69 E P-72 A G P-71 A G P-74 CP-73 D P-76 A F P-75 A G P-78 A F P-77 A P-80 A F P-79 A P-82 A G P-81 B P-84 EP-83 A GAttorney Docket No. PSE-002WOINCORPORATION BY REFERENCE[000413] All publications and patents mentioned herein, including those items listed below, are hereby incorporated by reference in their entirety for all purposes as if each individual publication or patent was specifically and individually incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.EQUIVALENTS AND SCOPE[000414] In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.[000415] Furthermore, the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is / are referred to as comprising particular elements and / or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and / or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-rangeAttorney Docket No. PSE-002WOwithin the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.[000416] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, Any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any claim, for any reason, whether or not related to the existence of prior art.[000417] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.
Claims
Attorney Docket No. PSE-002WOCLAIMS1. A compound of Formula (A):Formula (A)or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, whereinindicates single bond or double bond;Ring A is selected from the group consisting of a 5-6-membered heterocyclyl substituted with one or two oxo or =NR’ and comprising one, two, or three nitrogen ring atoms, a 5-membered heterocyclyl comprising at least one oxygen or sulfur ring atom, aN-bound 5-membered heteroaryl comprising one, two, or three nitrogen ring atoms, a C-bound 5-membered heteroaryl comprising at least one oxygen or sulfur ring atom, and a 6-membered heteroaryl comprising one or two nitrogen ring atoms;R' is H or C1-C4 alkyl;Z is CR7orN;L is selected from the group consisting of bond, C(O), S(0)o-2, O, CH2, and CF2;R1is selected from the group consisting of H, C1-C4 alkyl, and C1-C4 alkylene-Ci-C4 alkoxy-Si(Ci-C4alkyl)3;R2is selected from the group consisting of H, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C3-C4 cycloalkoxy, and 4-5 membered heterocycloalkoxy;X5is CR10or N, provided thati) when X5is CR10, R9and R10together with the carbon atoms to which the R9and R10are attached form a phenyl, 5-8 membered carbocyclyl, 5-6 membered heterocyclyl, or 6-membered heteroaryl, wherein the phenyl, 5-8 membered carbocyclyl, 5-6 memberedAttorney Docket No. PSE-002WOheterocyclyl, or 6-membered heteroaryl is optionally substituted with one, two, three, or four R4; andii) when X5is N, R2and R9together with the carbon atoms to which the R2and R9are attached form a 5-8 membered carbocyclyl or 5-6 membered heterocyclyl, wherein the 5-8 membered carbocyclyl or 5-6 membered heterocyclyl is optionally substituted with one or two RD;R3is each independently selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and C3-C6 cycloalkyl,or two R3S on the same carbon together with the carbon atom to which the two R3S are attached form a C3-C6 cycloalkylene, or two R3s on different carbons within the ring form a C1-C4 bridging alkylene;R4is each independently selected from the group consisting of H, halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkylene-Cs-Ce cycloalkyl, Ci-Ce haloalkylene-Cs-Ce cycloalkyl, Ci-Ce alkoxy-Cs-Ce cycloalkyl, Ci-Ce haloalkoxy-C3-Ce cycloalkyl, Ci-Ce alkoxy-4-6 membered heterocyclyl, Ci-Ce alkoxy-5-6 membered heteroaryl, N(R8)2, and 4-6 membered heterocyclyl, wherein the Ci-Ce alkoxy, C -C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkoxy-Cs-Ce cycloalkyl, Ci-Ce haloalkoxy-C3-Ce cycloalkyl, and 4-6 membered heterocyclyl are optionally substituted with one, two, three, or four RA;R5is each independently selected from the group consisting of H, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, and N(R8)2;or two adjacent R5s together with the atoms to which the R5s are attached form a phenyl, 5-6 membered carbocyclyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl, wherein the phenyl or 5-6 membered heteroaryl is optionally substituted with RB, and the 5-6 membered carbocyclyl or 5-6 membered heterocyclyl is optionally substituted with Rc;when is double bond, R7is absent; when is single bond, R7is selected from the group consisting of H, hydroxy, cyano, and C1-C4 alkyl;R8is each independently H or Ci-Ce alkyl;Attorney Docket No. PSE-002WORAis each independently selected from the group consisting of halogen, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce alkyl-Ci-Ce alkoxy, and Ci-Ce haloalkoxy;RBis selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkyl;Rcis selected from the group consisting of oxo, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkyl;RDis each independently selected from the group consisting of halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, and Ci-Ce haloalkoxy;n is 0, 1, 2, 3, or 4;t is 0, 1, or 2;p is 0 or 1; andq is 0 or 1.
2. A compound of Formula (I):Formula (I)or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, whereinindicates single bond or double bond;X1, X2, X3, and X4are each independently CR4or N, provided that no more than two of X1, X2, X3, and X4are N;Ring A is selected from the group consisting of a 5-6-membered heterocyclyl substituted with one or two oxo or =NR’ and comprising one, two, or three nitrogen ring atoms, a 5-membered heterocyclyl comprising at least one oxygen or sulfur ring atom, a N-bound 5-membered heteroaryl comprising one, two, or three nitrogen ring atoms, a C-bound 5-membered heteroaryl comprising at least one oxygen or sulfur ring atom, and a 6-membered heteroaryl comprising one or two nitrogen ring atoms;Attorney Docket No. PSE-002WOZ is CR7orN;L is selected from the group consisting of bond, C(O), S(0)o-2, O, CH2, and CF2;R1is selected from the group consisting of H, C1-C4 alkyl, and C1-C4 alkylene-Ci-C4 alkoxy-Si(Ci-C4alkyl)3;R2is selected from the group consisting of H, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C3-C4 cycloalkoxy, and 4-5 membered heterocycloalkoxy;R3is each independently selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Cg haloalkyl, and C3-C6 cycloalkyl,or two R3S on the same carbon together with the carbon atom to which the two R3S are attached form a C3-C6 cycloalkylene, or two R3s on different carbons within the ring form a C1-C4 bridging alkylene;R4is each independently selected from the group consisting of H, halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkylene-Cs-Ce cycloalkyl, Ci-Ce haloalkylene-Cs-Ce cycloalkyl, Ci-Ce alkoxy-C3-Ce cycloalkyl, Ci-Ce haloalkoxy-C3-Ce cycloalkyl, Ci-Ce alkoxy-4-6 membered heterocyclyl, Ci-Ce alkoxy-5-6 membered heteroaryl, N(R8)2, and 4-6 membered heterocyclyl, wherein the Ci-Ce alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkoxy-Cs-Ce cycloalkyl, Ci-Ce haloalkoxy-C3-Ce cycloalkyl, and 4-6 membered heterocyclyl are optionally substituted with one, two, three, or four RA;R5is each independently selected from the group consisting of H, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, and N(R8) ;or two adjacent R5s together with the atoms to which the R5s are attached form a phenyl, 5-6 membered carbocyclyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl, wherein the phenyl or 5-6 membered heteroaryl is optionally substituted with RB, and the 5-6 membered carbocyclyl or 5-6 membered heterocyclyl is optionally substituted with Rc;when - is double bond, R7is absent; when - is single bond, R7is selected from the group consisting of H, hydroxy, cyano, and C1-C4 alkyl;R8is each independently H or Ci-Ce alkyl;Attorney Docket No. PSE-002WORAis each independently selected from the group consisting of halogen, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce alkyl-Ci-Ce alkoxy, and Ci-Ce haloalkoxy;RBis selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkyl;Rcis selected from the group consisting of oxo, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkyl;n is 0, 1, 2, 3, or 4;tis 0, 1, or 2;p is 0 or 1; andq is 0 or 1.
3. The compound of claim 1 or 2, wherein L is bond.
4. The compound of claim 1 or 2, wherein L is CH2.
5. The compound of any one of claims 2-4, wherein X1is CR4.
6. The compound of any one of claims 2-4, wherein X1is N.
7. The compound of any one of claims 2-6, wherein X2is CR4.
8. The compound of any one of claims 2-6, wherein X2is N.
9. The compound of any one of claims 2-8, wherein X3is CR4.
10. The compound of any one of claims 2-8, wherein X3is N.
11. The compound of any one of claims 2-10, wherein X4is CR4.
12. The compound of any one of claims 2-10, wherein X4is N.
13. The compound of any one of claims 1-12, wherein p is 0.
14. The compound of any one of claims 1-12, wherein p is 1.
15. The compound of any one of claims 1-14, wherein q is 0.
16. The compound of any one of claims 1-14, wherein q is 1.
17. The compound of any one of claims 1-16, wherein Ring A is 5-6-membered heterocyclyl substituted with one or two oxo or =NH and comprising one, two, or three nitrogen ring atoms.
18. The compound of any one of claims 1-16, wherein Ring A is 6-membered heterocyclyl substituted with one or two oxo and comprising one or two nitrogen ring atoms.
19. The compound of any one of claims 1-16, wherein Ring A is 5-membered heterocyclyl substituted with oxo or =NH and comprising one, two, or three nitrogen atoms.Attorney Docket No. PSE-002WO20. The compound of any one of claims 1-16, wherein Ring A is C-bound 5-membered heteroaryl comprising at least one oxygen or sulfur ring atom.
21. The compound of claim 20, wherein the heteroaryl comprises one oxygen or sulfur ring atom and one or two nitrogen ring atoms.
22. The compound of any one of claims 1-16, wherein Ring A is N-bound 5-membered heteroaryl comprising one, two, or three nitrogen ring atoms.
23. The compound of any one of claims 1-16, wherein Ring A is 6-membered heteroaryl comprising one or two nitrogen ring atoms.
24. The compound of any one of claims 1-16, wherein Ring A is selected from the group consisting ofAttorney Docket No. PSE-002WO25. The compound of any one of claims 1-16, wherein Ring A is selected from the group consisting of:Attorney Docket No. PSE-002WO26. A compound of Formula (II):or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, whereinRing A is selected from the group consisting of a 5-6-membered heterocyclyl substituted with one or two oxo or =NR’ and comprising one, two, or three nitrogen ring atoms, a 5-membered heterocyclyl comprising at least one oxygen or sulfur ring atom, a N-bound 5-membered heteroaryl comprising one, two, or three nitrogen ring atoms, a C-bound 5-membered heteroaryl comprising at least one oxygen or sulfur ring atom, and a 6-membered heteroaryl comprising one or two nitrogen ring atoms;R' is H or C1-C4 alkyl;Z is CR7orN;Attorney Docket No. PSE-002WOR1is H or C1-C4 alkyl;R2is selected from the group consisting of H, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C3-C4 cycloalkoxy, and 4-5 membered heterocycloalkoxy;R3is each independently selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, and C3-C6 cycloalkyl,or two R3S on the same carbon together with the carbon atom to which the two R3S are attached form a C3-C6 cycloalkylene, or two R3s on different carbons within the ring form a C1-C4 bridging alkylene;R4is selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkylene-C -C6 cycloalkyl, Ci-Ce haloalkylene-C3-C6 cycloalkyl, Ci-Ce alkoxy-Cs-Ce cycloalkyl, Ci-Ce haloalkoxy-Cs-Ce cycloalkyl, Ci-Ce alkoxy-4-6 membered heterocyclyl, Ci-Ce alkoxy-5-6 membered heteroaryl, N(R8)2, and 4-6 membered heterocyclyl,wherein the Ci-Ce alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkoxy-Cs-Ce cycloalkyl, Ci-Ce haloalkoxy-Cs-Ce cycloalkyl, and 4-6 membered heterocyclyl are optionally substituted with one, two, three, or four RA;R5is each independently selected from the group consisting of H, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, and N(R8)2;when - is double bond, R7is absent; when - is single bond, R7is selected from the group consisting of H, hydroxy, cyano, and C1-C4 alkyl;R8is each independently H or Ci-Ce alkyl;RAis each independently selected from the group consisting of halogen, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce alkyl-Ci-Ce alkoxy, and Ci-Ce haloalkoxy;tis 0, 1, or 2; andn is 0, 1, 2, 3, or 4.
27. The compound of any one of claims 1-26, wherein Z is CR7.
28. The compound of claim 27, wherein R7is selected from the group consisting of H, hydroxy, and C1-C2 alkyl.
29. The compound of claim 28, wherein R7is H.Attorney Docket No. PSE-002WO30. The compound of any one of claims 1-26, wherein Z is N.
31. The compound of any one of claims 1-30, wherein R1is H.
32. The compound of any one of claims 1-31, wherein R2is selected from the group consisting of H, halogen, C1-C4 alkyl, and C3-C4 cycloalkoxy.
33. The compound of any one of claims 1-32, wherein R2is H.
34. The compound of any one of claims 1-33, wherein n is 0, 1, or 2.
35. The compound of any one of claims 1-34, wherein n is 0.
36. The compound of any one of claims 1-34, wherein n is 1.
37. The compound of any one of claims 1-34, wherein n is 2.
38. The compound of any one of claims 1-34 and 36-37, wherein R3is each independently selected from the group consisting of halogen, Ci-Ce alkyl, and C3-C6 cycloalkyl.
39. The compound of any one of claims 1-34 and 36-38, wherein R3is each independently C1-C4 alkyl or C3-C4 cycloalkyl.
40. The compound of any one of claims 1-34 and 36-39, wherein R3is each independently C1-C2 alkyl.
41. The compound of any one of claims 1-34 and 37, wherein two R3s on the same carbon together with the carbon atom to which the two R3s are attached form a C3-C4 cycloalkylene.
42. The compound of any one of claims 1-34 and 37, wherein two R3s on different carbons within the ring form a C2-C3 bridging alkylene.
43. The compound of any one of claims 1-25 and 27-42, wherein R4is each independently selected from the group consisting of H, halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkoxy-Cs-Ce cycloalkyl, N(R8)2, and 4-6 membered heterocyclyl, wherein the C3-C6 cycloalkyl, C3-C6 cycloalkoxy, 4-6 membered heterocycloalkoxy, Ci-Ce alkoxy-Cs-Ce cycloalkyl, and 4-6 membered heterocyclyl are optionally substituted with one or two RA.
44. The compound of any one of claims 1-25 and 27-43, wherein R4is each independently selected from the group consisting of H, halogen Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C -C6 cycloalkyl, and C -C6 cycloalkoxy.Attorney Docket No. PSE-002WO45. The compound of any one of claims 1-25 and 27-44, wherein R4is each independently selected from the group consisting of H, Ci-Ce alkoxy, Ci-Ce haloalkoxy, and C3-C6 cycloalkoxy.
46. The compound of any one of claims 1-45, wherein R4is each independently selected from the group consisting of C1-C6 alkoxy, C1-C6 haloalkoxy, and C3-C6 cycloalkoxy.
47. The compound of any one of claims 1-46, wherein R5is each independently selected from the group consisting of H, halogen, hydroxy, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 cycloalkyl, andN(R8)2.
48. The compound of any one of claims 1-47, wherein R5is each independently selected from the group consisting of H, halogen, hydroxy, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C3-C4 cycloalkyl, and NH2.
49. The compound of any one of claims 1-48, wherein R5is each independently selected from the group consisting of H, F, Cl, hydroxy, cyano, C1-C4 alkyl, C1-C4 haloalkyl, Ci- C4 alkoxy, and NH2.
50. The compound of any one of claims 1-24 and 26-49, wherein t is 0 or 1.
51. The compound of any one of claims 1-24 and 26-50, wherein t is 0.
52. The compound of any one of claims 1-24 and 26-50, wherein t is 1.
53. The compound of any one of claims 26-52, wherein Ring A is 5-6-membered heterocyclyl substituted with one or two oxo or =NH and comprising one, two, or three nitrogen ring atoms.
54. The compound of any one of claims 26-52, wherein Ring A is 6-membered heterocyclyl substituted with one or two oxo and comprising one or two nitrogen ring atoms.
55. The compound of any one of claims 26-52, wherein Ring A is 5-membered heterocyclyl substituted with oxo or =NH and comprising one, two, or three nitrogen atoms.
56. The compound of any one of claims 26-52, wherein Ring A is C-bound 5-membered heteroaryl comprising at least one oxygen or sulfur ring atom.
57. The compound of claim 56, wherein the heteroaryl comprises one oxygen or sulfur ring atom and one or two nitrogen ring atoms.
58. The compound of any one of claims 26-52, wherein Ring A is N-bound 5-membered heteroaryl comprising one, two, or three nitrogen ring atoms.Attorney Docket No. PSE-002WO59. The compound of any one of claims 26-52, wherein Ring A is 6-membered heteroaryl comprising one or two nitrogen ring atoms.
60. The compound of any one of claims 26-52, wherein Ring A is selected from the group consisting of:
61. The compound of any one of claims 26-52, wherein Ring A is selected from the group consisting ofAttorney Docket No. PSE-002WO62. A compound of Formula (III):R11°Formula (III)or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein indicates single bond or double bond;Ring A is 6-membered heterocyclyl substituted with oxo and comprising one or two nitrogen ring atoms;X15is CH orN;L2is bond or C(O);Attorney Docket No. PSE-002WOR11is H or C1-C4 alkyl;R13is each independently selected from the group consisting of halogen, hydroxy, cyano, Ci-Ce alkyl, and Ci-Ce haloalkyl;R14is each independently selected from the group consisting of halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy, and Ci-Ce haloalkoxy;s is 0, 1, 2, or 3; andt is 0, 1, or 2.
63. The compound of claim 62, wherein R11is H.
64. The compound of claim 62 or 63, wherein s is 0, 1, or 2.
65. The compound of any one of claims 62-64, wherein R14is each independently C1-C4 alkyl or C1-C4 haloalkyl.
66. The compound of any one of claims 62-65, wherein t is 0.
67. A compound selected from Table 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
68. A pharmaceutical composition, comprising a compound of any one of claims 1-67, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
69. A method of modulating AKR1C3 in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of claims 1-67, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof or the pharmaceutical composition of claim 68.
70. A method of treating a disease, disorder, or condition associated with suboptimal AKR1C3 activity, comprising administering to the subject an effective amount of a compound of any one of claims 1-67, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof or the pharmaceutical composition of claim 68.
71. The method of claim 70, wherein the disease, disorder, or condition associated with suboptimal AKR1C3 activity is hyperandrogenism.
72. The method of claim 70, wherein the disease, disorder, or condition associated with suboptimal AKR1C3 activity is polycystic ovary syndrome (PCOS).
73. The method of claim 70, wherein the disease, disorder, or condition associated with suboptimal AKR1C3 activity is hirsutism.Attorney Docket No. PSE-002WO74. The method of claim 70, wherein the disease, disorder, or condition associated with suboptimal AKR1C3 activity is endometriosis.
75. The method of claim 70, wherein the disease, disorder, or condition associated with suboptimal AKR1C3 activity is cancer.
76. The method of claim 70, wherein the disease, disorder, or condition associated with suboptimal AKR1C3 activity is a metabolic disorder.
